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Articles

Global, regional, and national life expectancy, all-cause
mortality, and cause-speciﬁc mortality for 249 causes of
death, 1980–2015: a systematic analysis for the Global
Burden of Disease Study 2015
GBD 2015 Mortality and Causes of Death Collaborators*

Summary
Background Improving survival and extending the longevity of life for all populations requires timely, robust evidence
on local mortality levels and trends. The Global Burden of Disease 2015 Study (GBD 2015) provides a comprehensive
assessment of all-cause and cause-speciﬁc mortality for 249 causes in 195 countries and territories from 1980 to 2015.
These results informed an in-depth investigation of observed and expected mortality patterns based on
sociodemographic measures.
Methods We estimated all-cause mortality by age, sex, geography, and year using an improved analytical approach
originally developed for GBD 2013 and GBD 2010. Improvements included reﬁnements to the estimation of child and
adult mortality and corresponding uncertainty, parameter selection for under-5 mortality synthesis by spatiotemporal
Gaussian process regression, and sibling history data processing. We also expanded the database of vital registration,
survey, and census data to 14 294 geography–year datapoints. For GBD 2015, eight causes, including Ebola virus
disease, were added to the previous GBD cause list for mortality. We used six modelling approaches to assess causespeciﬁc mortality, with the Cause of Death Ensemble Model (CODEm) generating estimates for most causes. We used
a series of novel analyses to systematically quantify the drivers of trends in mortality across geographies. First, we
assessed observed and expected levels and trends of cause-speciﬁc mortality as they relate to the Socio-demographic
Index (SDI), a summary indicator derived from measures of income per capita, educational attainment, and fertility.
Second, we examined factors aﬀecting total mortality patterns through a series of counterfactual scenarios, testing the
magnitude by which population growth, population age structures, and epidemiological changes contributed to shifts
in mortality. Finally, we attributed changes in life expectancy to changes in cause of death. We documented each step
of the GBD 2015 estimation processes, as well as data sources, in accordance with Guidelines for Accurate and
Transparent Health Estimates Reporting (GATHER).
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Findings Globally, life expectancy from birth increased from 61·7 years (95% uncertainty interval 61·4–61·9) in 1980
to 71·8 years (71·5–72·2) in 2015. Several countries in sub-Saharan Africa had very large gains in life expectancy from
2005 to 2015, rebounding from an era of exceedingly high loss of life due to HIV/AIDS. At the same time, many
geographies saw life expectancy stagnate or decline, particularly for men and in countries with rising mortality from
war or interpersonal violence. From 2005 to 2015, male life expectancy in Syria dropped by 11·3 years (3·7–17·4), to
62·6 years (56·5–70·2). Total deaths increased by 4·1% (2·6–5·6) from 2005 to 2015, rising to 55·8 million
(54·9 million to 56·6 million) in 2015, but age-standardised death rates fell by 17·0% (15·8–18·1) during this time,
underscoring changes in population growth and shifts in global age structures. The result was similar for noncommunicable diseases (NCDs), with total deaths from these causes increasing by 14·1% (12·6–16·0) to 39·8 million
(39·2 million to 40·5 million) in 2015, whereas age-standardised rates decreased by 13·1% (11·9–14·3). Globally, this
mortality pattern emerged for several NCDs, including several types of cancer, ischaemic heart disease, cirrhosis, and
Alzheimer’s disease and other dementias. By contrast, both total deaths and age-standardised death rates due to
communicable, maternal, neonatal, and nutritional conditions signiﬁcantly declined from 2005 to 2015, gains largely
attributable to decreases in mortality rates due to HIV/AIDS (42·1%, 39·1–44·6), malaria (43·1%, 34·7–51·8),
neonatal preterm birth complications (29·8%, 24·8–34·9), and maternal disorders (29·1%, 19·3–37·1). Progress was
slower for several causes, such as lower respiratory infections and nutritional deﬁciencies, whereas deaths increased
for others, including dengue and drug use disorders. Age-standardised death rates due to injuries signiﬁcantly
declined from 2005 to 2015, yet interpersonal violence and war claimed increasingly more lives in some regions,
particularly in the Middle East. In 2015, rotaviral enteritis (rotavirus) was the leading cause of under-5 deaths due to
diarrhoea (146 000 deaths, 118 000–183 000) and pneumococcal pneumonia was the leading cause of under-5 deaths
due to lower respiratory infections (393 000 deaths, 228 000–532 000), although pathogen-speciﬁc mortality varied by
region. Globally, the eﬀects of population growth, ageing, and changes in age-standardised death rates substantially
diﬀered by cause. Our analyses on the expected associations between cause-speciﬁc mortality and SDI show the
regular shifts in cause of death composition and population age structure with rising SDI. Country patterns of
www.thelancet.com Vol 388 October 8, 2016

1459

Articles

premature mortality (measured as years of life lost [YLLs]) and how they diﬀer from the level expected on the basis of
SDI alone revealed distinct but highly heterogeneous patterns by region and country or territory. Ischaemic heart
disease, stroke, and diabetes were among the leading causes of YLLs in most regions, but in many cases, intraregional
results sharply diverged for ratios of observed and expected YLLs based on SDI. Communicable, maternal, neonatal,
and nutritional diseases caused the most YLLs throughout sub-Saharan Africa, with observed YLLs far exceeding
expected YLLs for countries in which malaria or HIV/AIDS remained the leading causes of early death.
Interpretation At the global scale, age-speciﬁc mortality has steadily improved over the past 35 years; this pattern of
general progress continued in the past decade. Progress has been faster in most countries than expected on the basis
of development measured by the SDI. Against this background of progress, some countries have seen falls in life
expectancy, and age-standardised death rates for some causes are increasing. Despite progress in reducing agestandardised death rates, population growth and ageing mean that the number of deaths from most noncommunicable causes are increasing in most countries, putting increased demands on health systems.
Funding Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.

Introduction
Comparable information about deaths and mortality
rates broken down by age, sex, cause, year, and geography
provides a starting point for informed health policy
debate. However, generating meaningful comparisons of
mortality involves addressing many data and estimation
challenges, which include reconciling marked discrepancies in cause of death classiﬁcations over time and
across populations; adjusting for vital registration system
data with coverage and quality issues; appropriately
synthesising mortality data from cause-speciﬁc sources,
such as cancer registries, and alternative cause of death

identiﬁcation tools, such as verbal autopsies; and
developing robust analytical strategies to estimate causespeciﬁc mortality amid sparse data.1–6 The annual Global
Burden of Disease (GBD) analysis provides a standardised
approach to addressing these problems, thereby
enhancing the capacity to make meaningful comparisons
across age, sex, cause, time, and place.
Previous iterations of the GBD study showed
substantial reductions in under-5 mortality, largely
driven by decreasing rates of death from diarrhoeal
diseases, lower respiratory infections, malaria, and,
in several countries, neonatal conditions and

Research in context
Evidence before this study
In 2012, the Global Burden of Disease 2010 study was published,
providing results from the ﬁrst complete revision of the Global
Burden of Disease (GBD) since the ﬁrst assessment in 1993. The
study reported on mortality and causes of death between 1990
and 2010 in 187 countries. In response to demand for up-to-date
information on the health of populations to inform health policy
debates, annual updates of the GBD study are now prepared,
with the ﬁrst of these, the GBD 2013 study, published in 2015.
For the ﬁrst time, collaborative teams undertook subnational
assessments for China, Mexico, and the UK as part of this study.
Added value of this study
The GBD 2015 assessment of mortality and causes of death
provides new and more robust evidence on the health of
populations worldwide through the inclusion of subnational data
from an expanded group of countries, including Brazil, India,
Japan, Kenya, Saudi Arabia, South Africa, Sweden, and the USA, in
addition to updates for China, Mexico, and the UK. This study
complies with the Guidelines for Accurate and Transparent Health
Estimates Reporting (GATHER) recommendations. Estimation of
mortality levels, patterns, and distribution for several new causes,
including Ebola virus disease, further disaggregations of
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carcinoma and leukaemia, motor neuron disease, and mortality
attributable to environmental heat and cold exposure have been
added for the GBD 2015 study. Furthermore, this analysis extends
the concept of sociodemographic status ﬁrst reported in GBD
2013, with important changes to computational methods,
resulting in a new Socio-demographic Index (SDI) for a more
robust positioning of countries and territories on the
development continuum.
Implications of all the available evidence
This study provides the most comprehensive assessment to date
of patterns and levels of mortality worldwide, expanding on
previous analyses by further investigating the main determinants
of epidemiological patterns and trends across geographies and
over time. The GBD 2015 study entails a complete reanalysis of
trends for each cause of death from 1990 to 2015; the time series
published here supersedes the results of the GBD 2013 study. The
expansion of geographic units, from 296 in GBD 2013 to 519 for
GBD 2015, is envisaged to continue so as to sustain comparability
over time and across all geographies. The comparison of
estimates of observed mortality levels with patterns expected
based on the SDI provides an in-depth understanding of national
health challenges and priority areas for intervention.
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capita, educational attainment, fertility, shifts in clinical
care and health system responsiveness, emergent health
threats such as disease outbreaks or increasing rates of
obesity, and geography-speciﬁc health contexts. An indepth understanding of national health gains and priority
areas for intervention can be provided by comparing
estimates of expected mortality patterns. These results
are of particular importance amid debates on ﬁnancing
and policy options for the newly adopted Sustainable
Development Goals, which include both ambitious
targets for maternal and child health and a much broader
health agenda also encompassing NCDs and injuries.
The GBD 2010 study presented results for
187 countries, encompassing all those with a population

malnutrition.7–11 Non-communicable diseases (NCDs)
and injuries claimed increasingly more lives throughout
the world, although age-standardised death rates fell
for many causes and countries.7 Examination of
epidemiological convergence among high-income,
middle-income, and low-income countries showed the
importance of evaluating both absolute and relative
changes in mortality, as solely focusing on absolutes can
mask rising relative inequality among certain age groups
and causes. The GBD 2015 study expands on these
analyses by further evaluating the drivers of epidemiological patterns across countries and over time.
Such mortality trends are generally shaped by a
combination of factors, including changes in income per
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Figure 1: Estimation of all-cause mortality by age and sex and HIV/AIDS incidence, prevalence, and mortality for GBD 2015
Data and analyses are indicated by shape and the ﬂow chart is colour coded by major estimation component. The process depicted is performed twice to bring in updated under-5 population estimates
and crude death rates due to HIV/AIDS. The inputs that are updated in the second run of the process are shown by patterned boxes in this ﬂow chart. Because of the very large and changing eﬀects of
HIV/AIDS on all-cause mortality in several countries with large HIV epidemics and limited data on all-cause mortality, the estimation of HIV/AIDS and all-cause mortality are closely linked and are
presented jointly here. GBD=Global Burden of Disease. 5q0=probability of death from birth to age 5 years. 45q15=probability of death from age 15 to 60 years. ART=antiretroviral therapy.
CBH=complete birth histories. CDR=crude death rate. COD=causes of death. DSP=disease surveillance points. ED=educational attainment in years per capita above age 15 years and mother’s
educational attainment in years per capita for children younger than 5 years. EPP=Estimation and Projection Package. HIV CDR=crude death rate due to HIV/AIDS. LDI=lagged distributed income per
capita. SBH=summary birth history. SRS=Sample Registration System. VR=vital registration.
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greater than 50 000 in the year 2000.12 In the GBD 2013
study, collaborative teams produced subnational
assessments for the UK, Mexico, and China, expanding
the number of geographies included in the GBD
analysis to 296.7,13–15 The value of such subnational
assessments to local decision makers16 has driven
further geographical disaggregation for GBD 2015
including in Brazil, India, Japan, Kenya, Saudi Arabia,
South Africa, Sweden, and the USA, in addition to
updates for China, Mexico, and the UK. The expansion
of the geographical units in the GBD studies will
continue in a way that will sustain the comparability
over time for the period 1990 to present and across all
geographic entities.
As with all revisions of the GBD, the GBD 2015 study
provides an update for the entire time series from
1990 to 2015 based on newly identiﬁed data sources
released or collected since GBD 2013. In response to
published commentaries and unpublished seminars
and communications about GBD methods, various
methodological reﬁnements have been implemented.17,18
Additionally, in the GBD 2015 cycle, a major eﬀort
towards data and code transparency has been made. As
with each GBD cycle, the full time series published here
supersedes previous GBD studies. This detailed
assessment of causes of death allows the exploration of
key questions including what are the leading causes of
deaths in each geography, which causes are increasing or
decreasing, what is the expected pattern of change in
causes of death with the epidemiological transition and
how does this expected pattern over time diverge across
geographies.

Methods
Overview

See Online for appendices

1462

GBD employs various analytical tools and a diverse set of
data sources to generate comparable estimates of deaths
and mortality rates broken down by age, sex, cause, year,
and geography. Multiple publications show more detail
on the various aspects of the methods.7,8,12,19 Part 1 of the
methods appendix (pp 4–51) is a structured and succinct
explanation of each step. Figure 1 shows all of the inputs,
analytical processes, and outputs from the analysis of allcause mortality and HIV/AIDS mortality, included
because of its important eﬀects on all-cause mortality in
countries with large HIV epidemics, and ﬁgure 2 does
the same for cause-speciﬁc mortality. Each input or
process is numbered for reference, with part 2 of the
methods appendix (pp 52–70) providing explanation for
each step. The GBD analytical approach to estimation is
guided by standardised solutions to some general
analytical problems: inconsistent case deﬁnitions or
coding over time or across geographies; missing data;
conﬂicting data for the same year and geography;
and population groups (eg, the poor, minorities,
and vulnerable groups) who are often missed in
administrative data sources. In this Article, we provide

only a very high-level summary. This analysis adheres to
the new Guidelines for Accurate and Transparent Health
Estimates Reporting (GATHER) proposed by the World
Health Organization (WHO) and others, which includes
recommendations on documentation of data sources,
estimation methods, and statistical analysis.20 Table 1
shows the precise ways in which we have adhered to each
element of the GATHER agreement.

Geographic units
We have organised geographies into a set of hierarchical
categories: seven super-regions; 21 regions nested
within the seven super-regions; and 195 countries and
territories nested within the 21 regions (table 2). Details
on the classiﬁcation of each geographical unit into each
level of this hierarchy are provided in the methods
appendix (pp 670–83). Compared with GBD 2013, we
have added seven territories—American Samoa,
Bermuda, Greenland, Guam, the Northern Mariana
Islands, Puerto Rico, and the Virgin Islands—because
of the availability of high-quality vital registration data.
These territories were not previously included in the
national totals of the USA, UK, or Denmark, and were
included only in GBD 2013 regional totals. We have
further disaggregated data for selected countries or
territories into subnational units: 26 states and one
district for Brazil, 34 provinces and municipalities for
China, 31 states and union territory groupings for India
that include 62 rural and urban units, 47 prefectures for
Japan, 47 counties for Kenya, 32 states and districts
for Mexico, 13 regions for Saudi Arabia, nine provinces
for South Africa, two regions for Sweden, 13 regions for
the UK (Northern Ireland, Scotland, Wales, England,
and nine subregions of England), and 51 states and
districts for the USA. At the ﬁrst subnational unit level,
we have 256 geographic units. Subnational level 1
geographies in the GBD 2015 analysis include countries
that have been subdivided into the ﬁrst subnational
level, such as states or provinces. The subnational
level 2 category applies only to India and England. In
this Article we present national, territory, and previously
published subnational units in the UK.13

Figure 2: Development of the GBD 2015 cause of death database
Figure shows (A) diﬀerent strategies used to model diﬀerent causes and to
(B) combine them into a consistent set of cause-speciﬁc deaths for each
location, age, sex, and year. Data and analytical processes are indicated by shape
and the ﬂow chart is colour coded by major estimation component. GBD=Global
Burden of Disease. BTL=basic tabulation list. CDC=Center for Disease Control and
Prevention. COD=cause of death. CODEm=Cause Of Death Ensemble model.
CR=cancer registry. CRS=civil registration system. DSP=disease surveillance
points. ICD=International Classiﬁcation of Diseases. MI=mortality/incidence
ratio. MCCD=medical certiﬁcation of causes of death. MM=maternal mortality.
MMR=maternal mortality ratio. MMS=maternal mortality surveillance.
PAF=population-attributable fraction. SCD=survey of causes of death.
SEER=Surveillance, Epidemiology, and End Results Program. SRS=Sample
Registration System. SR MAD=super-region median average deviation.
ST-GPR=spatiotemporal Gaussian process regression. VA=verbal autopsy.
VR=vital registration. YLL=years of life lost.
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GATHER checklist item

Description of compliance

Reference

Objectives and funding
1

Deﬁne the indicators, populations, and time periods for which estimates
were made

Narrative provided in paper and methods
appendix describing indicators,
deﬁnitions, and populations

Main text (Methods—Geographic units, GBD cause
list, Time periods) and methods appendix (pp 4–70)

2

List the funding sources for the work

Funding sources listed in paper

Summary (Funding)

Data inputs
For all data inputs from multiple sources that are synthesised as part of the study
3

Describe how the data were identiﬁed and how the data were accessed

Narrative description of data seeking
methods provided

Main text (Methods) and methods appendix
(pp 4–283)

4

Specify the inclusion and exclusion criteria; identify all ad-hoc exclusions

Narrative about inclusion and exclusion
criteria by data type provided

Main text (Methods) and methods appendix
(pp 4–283)

5

Provide information on all included data sources and their main
characteristics; for each data source used, report reference information or
contact name or institution, population represented, data collection
method, years of data collection, sex and age range, diagnostic criteria or
measurement method, and sample size, as relevant

An interactive, online data source tool that Online data citation tools
provides metadata for data sources by
component, geography, cause, risk, or
impairment has been developed

6

Identify and describe any categories of input data that have potentially
important biases (eg, based on characteristics listed in item 5)

Summary of known biases by cause
included in methods appendix

Methods appendix (pp 4–283)

Describe and give sources for any other data inputs

Included in online data source tool

Online data citation tools

Provide all data inputs in a ﬁle format from which data can be eﬃciently
extracted (eg, a spreadsheet as opposed to a PDF), including all relevant
metadata listed in item 5; for any data inputs that cannot be shared due
to ethical or legal reasons, such as third-party ownership, provide a
contact name or the name of the institution that retains the right to
the data

Downloads of input data available through Online data visualisation tools, data query tools, and
the Global Health Data Exchange
online tools, including data visualisation
tools and data query tools; input data not
available in tools will be made available
upon request

9

Provide a conceptual overview of the data analysis method; a diagram
may be helpful

Flow diagrams of the overall methodological Main text (Methods, ﬁgures 1 and 2) and methods
appendix (pp 4–287)
processes, as well as cause-speciﬁc
modelling processes, have been provided

10

Provide a detailed description of all steps of the analysis, including
mathematical formulae; this description should cover, as relevant, data
cleaning, data pre-processing, data adjustments and weighting of data
sources, and mathematical or statistical models

Flow diagrams and corresponding
methodological write-ups for each cause,
as well as the demographics and causes of
death databases and modelling processes,
have been provided

Main text (Methods, ﬁgures 1 and 2) and methods
appendix (pp 4–287)

11

Describe how candidate models were evaluated and how the ﬁnal
models were selected

Provided in the methodological write-ups

Methods appendix (pp 71–283)

12

Provide the results of an evaluation of model performance, if done, as
well as the results of any relevant sensitivity analysis

Provided in the methodological write-ups

Methods appendix (pp 71–283)

13

Describe methods for calculating uncertainty of the estimates; state
which sources of uncertainty were, and were not, accounted for in the
uncertainty analysis

Provided in the methodological write-ups

Methods appendix (pp 71–283)

14

State how analytic or statistical source code used to generate estimates
can be accessed

Access statement provided

Code is provided in an online repository

For data inputs that contribute to the analysis but were not synthesised as part of the study
7
For all data inputs
8

Data analysis

(Table 1 continues on next page)

For the data citation tools see
http://ghdx.healthdata.org/gbddata-input-sources
For the data visualisation tools
see http://www.healthdata.org/
results/data-visualizations
For the data query tools see
http://ghdx.healthdata.org/gbddata-tool
For the Global Health Data
Exchange see http://ghdx.
healthdata.org/
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GBD cause list
The GBD cause list is the crucial organising framework
for the analysis of causes of death and premature
mortality, as well as disease incidence and prevalence
and years lived with disability.21 The GBD cause list has
evolved during the 25 years of the GBD study to become
a list of causes that have public health and medical care
importance either because they are major causes of lost
health or because of policy relevance.7,21–24 Because
diﬀerent levels of cause aggregation are appropriate for
diﬀerent purposes and users, the GBD cause list is
organised hierarchically (table 2). At each level of the

cause hierarchy, the set of causes is mutually exclusive
and collectively exhaustive.21 At the ﬁrst level of the
cause list, there are three broad causes: communicable,
maternal, neonatal, and nutritional diseases; NCDs;
and injuries. At the second level of the hierarchy, these
three causes are broken down into 21 cause groups
such as neoplasms (cancers) or cardiovascular diseases.
Levels 3 and 4 of the cause list provide more
disaggregated causes. Based on policy interest and by
approval of the GBD Scientiﬁc Council, we have added
eight causes to the GBD cause list: Ebola virus disease,
motor neuron disease, environmental heat and cold
www.thelancet.com Vol 388 October 8, 2016
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GATHER checklist item

Description of compliance

Reference

(Continued from previous page)
Results and discussion
15

Provide published estimates in a ﬁle format from which data can be
eﬃciently extracted

Main text, methods appendix, and online data tools
GBD 2015 results are available through
online data visualisation tools, the Global (data visualisation tools, data query tools, and the
Health Data Exchange, and the online data Global Health Data Exchange)
query tool

16

Report a quantitative measure of the uncertainty of the estimates
(eg, uncertainty intervals)

Uncertainty intervals are provided with all
results

17

Interpret results in light of existing evidence; if updating a previous set of Discussion of methodological changes
estimates, describe the reasons for changes in estimates
between GBD rounds provided in the
narrative of the Article and methods
appendix

18

Discuss limitations of the estimates; include a discussion of any
modelling assumptions or data limitations that aﬀect interpretation of
the estimates

Discussion of limitations provided in the
narrative of the main paper, as well as in
the methodological write-ups in the
methods appendix

Main text, methods appendix, and online data tools
(data visualisation tools, data query tools, and the
Global Health Data Exchange)
Main text (Methods and Discussion) and methods
appendix (pp 4–287)

Main text (Limitations) and methods appendix
(pp 4–283)

GBD 2015=Global Burden of Disease 2015 Study. GATHER=Guidelines for Accurate and Transparent Health Estimates Reporting.

Table 1: GATHER checklist with description of compliance and location of information in the GBD 2015 mortality and causes of death study

exposure, squamous-cell carcinoma, acute lymphoid
leukaemia, chronic lymphoid leukaemia, acute myeloid
leukaemia, and chronic myeloid leukaemia. Bulimia
nervosa has also been added as a cause of death. In
total, there are now three causes at Level 1, 21 at Level 2,
166 at Level 3, and 261 at Level 4. Some causes, such as
acne, medication overuse headache, and cutaneous
leishmaniasis, are not considered causes of death
according to the rules of the International Classiﬁcation
of Diseases (ICD), so the number of causes included in
this analysis of causes of death is three at Level 1, 21
at Level 2, 144 at Level 3, and 200 at Level 4. The
full GBD cause list, including those for which we
estimate deaths, is available in the methods appendix
(pp 684–90).

are closely linked and presented jointly in ﬁgure 1. We
divided the estimation eﬀort into ﬁve distinct
components: estimation of under-5 mortality rate (5q0);
estimation of the adult mortality rate (45q15); age-speciﬁc
mortality estimation; HIV/AIDS mortality estimation;
and addition of the eﬀects of events such as wars,
pandemics, and disasters, which can cause abrupt
discontinuities in death numbers (fatal discontinuities).
Because of the interdependencies in the estimation of
HIV/AIDS incidence, prevalence, and mortality and allcause mortality, the estimation steps shown in ﬁgure 1
were repeated, with the HIV/AIDS crude death rates
produced in step 4.7 used as covariates in steps 1.5, 1.11,
2.4, and 3.3 in the ﬂow diagram.

For the online repository see
http://ghdx.healthdata.org/
global-burden-diseasestudy-2015

Under-5 mortality estimation
Time periods
Because of the greater availability of data on all-cause
mortality than cause-speciﬁc mortality, the all-cause
mortality analysis for GBD 2015 covered 1970 to 2015.
The cause of death analysis of GBD 2015 covered 1980 to
2015. A complete set of age-speciﬁc, sex-speciﬁc, causespeciﬁc, and geography-speciﬁc death numbers and rates
were generated. We present results covering diﬀerent
periods. However, for the main global and national
results, we have focused on trends in the past decade,
from 2005 to 2015, and detailed ﬁndings in 2015. Data
visualisation tools are available online and provide results
for each year from 1990 to 2015.

All-cause mortality and HIV/AIDS mortality
Because of the very large and changing eﬀects of
HIV/AIDS on all-cause mortality in several countries
with large HIV epidemics and scarce data on all-cause
mortality, especially in eastern and southern Africa,11 the
estimation of HIV/AIDS mortality and all-cause mortality
www.thelancet.com Vol 388 October 8, 2016

Seven types of primary data contributed to the
estimation process (oval shapes in ﬁgure 1). The most
important set of inputs were the data for estimating the
overall level of under-5 mortality (5q0) that were
obtained from vital registration systems, surveys, and
censuses. Figure 3A provides information about the
proportion of the 519 geographies included in the
analysis for which data were available in each year from
1980 to 2015. Because of lags in reporting of both vital
registration data and the release of household survey or
census data, the availability of data was much lower for
2014 and 2015 than for previous years. Diﬀerent data
types, such as summary or complete birth histories,
were processed to yield estimates for each year of the
under-5 death rate; country-speciﬁc and year-speciﬁc
details of the measurements are provided in the
methods appendix (pp 4–19). Figure 3B shows the
nature of the data and estimation process for under-5
mortality using the example of Zambia, as well as the
uncorrected and bias-adjusted datapoints for each

For the online data
visualisation tools see
http://vizhub.healthdata.org/
gbd-compare
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Number of geographies
Geographical levels
Super-region
Regions

7
21

Nations and territories

195

Subnational level 1

480

Subnational level 2

519

Cause levels
Level 1
Total causes

3

YLD causes

3

YLL causes

3

Level 2
Total

21

YLD

21

YLL

21

Level 3
Total causes

166

YLD causes

161

YLL causes

144

Level 4
Total causes

261

YLD causes

256

YLL causes

200

Nations and territories includes countries, territories, and non-sovereign states.
Subnational level 1 includes countries that, in the GBD analysis, have been
subdivided into the ﬁrst subnational level such as states or provinces. Subnational
level 2 applies only to India and England. In India, states have been divided into
urban and rural units. England has been divided into nine regions. For each level,
the number of geographies includes the geographies at that level plus the number
of most-detailed geographies at each higher level such that at each level of the
hierarchy, all geographies create a collectively exhaustive and mutually exclusive
set covering the world. Likewise, the GBD cause list is mutually exclusive and
collectively exhaustive. The three Level 1 GBD causes consist of communicable,
maternal, neonatal, and nutritional disorders; non-communicable diseases; and
injuries. Level 2 causes consist of 21 cause groups, such as neoplasms and
cardiovascular diseases. Levels 3 and 4 consist of disaggregated causes, such as
liver cancer and cerebrovascular disease (Level 3), and liver cancer due to
hepatitis C and ischaemic stroke (Level 4). GBD=Global Burden of Disease.
YLD=years lived with disability. YLL=years of life lost.

Table 2: Number of geographies and causes at each hierarchical level for
GBD 2015

source. We used spatiotemporal Gaussian process
regression to synthesise the sources and simultaneously
correct for biases in speciﬁc source types.8 Bias
corrections were made by comparison to reference
sources, which for Zambia were the Demographic and
Health Surveys. Further details of this estimation
process are provided in the methods appendix (pp 4–19).
Because there are many sources for measuring under-5
mortality, such as summary birth histories from censuses
and surveys, that do not provide sex and speciﬁc age
group detail, we ﬁrst estimated under-5 mortality and
then split it into mortality for four age groups: early
neonatal (0–6 days), late neonatal (7–28 days), postneonatal (29–364 days), and ages 1–4 years. Splitting into
these age groups was based on a statistical model using
1466

the analysis of available data that provide breakdowns
by age and sex. Figure 3C shows the availability by
country–year of data used to build the model to estimate
mortality for speciﬁc age–sex groups younger than age
5 years. We modelled the ratio of male-to-female
probability of death from birth to age 5 years as a function
of both sexes’ combined under-5 mortality rate and
country and regional random eﬀects. We further
disaggregated sex-speciﬁc probability of death between
birth and age 5 by modelling the ratio between age-andsex-speciﬁc probability of deaths in the early neonatal,
late neonatal, post-neonatal, and 1–4 year age groups and
sex-speciﬁc probability of death between birth and age
5 years. This model allowed for the association between
these age-and-sex-speciﬁc probabilities and the under-5
death rate to be non-linear, and included other covariates
consisting of the death rate due to HIV/AIDS in children
younger than 5 years, average years of schooling among
females of reproductive age, and country and regional
random eﬀects. More details, including the equations are
provided in the methods appendix (p 18). Figure 3D
shows an example of the empirical ﬁt for the postneonatal period for Bangladesh. This model was applied
to all countries to generate the under-5 estimates for each
geography–year.
With the estimated mortality by detailed age group, we
generated both deaths and population estimates for the
respective age groups for each location, sex, and year.

Adult mortality estimation
Measurements of adult mortality (45q15) were mainly
derived from vital registration data and household surveys
that ask about the birth and death of siblings.25 In a
smaller set of cases, information was obtained from
censuses or surveys about household deaths in a deﬁned
interval before the interview. Figure 4A shows the number
of geographies for which data in each year were available
for adult mortality estimation. Vital registration data were
assessed for completeness with death distribution
methods optimised for performance.26,27 We generated a
best estimate of the completeness of vital registration in
each geography over time by combining estimated
completeness of registration for under-5 deaths with the
results for diﬀerent intercensal periods of the application
of three death distribution methods. These sources were
combined by use of spatiotemporal Gaussian process
regression—details are provided in the methods appendix
(p 21). Data from sibling histories were corrected for
known biases, including selection bias, zero reporter bias,
and recall bias.7,25 Our sibling history method can also
deal with data sparsity in many sibling survival modules
(ie, sibling history questions and variables from surveys).
The predictive validity of the sibling history analytical
methods has been assessed with simulated data and
shown to be unbiased.25 Additionally, we compared
estimates of adult mortality rates from sibling survival
data with completeness-adjusted vital registration data in
www.thelancet.com Vol 388 October 8, 2016
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Figure 3: Examples of under-5 mortality data availability and estimation
(A) Percentage of global under-5 population covered by under-5 mortality data for each year, 1980−2015. The percentage of under-5 population covered was calculated by dividing the population of
children aged 0–4 years in locations covered by available under-5 mortality data by the total global under-5 population. Because of lags in reporting of both vital registration data and the release of
household survey or census data, the availability of data was much lower for 2014 and 2015 than for previous years. (B) Country-speciﬁc example of data and under-5 mortality estimates in Zambia,
1980–2015. The black line shows Gaussian process regression ﬁt with 95% uncertainty interval shown in grey. Black circles denote reference data. Triangles denote complete birth history data. Inverted
triangles denote summary birth history data. Transparent symbols are the data post-adjustment for non-sampling error. Hollow shapes represent data identiﬁed as outliers. (C) Percentage of global
under-5 population covered by under-5 age-speciﬁc and sex-speciﬁc data for each year, 1980–2015. The percentage of under-5 population covered was calculated by dividing the population of children
aged 0–4 years in locations covered by available under-5 age-speciﬁc and sex-speciﬁc data by the total global under-5 population. Because of lags in reporting both vital registration data and the
release of household survey or census data, the availability of data was much lower for 2014 than for previous years, and no data existed for 2015. (D) Country-speciﬁc example of probability of female
post-neonatal mortality in Bangladesh, 1980–2015. Standard Demographic and Health Surveys generally include large population samples and standard sets of questions. Special Demographic and
Health Surveys can survey smaller, more targeted populations, such as women who have given birth. The black line shows probability of death, with 95% uncertainty interval shown in grey.
Solid circles represent data sources. Hollow circles represent outliers. The post-neonatal period is 28–364 days.

countries from which both sources are available and
found no systematic biases from sibling survival method
(methods appendix p 292).7,25,26 We synthesised vital
registration data corrected for completeness and adjusted
sibling history data into a best time series estimate of
adult 45q15 using spatiotemporal Gaussian process
regression. Examples of the application of these steps in
three types of settings are shown in ﬁgure 4.
The spatiotemporal Gaussian process regression
method used to ﬁt the model to the available data
included lag distributed income per capita, educational
attainment, and the estimated HIV/AIDS death rate as
covariates. Because the estimation of the HIV/AIDS
death rate used the estimate of HIV-free mortality rate by
age and sex as an input, the entire estimation loop was
www.thelancet.com Vol 388 October 8, 2016

repeated once, which dealt with this interconnection.
Step 2.9 in ﬁgure 1 deals with situations in which
an inconsistency exists between the spatiotemporal
Gaussian process regression-estimated adult mortality
rate and the separately estimated crude death rate due to
HIV/AIDS. When the HIV/AIDS death rate as estimated
from the natural history model is too high compared
with demographic sources, there is a risk that HIV-free
death rates are depressed to implausibly low levels. In
step 2.9, we scaled the HIV/AIDS crude death rate by
imposing a maximum proportion of deaths that can be
attributed to HIV/AIDS, as shown in our version of
UNAIDS’ Spectrum model, which estimates HIV/AIDS
prevalence and deaths by age and sex. Our adult mortality
estimation is for ages 15–60 years (45q15), but other adult
1467
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Figure 4: Examples of adult mortality data availability and estimation
(A) Percentage of global adult population covered by adult mortality data from vital registration systems, sibling survival surveys, sample registration systems, or censuses, 1980–2015.
The percentage of available data was calculated by dividing the population of adults aged 15–59 years in locations covered by available adult mortality data by the total global population aged
15–49 years. Because of lags in reporting both vital registration data and the release of household survey or census data, the availability of data was much lower for 2014 than for previous years,
and no data existed for 2015. Country-speciﬁc examples of (B) vital registration data and adult male mortality (45q15) estimation for a country with complete vital registration and large population
(USA), 1980–2015; (C) vital registration data and adult male mortality (45q15) estimation for a country with complete vital registration and small population (Iceland), 1980–2015; and (D) sibling
survival data and adult female mortality (45q15) estimation (Malawi), 1980–2015. Black line shows ﬁnal estimates of adult mortality among males or females in each country, with 95% uncertainty
interval shown in grey. Squares show sibling survival histories. 45q15=probability of death from age 15 years to 60 years.

age groups that can be calculated for other purposes
include 35q15 (ages 15–50 years, corresponding to the
reproductive age period), and 20q50 (ages 20–70 years).

Age-speciﬁc mortality
In demographic estimation, measures of child mortality,
adult mortality, or both are used alongside a model life
table system to predict age-speciﬁc mortality.27–30 The UN
mostly still uses the Coale-Demeny model life tables,
which were based on 192 empirical tables gathered
before 1963, and in a few cases they use the 33-year-old
UN Model Life Table for Developing Countries.31,32
Murray and colleagues33 developed the Modiﬁed Logit
Model Life Table system that is used by WHO to estimate
age-speciﬁc mortality, which captures a much wider
range of age patterns of mortality through the year 2000.
The GBD approach uses three inputs to generate agespeciﬁc mortality: 5q0, 45q15, and a relevant empirical
1468

reference pattern of mortality by age.7 The reference in
the GBD system was selected on the basis of empirical
age patterns that are closest to the population in space
and time.7 The reference was developed with a database
of 16 507 age patterns of mortality from settings that meet
explicit inclusion criteria as described in the methods
appendix (pp 34–42). Table 3 shows a summary of the
availability of empirical age–sex patterns of mortality in
the GBD database.
To account for the eﬀect of HIV/AIDS on the age
pattern of mortality, the GBD model life table system
for locations aﬀected by HIV/AIDS and without highquality vital registration data used a two-step process
whereby we ﬁrst estimated an HIV-free age pattern of
mortality assuming that deaths due to HIV/AIDS were
removed. This was accomplished by use of the HIVfree and without-fatal-discontinuity 5q0 and 45q15
estimates, crude death rates due to HIV/AIDS in age
www.thelancet.com Vol 388 October 8, 2016
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groups 0–4 and 15–59 years, and the methods detailed
in the methods appendix (p 44), which reconcile the
potential disconnect between HIV/AIDS mortality
implied in the spatiotemporal Gaussian process
regression estimates of all-cause mortality and those
estimated by the Estimation and Project Package (EPP)Spectrum. We then added the excess mortality due to
HIV/AIDS to speciﬁc age groups to match the withHIV/AIDS 5q0 and 45q15 by using the estimated age
pattern of excess mortality due to HIV/AIDS for
generalised and concentrated epidemics. These age
patterns of excess mortality were based on ICD-10coded vital registration data from various countries,
including high-income countries with good-quality vital
registration data and other middle-income nations that
are aﬀected by HIV/AIDS such as South Africa,
Thailand, and Trinidad and Tobago. A list of country–
years for which we obtained the empirical age pattern
of HIV/AIDS excess mortality rate is shown in the
methods appendix (p 313).
Figure 5 shows examples of the life table system
estimates of age-speciﬁc mortality compared with
observed patterns for males and females in France in
2011. There was a very close ﬁt between the estimated
age-speciﬁc mortality and the observed mortality.
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and Oceania
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Numbers show available empirical life tables in the GBD 2015 database. All life tables included in the database meet
quality inclusion criteria whereby the observed age-speciﬁc mortality rate in an empirical life table conforms to the age
pattern of mortality as described by the Gompertz–Makeham law of mortality and that observed in countries with
high-quality vital and civil registration systems. GBD=Global Burden of Disease.

Table 3: Distribution of empirical life tables by GBD super-region and decade, 1950–2015
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Because HIV/AIDS estimation is so closely connected
to all-cause mortality estimation, we discuss HIV/AIDS
estimation separately here rather than in the later
section about estimating other causes of death. We
divided geographies into two broad groups: countries
with larger epidemics and incomplete or non-existent
vital registration systems and the remaining
geographies. For the ﬁrst group of geographies for
which we had necessary information about the
transmission of HIV/AIDS among adults and children
and other programme information, we ﬁtted a modiﬁed
version of EPP-Spectrum11,34 to the data on prevalence
collated by UNAIDS from antenatal clinic serosurveillance and household surveys. EPP-Spectrum is a
natural history model of the HIV/AIDS epidemic that
has two distinct components. In the EPP component,
data on the prevalence of HIV are used to back-estimate
incidence of HIV. In the Spectrum component, the
estimated incidence and a set of assumptions are used
to estimate prevalence and deaths by age and sex. These
assumptions are informed by published or unpublished
cohort studies on the initial CD4 distribution of new
HIV infections, rates of decline in CD4 counts, death
rates on and oﬀ antiretroviral therapy (ART)
diﬀerentiated by age, sex, and CD4 count, and
prevention of mother-to-child transmission (PMTCT)
coverage data, as well as other demographic
assumptions, such as the HIV-free death rate. We have
modiﬁed EPP-Spectrum to enhance the internal
consistency between EPP and Spectrum and to more
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Figure 5: Age-speciﬁc mortality estimation with GBD life table method versus observed data excluded from
the model
Country-speciﬁc examples for (A) males and (B) females in France, 2011. The red line shows the GBD 2015 life table
system estimates of age-speciﬁc mortality rates from birth through age 75 years in log space, compared with observed
age-speciﬁc mortality (blue line). Year 2011 selected for illustration purposes. GBD=Global Burden of Disease.
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accurately reﬂect published cohort data on CD4
progression and death rates on and oﬀ ART.
At this point in the estimation process for the ﬁrst
group of geographies, we generated two estimates of
HIV/AIDS. One is informed by available data on all-cause
mortality and the statistically related association between
all-cause mortality and the HIV/AIDS crude death rate;
the other is the EPP-Spectrum natural history model. In
some locations, these estimates can be quite diﬀerent.
Given the inherent uncertainties in both methods, for
GBD 2015 we have adopted an ensemble model which is
the average of HIV/AIDS deaths for each age–sex–year
from the two approaches. Figure 6 shows the results of
this process using Zimbabwe as an example for incidence,
prevalence, and deaths from HIV/AIDS. For comparison,
we provide prevalence data from surveys and the UNAIDS
estimates from their 2014 round of estimation.35,36
For the second group of geographies, we estimated
mortality due to HIV/AIDS on the basis of vital
registration data if available. Estimates of incidence and
prevalence for HIV were based on calibrating Spectrum
to match the observed numbers of HIV/AIDS deaths after
accounting for under-registration of the vital registration
system. This calibration method is based on tracking
incidence cohorts through Spectrum and adjusting
incidence to ﬁt the observed deaths for that cohort in each
year in a speciﬁc age group (methods appendix p 44).
Using the methods discussed in the age-speciﬁc mortality
section, with-HIV/AIDS all-cause mortality was estimated
for these countries. Depending on the subgroup
categorisation within the second group of geographies
(methods appendix pp 44–45), we generated the
HIV/AIDS-speciﬁc mortality either by applying spatiotemporal Gaussian process regression to HIV/AIDS
cause-speciﬁc data from the vital registration system if
the quality of vital registration was deemed high
(methods appendix pp 21–26) or by using cohort incidence
bias-adjusted mortality estimates from Spectrum.

Fatal discontinuities
The ﬁfth stage of estimation (ﬁgure 1) re-estimates
all-cause mortality by incorporating the eﬀects of
HIV/AIDS and fatal discontinuities. To incorporate
fatal discontinuities from natural disasters (eg, the 2011
Japan earthquake and tsunami), wars, pandemics,
wildﬁres (eg, the Australian bushﬁres in 2009), or
major transportation accidents (eg, the Al Ayyat train
accident in Egypt in 2002), we used death counts
reported in a wide range of international databases
such as the International Disaster Database, the
Uppsala Conﬂict Data Program, the International
Institute for Strategic Studies Armed Conﬂict
Databases, the Robert S Strauss Center, and various
internet sources for more recent events such as the
ongoing Syrian and Yemeni conﬂicts (databases are
listed in the methods appendix [p 270], and additional
sources are downloadable from the online source
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tool).37–40 When multiple sources for the same fatal
discontinuity event exist, we prioritised data from vital
registration systems if it had the highest estimate, and
gave least priority to data from internet searches. We
constructed uncertainty on the basis of high and low
estimates when available. We generated regional and
cause-speciﬁc uncertainty intervals in relative terms
and applied them to fatal discontinuities when only the
mean estimate was provided by a speciﬁc source. The
fatal discontinuity section of the methods appendix
(pp 270–73) provides more detail on how we assigned
fatal discontinuity deaths to diﬀerent GBD causes as
appropriate and how we applied a cause-speciﬁc age–
sex splitting model to arrive at age-and-sex-speciﬁc
deaths due to speciﬁc fatal discontinuity events.
Given that all-cause mortality analysis requires estimates
of crude death rates from HIV/AIDS as initial inputs and
that the ensemble model changes the HIV/AIDS-speciﬁc
and with-HIV/AIDS age-speciﬁc mortality rates, the allcause mortality and HIV/AIDS estimation processes were
performed twice. Crude death rates due to HIV/AIDS and
under-5 population estimates were generated in the ﬁrst
run of the processes and propagated the second run of the
processes to make the HIV/AIDS-speciﬁc and all-cause
mortality processes more consistent.

Causes of death estimation
The GBD cause list relies on categorical attribution of
deaths to a single underlying cause in accordance with
the principles outlined in the ICD. The core principle of
the ICD is to assign each death to only the underlying
cause of death; ie, the cause that initiated the series of
events leading to death. We used the ICD principle of
underlying cause of death for the primary tabulations in
this Article. Data from vital registration sources, verbal
autopsy studies, and other sources all adhere to the same
principle that one death can only have one cause. The
categorical attribution of causes of death diﬀers from a
counterfactual approach, which answers the question “in
the absence of the disease of interest how many deaths
would not have occurred?”, similar to how we estimate
burden due to risk factors in GBD. The categorical
attribution of causes of death also diﬀers from excess
mortality in people with a disease followed up over time
in a cohort study or through linkage of a disease registry
to vital registration data. The excess mortality in such
studies might contain deaths that are assigned as the
underlying cause, those that are causally related to the
disease, and those that are due to confounding, such as
by a common underlying risk that predisposes to the
disease but where there are also additional pathways
to death. These counterfactual and excess mortality
relationships are important and need to be quantiﬁed by
considering the underlying risk, such as elevated fasting
plasma glucose.
Figure 2 shows the steps in the estimation of causes of
death, which are divided into seven categories: cause of
www.thelancet.com Vol 388 October 8, 2016
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Figure 6: Comparisons of GBD 2015 estimates and UNAIDS 2014 estimates for Zimbabwe
Country-speciﬁc example comparing estimates of deaths due to HIV/AIDS (A), new HIV infections (B), and people living with HIV/AIDS (C) in Zimbabwe from
GBD 2015 and UNAIDS 2014. Curves show the estimation process of a particular country and highlight the diﬀerences in results from the GBD and UNAIDS analysis of
the same prevalence data. Numbers are reported in thousands. Uncertainty intervals are shown in red and blue shading. GBD=Global Burden of Disease.
UNAIDS=The Joint United Nations Programme on HIV and AIDS.

death database development (ﬁgure 2A), Cause of Death
Ensemble modelling (CODEm), negative binomial
models for rare causes, natural history models, subcause
proportion models, prevalence-based models, and
CodCorrect (ﬁgure 2B). For each component, we discuss
the steps, with more extensive detail provided in the
methods appendix (pp 52–283). Details about the
modelling of HIV/AIDS and fatal discontinuities are
www.thelancet.com Vol 388 October 8, 2016

also described in detail in the methods appendix
(pp 255–64, 270–73).

Cause of death database development
Figure 2A shows the detailed steps from data inputs and
processing to the ﬁnalisation of the cause of death
database. The methods appendix (pp 52–70) includes
details on each step. Cause of death data collected
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through vital registration systems are available from
governments and coded to diﬀerent variants of the ICD
including various national ICD variants. Multiple sources
were used in addition to vital registration data, including
verbal autopsy data, cancer registries, maternal mortality
surveillance, census and survey data on maternal death,
census and survey data on selected injuries, and police
records for some injuries. Figure 2A shows how each
type of data were processed to deal with the challenges of
diﬀerent coding schemes, diﬀerent age group reporting,
variation in certiﬁcation, misclassiﬁcation of HIV/AIDS
deaths, misclassiﬁcation of maternal HIV/AIDS deaths,
and incorporation of population-based cancer registry
data. The ﬁrst and second steps in the cause of death
database development were standardisation of multiple
data formats to a single GBD standard, then the mapping
of each ICD or verbal autopsy variant to the GBD cause
map. Figure 7A shows the number of deaths captured for
each year in the GBD causes of death database by coding
version. In step 3, we split a small subset of data reported
in non-GBD-standard age formats into GBD age
categories using the global relative age pattern of
mortality for each cause as estimated from the pooled
data that provide full age detail. In step 4, based on expert
judgment, some causes were not allowed for certain age–
sex groups, for example, male uterine cancer.
In step 5, deaths assigned to causes that cannot be
underlying causes of death (ie, garbage coded) were
reassigned to their likely underlying cause of death.4,7
These redistribution algorithms are based on three
approaches. For some garbage codes, such as senility or
old age, deaths were proportionately reassigned to all
causes that are not garbage codes for a country–age–sex–
year. For HIV/AIDS in many countries, deaths from
HIV/AIDS have been misclassiﬁed as opportunistic
infections, tuberculosis, cancer, digestive diseases, and
immune deﬁciencies. In step 6, using methods developed
by Birnbaum and colleagues,41 these deaths were
identiﬁed and reclassiﬁed as HIV/AIDS in select
countries with evidence of misclassiﬁcation. In step 7,
data from the China Center for Disease Control
and Prevention (CDC) vital registration system were

re-weighted to take into account potential selection bias
caused by a larger fraction of deaths being captured in
hospital than out of hospital in some locations.14 Step 8
ensured that the process of redistributing garbage codes
or identifying misclassiﬁed HIV/AIDS deaths would not
assign deaths to causes in an age–sex–country–year that
violated age–sex or other restrictions.
Step 9 excluded vital registration sources that were less
than 50% complete in a given geography from the
database, because of the potential for selection bias in
highly incomplete sources. Sources estimated to be
50–70% complete were identiﬁed as non-representative,
which was information that we used in the building of
the cause of death statistical model to increase the
estimated data variance for these datapoints. All included
sources were corrected to be 100% complete by
multiplying the cause fraction in a source for a country–
age–sex–year by the estimate of all-cause mortality for
that country–age–sex–year. Step 10 aggregated causes of
death from most to least detailed levels of the GBD
hierarchy, ensuring deaths for a given cause were
representative of all branches of the hierarchy that fall
beneath it. In step 11, deaths due to HIV/AIDS and
various types of fatal discontinuities were removed before
cause fractions were computed. Because of the very large
eﬀects of fatal discontinuities, such as wars and natural
disasters in some cases, and the impact of HIV/AIDS in
countries with large epidemics, we converted cause
fractions to be cause fractions excluding HIV/AIDS and
fatal discontinuities in the denominator. Deaths from
HIV/AIDS and the fatal discontinuities were added back
during the ﬁnal stages of the modelling process. Because
many sources on maternal mortality identify deaths
during pregnancy and the post-partum period and not
maternal deaths, the separation of HIV/AIDS deaths
during pregnancy and HIV/AIDS deaths aggravated by
pregnancy was more complicated (methods appendix p 66).
Figure 7B provides information about the fraction of
the 519 geographies in the analysis for which cause of
death data were available in each year from 1980 to 2015
for any cause, including maternal death and injuries.
Data availability by geography–year by cause is shown in

Figure 7: Availability and quality of cause of death data in the GBD 2015 database
(A) Total deaths with a WHO-standard death certiﬁcate available in the GBD 2015 cause of death database classiﬁed by the variant of the International Classiﬁcation of
Diseases used for reporting. Cause of death data have been reported in national variants of ICD-8, ICD-9, and ICD-10 during the interval 1980–2015. Because of lags in
reporting of both vital registration data and the release of household survey or census data, the availability of data was much lower for 2014 than for previous years and
no data existed for 2015. (B) Percentage of global population covered by cause-speciﬁc data in the cause of death database for GBD 2015, 1980–2015; the percentage
of available data was calculated by dividing the population of locations covered by available cause-speciﬁc data by the total global population. This ﬁgure is computed
using vital registration, verbal autopsy, maternal, cancer, and injury sources. (C) Overall classiﬁcation of each GBD subnational level 1 geography by availability and
quality of cause of death data for the period 1980 to 2015. Countries have been assigned on the basis of the available time series of data into one of six categories. The
ﬁgure uses GBD subnational level 1 geographies because subnational level 2 cannot be easily seen on a map. Extensive complete representative vital registration was
deﬁned as 25 total years or more of vital registration data with an estimated 95% completeness or above. All geographies that do not meet the threshold for extensive
complete representative vital registration are classiﬁed as one of the following: limited years of complete representative vital registration, deﬁned as 5 years or more of
vital registration data with an estimated 95% completeness or above; incomplete representative vital registration, deﬁned as at least 1 year of vital registration data
with an estimated 70% completeness or above; more than 200 cause-years VA or non-representative VR, deﬁned as more than 200 cause-years of verbal autopsy or at
least 1 year of vital registration with an estimated 50% completeness or above; less than 200 cause-years of VA; or no data. Cause-years are deﬁned as the number of
years for each cause for which data are available. GBD=Global Burden of Disease. ICD=International Classiﬁcation of Diseases. BTL=basic tabulation list. VA=verbal
autopsy. VR=vital registration. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia. TTO=Trinidad and Tobago. TLS=Timor-Leste.
FSM=Federated States of Micronesia.
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the methods appendix (pp 318–401). To facilitate
understanding of the range of quality and availability of
data for each geography, we classiﬁed geographies into
six categories: extensive complete representative vital
registration (vital registration data that are 95% complete
and cover more than 25 years); moderate data (vital
registration data that are 95% complete but cover fewer
than 25 years); incomplete representative vital registration
(all other geographies with some representative vital
registration data); extensive verbal autopsy and other
sources (covering more than 20% of cause-years); limited
verbal autopsy or other data (all others with some data
available); and no data for any cause (methods appendix
pp 691–710). Figure 7C shows this designation for each
class of country.

CODEm
Figure 2B shows the analytical ﬂow chart for modelling
diﬀerent causes of death and combining them into
internally consistent estimates of cause-speciﬁc mortality
that sum to all-cause mortality with uncertainty levels.
167 individual causes of death were modelled using
CODEm. Developed for GBD 2010,5 CODEm tests a large
number of model speciﬁcations, comparing diﬀerent
functional forms and permutations of relevant covariates
for each cause of death. Models that met requirements for
direction and signiﬁcance of the regression coeﬃcients
were then evaluated for out-of-sample predictive validity
through multiple iterations of cross-validation testing. We
then combined these models into an ensemble, weighting
them such that top performing models (in terms of outof-sample prediction error on levels and trends)
contributed the most to the ﬁnal prediction. Out-of-sample
predictive validity testing was also used to select the psi
parameter that determines the number of models and
their weight in the ﬁnal ensemble (ﬁgure 8).
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Negative binomial models
For ten causes of death, the number of events are so low,
including many zero counts in countries with high
income per capita or high educational attainment, that
CODEm out-of-sample predictive validity testing was
unstable. For these rare causes of death, which included
other intestinal infectious diseases, upper respiratory
infections, diphtheria, varicella and herpes zoster,
malaria, schistosomiasis, cysticercosis, cystic echinococcosis, ascariasis, and iodine deﬁciency, we used
negative binomial regression to develop simple models to
predict deaths. More details are available in the methods
appendix (pp 185–200; negative binomial models).

Natural history models
For some causes, deaths are rarely recorded in either vital
registration data or verbal autopsy data. Partly, this is
because of the geographical location of the deaths or
because of the potential for systematic bias in vital
registration data or verbal autopsy data. For 14 causes, we
have developed natural history models in which
incidence and case-fatality rates are modelled separately
and combined to yield estimates of cause-speciﬁc
mortality. We developed natural history models for
typhoid fever, paratyphoid fever, whooping cough,
measles, visceral leishmaniasis, African trypanosomiasis,
yellow fever, syphilis (congenital), and acute hepatitis A,
B, C, and E. Additionally, for malaria in sub-Saharan
Africa, we have used a natural history model based on
the incidence estimated by the Malaria Atlas Project and
age–sex-speciﬁc case-fatality rates estimated from
available data. Further details on the development of
these natural history models are available in the methods
appendix (pp 201–26; natural history models).
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Figure 8: Distribution of out-of-sample model performance for CODEm models used for GBD 2015
Model performance was assessed by use of the root mean square error of the ensemble model predictions of the log of
the age-speciﬁc death rates for a cause assessed with 15% of the data held out from the statistical model building.
The ﬁgure shows the distribution of root mean square error across the set all models for all causes. Model performance
varies substantially across causes. GBD=Global Burden of Disease. CODEm=cause of death ensemble modelling.

1474

For each cause of death, we ran independent CODEm
models by sex and for countries with extensive complete
vital registration representation and all other countries.
We included all datapoints for the other categories of
geographies, whereas for countries with extensive
complete vital registration representation, we included
only datapoints from those countries, so that
heterogeneous data from other countries did not inﬂate
the uncertainty interval.

For meningitis, maternal disorders, liver cancer, cirrhosis,
and chronic kidney disease, we estimated detailed causes
for each of these cause groupings by modelling the
proportion of the cause grouping (parent cause) due to
each of the component causes. We used this approach
because the available data on the speciﬁc causes can come
from sources other than vital registration, such as endstage renal disease registries, or from too few places to
model the death rates directly. For these causes, the
parent cause was ﬁrst estimated with CODEm and the
fraction of the parent due to each component cause for
www.thelancet.com Vol 388 October 8, 2016

Articles

each age–sex–geography–year was generally estimated
with DisMod-MR 2.1, a Bayesian meta-regression method
developed for the GBD studies.42,43 Details for each cluster
of causes analysed in this way are shown in the methods
appendix (pp 233–52; subcause proportion models).

Prevalence-based models
For Alzheimer’s disease and other dementias and atrial
ﬁbrillation and ﬂutter, there is evidence of marked
changes over time in the propensity of individuals who
completed death certiﬁcates to list these causes as
underlying causes of death.44,45 These changes created
increases in the reported death rates. Conversely,
prevalence surveys do not show a matching increase
in age-speciﬁc disease prevalence. Garbage code
redistribution algorithms used in the development of the
cause of death database have so far not accurately
captured this shift over time in the certiﬁcation of
underlying causes of death. For these two causes, we
based our estimates on prevalence surveys and estimates
of excess mortality based on deaths certiﬁed in countries
with the greatest proportion of deaths allocated to the
correct underlying cause of death in recent years. In both
cases, more detail is available in the methods appendix
(pp 227–32; prevalence-based models). We developed
models for prevalence and excess mortality using
DisMod-MR 2.1.

CodCorrect
Depending on the speciﬁc data availability and details of
individual causes, we adopted diﬀerent modelling
strategies for each cause. We generated a set of underlying
cause of death estimates, with uncertainty intervals, that
equalled all-cause mortality, with uncertainty intervals,
for each age–sex–year–geography and cause and all-cause
mortality at the individual draw level.24 In CodCorrect, for
each draw from the posterior distribution of each cause,
the sum of cause-speciﬁc estimates is rescaled to equal
the draw from the all-cause distribution (methods
appendix p 285).

Pathogen counterfactual analysis
We used a counterfactual analysis approach to estimate
aetiology-speciﬁc population attributable fraction for
mortality due to lower respiratory infections and
diarrhoeal diseases. This approach involved analysing
changes in mortality on the basis of the estimated
prevalence of each pathogen and relative risk of
developing disease given pathogen exposure.
The prevalence of each pathogen in diarrhoeal cases
was extracted from a systematic literature review and
modelled with DisMod-MR 2.1. The odds ratios of an
episode of diarrhoea given exposure to the pathogen
were estimated from a reanalysis of the Global Enteric
Multicentre Study (GEMS) that used the TaqMan Array
Card (TAC), which is based on a quantitative polymerase
chain reaction diagnostic (qPCR).46,47 We attributed
www.thelancet.com Vol 388 October 8, 2016

mortality to all pathogens, even if the odds ratio was not
signiﬁcant in all age groups. We corrected the estimated
prevalence for each pathogen on the basis of conventional
laboratory techniques, such as bacterial culture or
enzyme-linked immunosorbent assay (ELISA), to be
consistent with the new qPCR method. Cholera mortality
was estimated by modelling the under-reporting to the
WHO cholera case notiﬁcation system and applying this
correction factor to estimate the number of cholera cases
and deaths (methods appendix p 281). The incidence and
mortality of Clostridium diﬃcile was modelled with
natural history and incidence data in DisMod-MR 2.1.
We estimated attributable mortality due to respiratory
syncytial virus and inﬂuenza with a similar approach to
that for diarrhoea. We used a counterfactual approach
whereby the prevalence in patients with lower respiratory
infection was extracted from a systematic literature review
and modelled with DisMod-MR 2.1. The odds ratios of
lower respiratory infections given pathogen presence were
obtained from a meta-analysis by Shi and colleagues.48 We
adjusted the population attributable fraction for lower
respiratory infection mortality due to respiratory
syncytial virus and inﬂuenza for the relative case-fatality
rate of viral to bacterial pneumonia episodes by age.
Haemophilus inﬂuenzae type b and pneumococcal
pneumonia (Streptococcus pneumonia) were estimated
with a vaccine probe approach whereby the attributable
fraction was calculated as the ratio of vaccine eﬃcacy
against non-speciﬁc pneumonia to vaccine eﬃcacy against
pathogen-speciﬁc and serotype-speciﬁc pneumonia.
Studies that report vaccine eﬃcacy against vaccine-type
invasive pneumococcal disease were adjusted for the
relative eﬃcacy against vaccine-type clinical pneumococcal
pneumonia using a uniform distribution of uncertainty
around this ratio.49,50

Socio-demographic Index and epidemiological
transition analysis
In this Article, we built on GBD 201351 concepts by
improving the interpretability of sociodemographic status
and characterising and describing this relationship in
more detail for years of life lost due to premature mortality
(YLLs), as well as highlighting changes in age-standardised
death rates, population age structure, and YLL rates. We
have made two important changes to the GBD 2013
computation. First, we have used only lag-dependent
income per capita, average educational attainment in the
population over age 15 years, and the total fertility rate. We
excluded the mean age of the population because it is
directly aﬀected by death rates. Second, we have applied
the methods used to compute the Human Development
Index to generate an interpretable scale, resulting in
the Socio-demographic Index (SDI).52 The Human
Development Index method weights each component
equally and rescales each component on a zero-to-one
scale with zero being the lowest value observed in the time
period 1980 to 2015 and 1 being the highest value observed.
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The ﬁnal composite SDI value is the geometric mean of
each of the components. The SDI ranges from 0·060 in
Mozambique in 1987 to 0·978 in Washington, DC, USA,
in 2015. The correlation of the SDI with the sociodemographic status principal component analysis used in
GBD 2013 was 0·982. The very high correlation is because
the principal component analysis yields weights that are
nearly equal across components. The advantage of the
index is that 1 can be interpreted as the level of SDI at
which a geography has the highest observed log income
per capita and educational attainment and lowest fertility
rate. We tested whether alternative lags of the components
of SDI would provide a better predictor of outcomes such
as life expectancy and age-speciﬁc probabilities of death.
Using lag distributed income per capita, educational
attainment, and the total fertility rate in the current year
was the most predictive of these mortality outcomes
(methods appendix p 286).
To report on aggregate results, we divided geographies
into SDI quintiles in 2015. Quintile cutoﬀs were based
on the entire distribution of geography–years from 1980
to 2015, excluding populations smaller than 1 million.
Figure 9 shows a map of the SDI level in 2015 categorised
into ﬁve groups including subnational geographies.
Because SDI includes educational attainment and the
total fertility rate, some countries which have very high
income, such as Saudi Arabia, are classiﬁed in the second
quintile of SDI because of lower educational attainment
and higher fertility rates.53
To capture the average relationships for each age–
sex–cause group, we used spline regression of death
rates on SDI (methods appendix pp 285–86). To ensure
a coherent set of estimated death rates for Levels 1, 2,
and 3 in the GBD cause hierarchy for each level of SDI,
the Level 2 death rates were rescaled such that for each
age–sex–cause bin, the sum of Level 2 death rates
equalled the Level 1 death rate. This procedure was
repeated for Level 3 and Level 2 causes. These rates
were used as the expected death rates by age–sex–cause
and SDI. Various summary measures have been
computed on the basis of the age–sex–cause-speciﬁc
predictions based on SDI, including age-standardised
death rates, age-standardised YLL rates, and life
expectancy at birth.
To further characterise how patterns of crude death rates
and death numbers change with SDI, we have computed
the average population age structure associated with each
SDI level. These population age structures have then been
used to estimate how crude death rates and death numbers
by cause are expected to change with rising SDI.

Decomposition of changes in global deaths
To analyse the drivers of change in the numbers of deaths
by cause or geography, we decomposed change from
2005 to 2015 into three explanatory components: change
due to growth of the total population; change in the
population structure by age or sex; and change in
1476

age-speciﬁc, sex-speciﬁc, and cause-speciﬁc rates. We
refer to all changes in age-speciﬁc, sex-speciﬁc, and
cause-speciﬁc death rates not explained by demographic
change (population growth and ageing) as the
epidemiological change. The observed change in the total
number of deaths equals the net change of these three
components.
Decomposition analyses for 1980 to 2015 and 2000 to
2015 are shown in the results appendix (pp 6–7). The
decomposition analysis uses methods developed in
demographic research by Das Gupta.54 As an example, we
describe our approach to decomposition for the 2005 to
2015 period. We used counterfactual scenarios to
calculate two diﬀerent sets of numbers for death. In the
ﬁrst scenario, for population growth, the number of
deaths in 2015 was the number expected if the total
population increased from 2005 as observed, but the
age–sex-speciﬁc population structure and rates of death
were the same in 2015 as in 2005. In the second scenario,
for population growth and ageing, the number of deaths
in 2015 was the number expected according to the 2015
age–sex-speciﬁc population structure, but with the
age–sex-speciﬁc rates of death held constant to 2005. The
diﬀerence between the number of deaths observed in
2005 and those estimated for 2015 with the population
growth scenario is the change in the number of deaths
exclusively from population growth. The diﬀerence
between the scenario for population growth alone and
the scenario for population growth and ageing is the
change in the number of deaths exclusively attributable
to population ageing.

Attribution of changes in life expectancy to changes in
causes of death
When considering the estimated levels and changes in
all-cause and cause-speciﬁc mortality rates for each
geographical area covered by GBD 2015, it is important
to understand the relative contribution of changes in
mortality due to each cause to the overall changes in life
expectancy at birth during the same period. To examine
the changes in life expectancy at birth between 2005 and
2015, we have applied the state-of-the-art life expectancy
cause-speciﬁc decomposition method developed by
Beltran-Sanchez, Preston, and Canudas-Romo.55

YLL computation
We computed YLLs using the standard GBD methods
whereby each death is multiplied by the normative
standard life expectancy at each age. The normative
standard life expectancy at birth is 86·59 years, which is
based on the lowest observed death rates for each 5-year
age group in populations larger than 5 million. For
GBD 2015, we computed age-standardised mortality
rates and YLL rates from the updated world population
age standard developed for GBD 2013.7 Details of the
GBD world population age standard are available in the
methods appendix (pp 286–287 and 314).
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Figure 9: SDI quintiles by GBD subnational level 1 geography, 2015
SDI is calculated for each geography as a function of lag-dependent income per capita, average educational attainment in the population older than age 15 years, and the total fertility rate. SDI units
are interpretable; a zero represents the lowest level of income per capita and educational attainment and highest total fertility rate observed during 1980–2015, whereas a one represents the highest
income per capita and educational attainment and lowest total fertility rate observed in the same period. Cutoﬀs on the SDI scale for the quintiles have been selected on the basis of examination of the
entire distribution of geographies 1980–2015. GBD=Global Burden of Disease. SDI=Socio-demographic Index. ATG=Antigua and Barbuda. VCT=Saint Vincent and the Grenadines. LCA=Saint Lucia.
TTO=Trinidad and Tobago. TLS=Timor-Leste. FSM=Federated States of Micronesia.

Uncertainty analysis
To account for uncertainties that arise from sample sizes
of data, adjustments to sources of all-cause mortality,
model speciﬁcations in spatiotemporal Gaussian process
regression and model life table systems, and causespeciﬁc model speciﬁcations and estimation, we have
estimated uncertainty intervals in key steps of the allcause mortality and cause-speciﬁc mortality estimation
processes. We have produced 1000 draws of all mortality
metrics, including under-5 mortality rate, adult mortality
rate, age-speciﬁc mortality rate and envelope, and
cause-speciﬁc mortality rates and death numbers for
each location by sex for all years covered by each
analytical step from the posterior distribution in the
estimation process. This allowed the quantiﬁcation and
propagation of uncertainty into the ﬁnal quantities of
interest. Because of computational time limitations, we
have not propagated uncertainty in covariates used in
cause of death models, nor have we been able to
propagate uncertainty in garbage code redistribution
algorithms into the ﬁnal results. Our tests on the
estimation of under-5 mortality rates show that the
incorporation of uncertainty for included ﬁrst stage
www.thelancet.com Vol 388 October 8, 2016

model covariates such as crude death rate due to
HIV/AIDS does not have a signiﬁcant impact on the
ﬁnal estimates (data not shown).

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. All authors had full access to the data in the
study and had ﬁnal responsibility for the decision to
submit for publication.

Results
Global life expectancy and mortality
Global life expectancy at birth increased by 10·2 years,
rising from 61·7 years (95% uncertainty interval [UI]
61·4–61·9) in 1980 to 71·8 years (71·5–72·2) in 2015
(table 4), equating to an average gain of 0·29 years per
year. By 2015, male life expectancy had risen by 9·4 years,
increasing from 59·6 years (59·3–60·0) in 1980 to
69·0 years (68·6–69·4), whereas female life expectancy
improved by 11·1 years, climbing from 63·7 years
(63·3–64·1) to 74·8 years (74·4–75·2). On average, an
additional 0·27 and 0·32 years of life were gained per
1477

Articles

Life expectancy at birth
(years)

Life expectancy at age 50
(years)

Age-standardised death rate
(per 100 000)

Age-standardised YLL rate
(per 100)

Total deaths (millions)

Male

Female

Male

Female

Male

Female

Male

Female

Male

Female

Both sexes

1980

59·6
(59·3–60·0)

63·7
(63·3–64·1)

23·1
(22·9–23·2)

26·4
(26·2–26·7)

1536·1
(1513·0–1558·5)

1194·6
(1172·4–1217·9)

49·8
(49·0–50·5)

40·8
(40·1–41·6)

23·5
(23·2–23·9)

21·6
(21·2–22·0)

45·2
(44·6–45·7)

1981

59·9
(59·6–60·2)

64·1
(63·7–64·4)

23·1
(22·9–23·3)

26·5
(26·3–26·8)

1525·0
(1502·7–1547·1)

1177·5
(1155·9–1199·6)

49·1
(48·4–49·8)

40·0
(39·3–40·7)

23·7
(23·4–24·1)

21·7
(21·3–22·1)

45·5
(44·9–46·0)

1982

60·3
(59·9–60·6)

64·5
(64·1–64·9)

23·2
(23·0–23·4)

26·7
(26·5–26·9)

1499·7
(1478·4–1521·2)

1155·8
(1134·3–1177·4)

48·1
(47·4–48·7)

39·1
(38·4–39·7)

23·8
(23·5–24·1)

21·7
(21·3–22·1)

45·5
(45·0–46·1)

1983

60·5
(60·1–60·9)

64·7
(64·3–65·2)

23·3
(23·1–23·5)

26·7
(26·5–26·9)

1486·1
(1463·7–1507·7)

1146·6
(1125·7–1167·7)

47·4
(46·7–48·2)

38·5
(37·8–39·2)

24·0
(23·6–24·4)

22·0
(21·6–22·4)

46·0
(45·5–46·6)

1984

60·8
(60·4–61·2)

65·1
(64·6–65·5)

23·4
(23·2–23·5)

26·8
(26·6–27·0)

1472·0
(1451·3–1493·7)

1132·5
(1112·4–1153·3)

46·7
(46·0–47·5)

37·7
(37·0–38·4)

24·2
(23·9–24·6)

22·1
(21·8–22·5)

46·4
(45·8–47·0)

1985

61·2
(60·9–61·6)

65·5
(65·1–65·9)

23·4
(23·3–23·6)

26·9
(26·7–27·1)

1453·9
(1434·0–1474·9)

1116·4
(1097·3–1135·7)

45·6
(45·0–46·3)

36·8
(36·2–37·4)

24·3
(24·0–24·7)

22·2
(21·9–22·6)

46·6
(46·0–47·1)

1986

61·7
(61·3–62·0)

66·0
(65·6–66·4)

23·6
(23·4–23·8)

27·1
(26·9–27·3)

1428·4
(1409·1–1450·0)

1091·5
(1073·4–1111·2)

44·5
(43·9–45·2)

35·7
(35·2–36·3)

24·3
(24·0–24·7)

22·1
(21·8–22·5)

46·5
(45·9–47·0)

1987

62·0
(61·6–62·3)

66·3
(65·9–66·7)

23·7
(23·5–23·9)

27·2
(27·0–27·4)

1411·7
(1392·5–1432·2)

1077·6
(1059·9–1097·0)

43·8
(43·2–44·4)

35·0
(34·5–35·6)

24·5
(24·1–24·8)

22·3
(21·9–22·6)

46·7
(46·2–47·3)

1988

62·1
(61·7–62·4)

66·5
(66·2–66·9)

23·7
(23·5–23·8)

27·2
(27·0–27·4)

1409·9
(1389·3–1430·2)

1068·2
(1051·0–1087·0)

43·5
(42·8–44·1)

34·5
(34·0–35·0)

24·9
(24·5–25·2)

22·5
(22·1–22·9)

47·3
(46·8–47·9)

1989

62·4
(62·0–62·7)

66·9
(66·5–67·2)

23·6
(23·5–23·8)

27·3
(27·1–27·5)

1401·9
(1380·9–1422·3)

1055·5
(1039·0–1073·2)

42·8
(42·2–43·4)

33·8
(33·3–34·3)

25·1
(24·7–25·4)

22·6
(22·3–23·0)

47·7
(47·2–48·2)

1990

62·5
(62·2–62·8)

67·1
(66·7–67·4)

23·7
(23·5–23·9)

27·4
(27·2–27·6)

1381·1
(1359·0–1401·6)

1035·1
(1019·1–1052·0)

42·4
(41·8–43·0)

33·2
(32·8–33·7)

25·3
(24·9–25·7)

22·6
(22·3–23·0)

47·9
(47·4–48·5)

1991

62·6
(62·3–62·9)

67·3
(66·9–67·6)

23·8
(23·6–24·0)

27·5
(27·3–27·7)

1371·9
(1349·3–1393·1)

1025·1
(1010·2–1041·2)

42·1
(41·4–42·7)

32·8
(32·4–33·3)

25·6
(25·2–26·0)

22·7
(22·4–23·1)

48·3
(47·8–48·8)

1992

62·8
(62·5–63·1)

67·5
(67·2–67·8)

23·8
(23·7–24·0)

27·6
(27·4–27·7)

1363·9
(1342·2–1384·4)

1016·1
(1001·2–1032·0)

41·6
(41·0–42·2)

32·3
(31·9–32·8)

25·8
(25·4–26·2)

22·9
(22·5–23·2)

48·7
(48·2–49·2)

1993

62·8
(62·5–63·1)

67·6
(67·3–67·9)

23·8
(23·6–24·0)

27·5
(27·3–27·7)

1367·1
(1347·1–1386·3)

1016·0
(1001·6–1031·0)

41·5
(40·9–42·1)

32·0
(31·6–32·5)

26·3
(25·9–26·6)

23·2
(22·8–23·5)

49·4
(48·9–49·9)

1994

62·6
(62·2–63·0)

67·7
(67·4–68·0)

23·8
(23·6–24·0)

27·6
(27·4–27·7)

1375·7
(1353·5–1399·0)

1014·1
(999·2–1029·5)

42·0
(41·2–43·0)

31·9
(31·5–32·4)

27·0
(26·5–27·5)

23·5
(23·2–23·8)

50·5
(49·9–51·2)

1995

63·1
(62·8–63·4)

68·0
(67·7–68·3)

23·9
(23·8–24·1)

27·7
(27·5–27·8)

1351·0
(1333·4–1368·4)

1000·7
(987·4–1014·9)

40·9
(40·4–41·4)

31·3
(30·9–31·7)

26·8
(26·5–27·2)

23·5
(23·2–23·9)

50·4
(49·9–50·9)

1996

63·4
(63·1–63·6)

68·3
(68·0–68·5)

24·1
(24·0–24·3)

27·9
(27·7–28·0)

1330·2
(1314·1–1347·0)

986·6
(974·0–999·9)

40·2
(39·7–40·7)

30·8
(30·5–31·2)

26·9
(26·6–27·2)

23·6
(23·3–23·9)

50·4
(50·0–50·9)

1997

63·7
(63·4–63·9)

68·5
(68·3–68·8)

24·3
(24·2–24·4)

28·0
(27·9–28·1)

1312·0
(1296·7–1327·7)

975·1
(962·9–986·9)

39·6
(39·1–40·0)

30·4
(30·0–30·7)

27·0
(26·6–27·3)

23·6
(23·3–23·9)

50·6
(50·1–51·1)

1998

63·9
(63·6–64·1)

68·8
(68·5–69·0)

24·4
(24·3–24·5)

28·1
(28·0–28·2)

1301·7
(1286·8–1316·9)

966·6
(954·7–978·8)

39·1
(38·7–39·5)

29·9
(29·6–30·3)

27·2
(26·8–27·5)

23·8
(23·5–24·1)

50·9
(50·5–51·4)

1999

64·0
(63·7–64·2)

68·9
(68·7–69·1)

24·4
(24·3–24·6)

28·1
(28·0–28·3)

1297·1
(1282·1–1312·1)

963·9
(952·1–976·1)

38·8
(38·4–39·2)

29·6
(29·3–30·0)

27·6
(27·2–27·9)

24·1
(23·8–24·4)

51·6
(51·2–52·1)

2000

64·2
(64·0–64·4)

69·1
(68·9–69·4)

24·5
(24·4–24·6)

28·2
(28·1–28·3)

1284·9
(1270·1–1299·5)

954·8
(943·4–966·3)

38·3
(37·9–38·7)

29·2
(28·8–29·6)

27·9
(27·5–28·2)

24·3
52·1
(24·0–24·6) (51·7–52·6)

2001

64·4
(64·2–64·7)

69·4
(69·1–69·6)

24·6
(24·5–24·7)

28·3
(28·2–28·4)

1272·5
(1258·1–1286·7)

944·1
(932·9–955·5)

37·7
(37·3–38·1)

28·7
(28·4–29·1)

28·1
(27·8–28·4)

24·5
(24·2–24·8)

52·6
(52·1–53·1)

2002

64·6
(64·4–64·9)

69·6
(69·4–69·8)

24·6
(24·5–24·8)

28·4
(28·2–28·5)

1265·8
(1251·2–1280·3)

933·4
(923·0–944·4)

37·2
(36·8–37·7)

28·2
(27·9–28·6)

28·5
(28·2–28·9)

24·7
(24·4–25·0)

53·2
(52·7–53·7)

2003

65·0
(64·8–65·2)

70·0
(69·7–70·2)

24·8
(24·7–24·9)

28·5
(28·4–28·7)

1240·0
(1225·5–1254·6)

915·4
(905·3–925·9)

36·4
(36·0–36·8)

27·5
(27·2–27·9)

28·6
(28·2–28·9)

24·7
(24·4–25·0)

53·3
(52·9–53·8)

2004

65·3
(65·1–65·5)

70·3
(70·1–70·5)

25·0
(24·8–25·1)

28·7
(28·6–28·9)

1216·5
(1202·2–1231·6)

895·9
(885·5–906·9)

35·8
(35·3–36·2)

26·9
(26·6–27·3)

28·7
(28·4–29·1)

24·7
(24·4–25·0)

53·5
(53·0–54·0)

2005

65·7
(65·5–65·9)

70·7
(70·5–71·0)

25·1
(25·0–25·3)

28·9
(28·8–29·0)

1195·0
(1180·9–1209·1)

878·1
(868·3–888·2)

34·9
(34·5–35·3)

26·1
(25·8–26·4)

28·9
(28·5–29·2)

24·8
(24·5–25·1)

53·6
(53·1–54·1)

2006

66·2
(65·9–66·4)

71·2
(71·0–71·5)

25·4
(25·3–25·5)

29·2
(29·1–29·3)

1163·8
(1150·2–1176·9)

852·4
(842·9–862·3)

33·8
(33·4–34·2)

25·2
(24·9–25·5)

28·7
(28·4–29·1)

24·6
(24·3–24·8)

53·3
(52·8–53·7)

2007

66·6
(66·3–66·8)

71·7
(71·5–72·0)

25·6
(25·4–25·7)

29·4
(29·3–29·5)

1141·3
(1127·7–1154·8)

830·4
(820·5–840·6)

33·0
(32·6–33·4)

24·4
(24·1–24·7)

28·8
(28·4–29·2)

24·5
(24·2–24·8)

53·3
(52·8–53·7)

(Table 4 continues on next page)
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Articles

Life expectancy at birth
(years)

Life expectancy at age 50
(years)

Age-standardised death rate
(per 100 000)

Age-standardised YLL rate
(per 100)

Total deaths (millions)

Male

Male

Female

Male

Female

Male

Female

Male

Female

Both sexes

Female

(Continued from previous page)
2008

66·8
(66·6–67·1)

72·1
(71·9–72·4)

25·7
(25·6–25·8)

29·6
(29·5–29·7)

1127·2
(1112·9–1140·8)

814·0
(803·9–823·4)

32·5
(32·0–32·9)

23·7
(23·4–24·1)

29·1
(28·7–29·5)

24·5
(24·2–24·8)

53·6
(53·1–54·1)

2009

67·3
(67·0–67·6)

72·6
(72·4–72·9)

25·9
(25·7–26·0)

29·9
(29·7–30·0)

1103·4
(1090·0–1116·6)

791·7
(782·3–801·5)

31·5
(31·1–31·9)

22·9
(22·6–23·2)

29·1
(28·7–29·5)

24·4
(24·1–24·7)

53·5
(52·9–54·0)

2010

67·5
(67·2–67·8)

72·9
(72·6–73·2)

26·0
(25·8–26·1)

30·0
(29·9–30·2)

1091·6
(1077·2–1105·6)

777·8
(767·4–788·0)

31·0
(30·6–31·5)

22·4
(22·0–22·7)

29·5
(29·1–29·9)

24·5
(24·2–24·8)

54·0
(53·4–54·6)

2011

68·0
(67·7–68·3)

73·4
(73·1–73·8)

26·2
(26·0–26·3)

30·3
(30·1–30·4)

1068·1
(1053·8–1083·1)

756·1
(745·4–767·2)

30·1
(29·7–30·5)

21·5
(21·2–21·9)

29·5
(29·0–29·9)

24·4
(24·0–24·7)

53·8
(53·3–54·4)

2012

73·9
68·3
(68·0–68·6) (73·5–74·2)

26·3
(26·1–26·5)

30·5
(30·3–30·6)

1051·9
(1037·1–1067·9)

739·9
(728·9–751·9)

29·4
(29·0–29·9)

20·8
(20·5–21·2)

29·7
(29·2–30·2)

24·4
54·1
(24·0–24·8) (53·5–54·7)

2013

68·6
(68·2–68·9)

74·2
(73·9–74·6)

26·4
(26·2–26·6)

30·6
(30·4–30·8)

1037·9
(1021·4–1055·4)

725·8
(714·1–738·9)

28·8
(28·3–29·3)

20·2
(19·9–20·6)

30·0
(29·5–30·5)

24·5
(24·1–25·0)

54·5
(53·8–55·1)

2014

68·8
(68·4–69·1)

74·5
(74·1–74·9)

26·5
(26·3–26·6)

30·7
(30·5–30·9)

1029·7
(1012·5–1048·3)

715·8
(703·8–729·6)

28·4
(27·9–28·9)

19·8
(19·4–20·2)

30·4
(29·9–31·0)

24·8
(24·3–25·2)

55·2
(54·4–55·9)

2015

69·0
74·8
(68·6–69·4) (74·4–75·2)

26·6
(26·4–26·8)

30·9
(30·7–31·1)

1018·6
(1000·4–1037·1)

703·4
(691·0–717·8)

27·9
(27·4–28·5)

19·3
(18·9–19·7)

30·9
(30·3–31·5)

24·9
(24·5–25·5)

55·8
(55·0–56·6)

Data in parentheses are 95% uncertainty intervals. Age-standardised rates are standardised using the GBD world population standard. YLLs=years of life lost. GBD=Global Burden of Disease.

Table 4: Global life expectancy at birth and at age 50, age-standardised death rates, age-standardised YLL rate, and total deaths, by sex, 1980–2015

year for males and females, respectively, since 1980.
Global gains in life expectancy were generally gradual
but steady, although catastrophic events, including the
Rwandan genocide and North Korean famines, and
escalating mortality due to HIV/AIDS, had worldwide
eﬀects on longevity. Slower gains were achieved for life
expectancy at 50 years, or the average number of
additional years of life 50 year olds can anticipate at a
given point in time. On average, 50-year-old females saw
an increase of 4·5 additional years of life since 1980, and
50-year-old males experienced an increase of 3·5 years.
Annual estimates of life expectancy, by sex and geography
are shown in the results appendix (pp 36–47).
Global mortality trends showed a 16·4% (95% UI
14·3–18·5) increase in total deaths between 1990 and
2015, whereas age-standardised rates of mortality fell by
28·5% (27·3–29·8) during this time. The trend was
similar from 2005 to 2015, with total deaths increasing by
4·1% (2·6–5·6) and age-standardised death rates
decreasing by 17·0% (15·8–18·1). In 2015, 55·8 million
deaths (55·0 million to 56·6 million) occurred worldwide,
an increase of 7·9 million deaths since 1990 and
2·2 million deaths since 2005 (table 4). From 1990 to
2015, total deaths rose by 21·9% (19·1–24·8) for males
and 10·3% (7·6–13·1) for females, whereas agestandardised death rates fell by 26·2% (24·5–27·9) for
males and 32·1% (30·4–33·8) for females. In 2015,
30·9 million (30·3 million to 31·5 million) males and
24·9 million (24·5 million to 25·5 million) females died,
representing an increase of 5·6 million male deaths and
2·3 million female deaths since 1990. Diﬀerences in total
deaths by sex widened over time, with increasingly more
males dying than females; this gap grew from 2·7 million
www.thelancet.com Vol 388 October 8, 2016

in 1990 to 4·1 million in 2005 and 6·0 million in 2015.
Age-standardised rates of YLLs per 100 population, a
measure of premature mortality, fell 34·1% (95% UI
32·5–35·6) for males and 42·1% (40·6–43·5) for females
between 1990 and 2015. Notably, the pace of decline in
YLL rates was faster from 2005 to 2015 (19·9%, 95% UI
18·3–21·5 for males and 26·3%, 24·6–27·9 for females)
than from 1990 to 2005 (17·7%, 16·2–19·2 for males and
21·4%, 20·0–22·7 for females).

Evolution of global and super-region life expectancy,
probabilities of death, and SDI
The diﬀerences between observed life expectancy and
mortality rates and those expected on the basis of SDI
show the complex interactions between gains in SDI and
improved health over time. Figure 10 summarises the
trends in observed and expected life expectancy or
mortality at the global level and for each GBD super-region
from 1980 to 2015. Some regions have higher than expected
levels, whereas others have lower levels than expected.
By 2015, global life expectancy had increased faster
than expected based on changes in SDI for both sexes,
equating to an increase of an additional 3·06 years for
males and 2·78 years for females (ﬁgure 10A); however,
before 2005, gains in life expectancy were lower than
expected, particularly for females. Observed life
expectancy consistently exceeded expected levels over
time in southeast and east Asia and Oceania; Latin
America and the Caribbean; and north Africa and the
Middle East. Furthermore, for the latter two superregions, gains for male life expectancy improved
following the 1980s and 1990s, when observed levels of
longevity were closer to expected life expectancy based
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on SDI. By contrast, observed life expectancy was
generally lower than expected based on SDI in highincome countries and central Europe, eastern Europe,
and central Asia. For high-income countries, however,
observed male life expectancy converged with expected
levels around 2005, whereas the gap between observed
and expected life expectancy based on SDI widened for
females in this super-region. In south Asia, where
average SDI more than doubled between 1980 and 2015,
observed male life expectancy consistently met or
slightly exceeded expected levels, whereas female life
expectancy gradually moved closer to expected levels
based on SDI. Amid its escalating HIV/AIDS epidemic,
sub-Saharan Africa recorded widening gaps between
observed and expected life expectancies for both sexes
between 1988 and 1999. From 2001 to 2015, during which
the region’s average SDI rose by 31%, observed life
expectancy quickly increased, particularly among
females, nearing expected levels.
Overall, global and regional trends for observed under-5
mortality steadily moved closer to expected levels, based
on rising SDI, and in some super-regions, such as Latin
America, the Caribbean, and north Africa and the
Middle East, observed rates of under-5 mortality became
lower than expected (ﬁgure 10B). Substantial progress
occurred in sub-Saharan Africa, with the gap between
observed and expected 5q0 decreasing from 0·055 in
1980 to 0·006 in 2015. Observed under-5 mortality was
consistently lower than expected, given rising SDI, in
southeast Asia, east Asia, and Oceania, whereas the
opposite was seen for central and eastern Europe and
central Asia, with observed under-5 mortality exceeding
expected levels from 1980 to 2015. With the exception of
south Asia, super-region under-5 mortality trends did not
substantially diﬀer by sex. Observed levels of male
under-5 mortality in south Asia gradually neared expected
rates of under-5 mortality over time, whereas female
under-5 mortality remained above expected levels
between 1980 and 2000; by 2015, however, this gap had
narrowed considerably.
Regional trends for observed and expected 35q15,
which represents the probability of dying between the
ages of 15 and 50 years, were much more variable than
life expectancy at birth or 5q0 (ﬁgure 10C). The 35q15
age band corresponds to the reproductive period; for the
analysis of changes in mortality with SDI, we include
results for these age groups because of their very strong
association with mortality from HIV/AIDS during the
reproductive age period. Except for three super-regions
(high income; sub-Saharan Africa; and central Europe,
eastern Europe, and central Asia), observed levels of
35q15 remained lower than would be expected based on
SDI between 1980 and 2015. However, relative trends, in
terms of proximity to expected levels of 35q15 over time
and by sex, shifted considerably. Although observed
rates of female 35q15 were lower than expected from
1980 to 2015 in three super-regions (Latin America and
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the Caribbean; north Africa and the Middle East; and
southeast and east Asia and Oceania), each super-region
registered improvements in 35q15 over time and moved
closer to expected levels by 2015. In sub-Saharan Africa,
observed 35q15 for both sexes increased to well above
expected levels between 1988 and 2000, a trend largely
attributable to HIV/AIDS. By 2004, however, gains in
SDI quickened in sub-Saharan Africa, and observed
35q15 began to fall closer to expected levels at a similar
pace. Central and eastern Europe and central Asia
experienced the most divergent patterns for 35q15 by
sex. For males in this super-region, observed 35q15
remained far above expected levels of mortality based on
SDI from 1980 to 2015, but observed 35q15 climbed
between 1986 and 1994. This rapid rise in observed male
mortality between the ages of 15 and 50 years, relative to
SDI, occurred in tandem with the collapse of the Soviet
Union and the widespread economic hardships that
followed. The gap between observed and expected male
35q15 began to gradually narrow during the late 1990s,
corresponding with rises in SDI; nonetheless, gains
stalled by 1999. For females in central and eastern
Europe and central Asia, observed 35q15 closely followed
expected levels from 1980 to 1990, after which observed
mortality jumped and remained higher than expected
35q15, based on SDI, through to 2015.
Results were similarly heterogeneous for observed and
expected trends for 20q50, or the probability of dying
between the ages 50 and 70 years, particularly by sex and
rising SDI (ﬁgure 10D). First, based on gains in SDI alone,
expected levels of 20q50 diﬀered substantially by sex. For
males, expected reductions for 20q50 were quite gradual
relative to improvements in SDI, until the 80th percentile,
after which expected 20q50 steeply fell. For females,
expected 20q50 followed a fairly linear trend with rising
SDI. Two regions—Latin America and the Caribbean and
north Africa and the Middle East—experienced observed
levels of 20q50 that were lower than expected from 1980 to
2015 for both sexes; however, for females in north Africa
and the Middle East, observed 20q50 shifted closer to
expected levels of mortality after 1999. After largely
following expected rates of 20q50 from 1989 to 1998,
southeast and east Asia and Oceania saw observed male
20q50 drop below expected levels. Observed female 20q50
generally remained lower than expected for this superregion, although observed levels approached expected
rates from 2000 to 2003 before declining again. Although
south Asia recorded large gains in SDI over time, from an
average of the 25th percentile in 1980 to the 54th in 2015,
observed rates of 20q50 remained higher than expected
for both sexes over time. Aside from a jump in observed
20q50 rates between 1995 and 2007, in sub-Saharan Africa,
observed 20q50 for both sexes mainly followed the
expected rates given rising SDI. Similar to the results for
35q15, observed levels of male and female 20q50 in central
and eastern Europe and central Asia followed a dissonant
pattern over time. For males, although observed 20q50
www.thelancet.com Vol 388 October 8, 2016
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Figure 10: Co-evolution of life expectancy and probabilities of death with SDI globally and for GBD super-regions, 1980 to 2015
(A) Life expectancy at birth and SDI; (B) under-5 death rate (5q0) and SDI; (C) probability of death between 15 and 50 years of age (35q15) and SDI; and (D)
probability of death between 50 and 70 years of age (20q50) and SDI. Coloured lines show global and super-region values. Each point in a line represents 1 year,
starting at 1980 and ending at 2015. In all super-regions, SDI has increased year on year so progress in SDI is associated with later years for a given super-region.
Black lines show trajectories expected for each geography on the basis of SDI alone. GBD=Global Burden of Disease. SDI=Socio-demographic Index.
5q0=probability of death from birth to age 5 years. 35q15=probability of death from age 15 years to 50 years. 20q50=probability of death from age 50 years to
70 years.
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surpassed expected rates between 1980 and 2015, observed
20q50 escalated from 1986 to 1994, rapidly increasing the
gap between observed and expected rates of mortality for
several years. The diﬀerence between observed and
expected 20q50 widened for females in central and eastern
Europe and central Asia during this time, albeit with a
much smaller magnitude of change. Notably, observed
levels of male 20q50 consistently exceeded expected rates
for high-income countries between 1980 and 1997 before
converging. Conversely, observed 20q50 for females in
high-income countries remained higher than expected
from 1980 to 2015.

Global causes of death

For online visualisation of the
detailed results see
http://vizhub.healthdata.org/
gbd-compare

Table 5 shows the global estimates of total deaths and
age-standardised death rates by cause for 2005 and 2015,
as well as the percentage change in mortality from 2005
to 2015. Annual mortality estimates from 1990 to 2015
and more detailed age–sex results can be viewed online.
Broadly, communicable, maternal, neonatal, and
nutritional diseases, known as Group 1 causes for GBD,
accounted for 20·2% (95% UI 19·7–20·7) of global deaths
in 2015 (11·3 million, 95% UI 10·9 million to 11·6 million),
NCDs caused 71·3% (70·9–72·0) of deaths (39·8 million,
39·2 million to 40·5 million), and injuries resulted in
8·5% (7·9–8·5) of deaths (4·7 million, 4·4 million to
4·9 million). Between 2005 and 2015, Group 1 causes saw
signiﬁcant reductions for both total deaths (decrease of
19·7% [17·8–21·6]) and age-standardised rates (decrease of
29·6% [27·9–31·3]). For NCDs, total deaths rose by 14·3%
(12·6–16·0), an increase of 5·0 million deaths (4·4 million
to 5·6 million) since 2005, but age-standardised rates
decreased from 719·1 deaths (711·9–727·3) per 100 000 in
2005 to 624·7 deaths (615·8–634·5) per 100 000 in 2015
(decrease of 13·1%, 11·9–14·3). Injuries caused about
4·7 million deaths in both 2005 and 2015, but the agestandardised rates due to injuries signiﬁcantly declined
during this time, decreasing by 15·8% (12·4–18·7) from
78·6 deaths (73·5–80·8) per 100 000 in 2005 to 66·2 deaths
(61·5–68·7) per 100 000 in 2015.

Communicable, maternal, neonatal, and nutritional
diseases
Marked reductions in total deaths and age-standardised
death rates were achieved for many of the world’s most
important communicable diseases. Total HIV/AIDS
deaths fell 33·4% (95% UI 30·0–36·2), from 1·8 million
(95% UI 1·7 million to 1·9 million) in 2005 to 1·2 million
(1·1 million to 1·3 million) in 2015, and age-standardised
death rates dropped even more rapidly (reduction of
42·1%, 39·1–44·6). Globally, HIV/AIDS mortality peaked
in 2005, underscoring the continued expansion of ART
and PMTCT. Malaria deaths decreased by 37·4%
(27·8–47·0), falling to 730 500 (555 800–904 000) in 2015.
Age-standardised death rates due to malaria fell slightly
more rapidly (43·1%, 34·7–51·8) during this time;
nonetheless, this rate of decline only partly represents the
1482

sustained gains against malaria, given that mortality
peaked in 2003, claiming 1·2 million lives (1·0 million to
1·4 million) that year. Age-standardised death rates due to
diarrhoeal diseases fell 32·2% (27·7–36·5) from 2005 to
2015, although total deaths fell more slowly (20·8%,
15·4–26·1) to 1·3 million deaths (1·2 million to 1·4 million).
Other communicable diseases that had signiﬁcant
reductions in mortality included tetanus (decreased by
47·5% [95% UI 39·0–54·6], to 56 700 deaths [48 200–80 000]),
measles (decreased by 75·0% [58·8–84·5], to 73 400 deaths
[26 100–161 400]), and African trypanosomiasis (decreased
by 75·3% [67·9–81·4], to 3510 deaths [1790–5660]).
Amid these gains, less pronounced progress occurred
for several communicable diseases, and fatalities climbed
rapidly for others, such as Ebola virus disease.
Tuberculosis, which killed fewer people than HIV/
AIDS in 2005 (1·3 million, 95% UI 1·2 million to
1·7 million), essentially matched HIV/AIDS’s toll by
2015, causing 1·1 million deaths (0·91 million to
1·4 million). Deaths due to tuberculosis decreased by
17·4% (11·3–24·4) between 2005 and 2015; however, agestandardised tuberculosis death rates dropped by 33·8%
(28·7–39·6). Total mortality due to lower respiratory
infections remained fairly constant from 2005 to 2015
(between 2·8 million and 2·7 million deaths), although
age-standardised death rates fell by 19·5% (16·9–22·3);
a similar trend was observed for meningitis. Deaths due
to hepatitis and age-standardised death rates decreased
(deaths fell by 14·0% [10·0–17·9], to 106 000
[101 000–111 000], and death rates fell by 28·0%
[24·7–31·1]), which was mainly driven by signiﬁcant
reductions in deaths due to acute hepatitis A (decrease of
34·0% [24·2–43·5], to 11 000 [7000–16 000]) since 2005.
Mortality due to other types of hepatitis improved less
rapidly. Dengue deaths increased by 48·7% (15·1–90·9),
resulting in 18 400 deaths (11 800–22 700) in 2015, and
Chagas disease, which largely aﬀects populations in
Latin America, claimed 8000 lives (7500–8600) that year.
Deaths due to leishmaniasis increased, albeit not
signiﬁcantly, between 2005 and 2015, causing
24 200 deaths (17 100–32 500) in 2015. The peak of the
west African Ebola virus disease outbreak occurred in
2014, causing 12 800 deaths (10 300–15 300) that year. In
2015, 5500 people (4400–6600) died from Ebola virus
disease, mainly in Guinea, Liberia, and Sierra Leone.
Among the leading causes of global maternal mortality,
most showed signiﬁcant reductions in both total deaths
and age-standardised death rates between 2005 and 2015.
Deaths due to maternal haemorrhage decreased by 16·6%
(95% UI 3·2–28·8), claiming 16 600 (3300–29 800) fewer
lives in 2015, and deaths due to abortion, miscarriage,
and ectopic pregnancies dropped by 23·1% (11·1–33·9),
to 32 000 (25 000–40 000); age-standardised death rates fell
by 25·0% (12·9–35·9) for maternal haemorrhage and by
30·7% (19·8–40·4) for abortion, miscarriage, and ectopic
pregnancies. For neonatal disorders, total deaths fell by
18·5% (16·4–20·4) and age-standardised death rates fell
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by 22·8% (–24·6 to –20·9) from 2005 to 2015, to
2·2 million (2·1 million to 2·2 million). Preterm birth
complications caused 282 200 (215 000–353 500) fewer
deaths in 2015 than in 2005 (reduction of 25·9%,
20·6–31·3) and age-standardised rates dropped by 29·8%
(24·8–34·9). Total deaths and age-standardised death
rates due to neonatal encephalopathy also decreased
signiﬁcantly during this time, albeit at a more moderate
pace. Overall, these trends probably reﬂect a combination
of decreasing fertility rates, improved maternal care, and
safer delivery practices in many settings.
Notably less progress occurred for nutritional
deﬁciencies, which caused 405 700 deaths (95% UI
331 700–495 600) in 2015. In 2015, iron-deﬁciency anaemia
led to 54 200 deaths (35 100–72 900) and protein-energy
malnutrition caused 323 200 deaths (264 900–400 800); in
combination, nutritional deﬁciencies accounted for 3·6%
(2·7–4·1) of lives lost to Group 1 disorders. Agestandardised death rates signiﬁcantly decreased for
nutritional deﬁciencies (decreased by 24·3%, 14·3–32·9).

Non-communicable diseases
In 2015, the leading causes of NCD deaths were
cardiovascular disease (17·9 million, 95% UI 17·6 million
to 18·3 million), cancers (8·8 million, 8·6 million to
8·9 million), and chronic respiratory diseases
(3·8 million, 3·7 million to 3·9 million). The global death
toll due to cancers increased by 17·0% (95% UI 14·8–19·3)
between 2005 and 2015, although age-standardised rates
of death fell by 10·0% (8·3–11·6). Tracheal, bronchus,
and lung cancer (total deaths 1·7 million, 1·7 million to
1·8 million) were the leading causes of cancer deaths, and
also had the highest age-standardised death rate
(26·6 deaths [25·9–27·4] per 100 000) among cancers in
2015. For several cancers, total deaths increased by 20%
or more between 2005 and 2015, including tracheal,
bronchus, and lung cancer (20·1% [16·7–24·0], to 1·7
million deaths [1·7 million to 1·8 million); colon and
rectum cancer (23·2% [20·6–26·0], to 832 000 deaths
[811 700–854 500]); malignant skin melanoma (27·2%
[20·0–32·6], to 59 800 deaths [47 600–72 700]); pancreatic
cancer (30·8% [28·3–33·6], to 411 600 deaths
[403 600–420 700]); and prostate cancer (31·9%
[28·2–35·4], to 365 900 deaths [303 500–459 600]). Breast
and ovarian cancers, which largely, if not exclusively,
aﬀect females, caused signiﬁcantly more deaths in 2015
than in 2005 (breast cancer increased by 21·3%
[14·9–27·2], to 534 000 deaths [502 000–553 000]; ovarian
cancer increased by 20·4% [16·5–24·4], to 161 000 deaths
[157 000–167 000]); however, age-standardised death rates
for both cancers signiﬁcantly declined during this time
(breast cancer decreased by 6·8% [2·5–11·5] and ovarian
cancer decreased by 7·9% [4·9–10·8]). The largest
reductions in death rates from 2005 to 2015 were recorded
for oesophageal cancer, which fell by 26·8% (22·9–30·3)
and Hodgkin’s lymphoma, which fell by 23·9%
(20·1–27·7). At the same time, signiﬁcant increases
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occurred in age-standardised death rates due to nonmelanoma skin cancer (increased by 7·6%, 3·4–11·1) and
mesothelioma (increased by 7·8%, 3·6–11·6).
Global cardiovascular disease deaths rose by 12·5%
(95% UI 10·6–14·4) between 2005 and 2015, whereas
age-standardised rates of death due to cardiovascular
disease fell 15·6% (14·2–16·9). These reductions were
largely driven by declining mortality rates due to
cerebrovascular disease (ie, stroke; decreased by 21·0%,
19·2–22·8) since 2005. Globally, deaths due to ischaemic
heart disease increased by 16·6% (14·6–18·6) from 2005
to 2015 to 8·9 million deaths (8·8 million to 9·1 million),
whereas age-standardised mortality rates for ischaemic
heart disease decreased at a more moderate pace (fell by
12·8%, 11·4–14·2). Ischaemic heart disease and stroke
accounted for 15·2 million deaths (15·0 million to
15·6 million) in 2015, equating to 85·1% (84·7–85·5) of
all deaths due to cardiovascular disease that year. Among
respiratory conditions, age-standardised death rates fell
by 22·9% (20·0–25·4) for chronic obstructive pulmonary
disease (COPD) and by 31·3% (19·4–38·9) for asthma;
total deaths due to these causes did not signiﬁcantly
diﬀer from 2005 to 2015. By contrast, for interstitial lung
disease and pulmonary sarcoidosis, signiﬁcant increases
occurred in total deaths, which rose by 51·5% (37·9–60·5)
to 121 800 deaths (94 100–135 200), and age-standardised
rates, which rose by 14·1% (4·1–20·9) from 2005 to 2015.
Mortality patterns were similar for other leading NCD
causes of death. Age-standardised mortality rates decreased
for all subtypes of cirrhosis, yet total deaths increased to
1·3 million in 2015 (95% UI 1·2 million to 1·4 million).
Total mortality also increased from 2005 to 2015 for
diabetes, which rose by 32·1% (95% UI 27·7–36·3), to
1·5 million deaths (1·5 million to 1·6 million), and chronic
kidney disease, which rose by 31·7% (27·7–35·6), to
1·2 million deaths (1·1 million to 1·3 million); by contrast,
changes in age-standardised death rates due to diabetes
and chronic kidney disease were not statistically signiﬁcant.
Chronic kidney disease due to diabetes mellitus caused
signiﬁcantly more deaths in 2015 than in 2005 (an increase
of 39·5% [35·4–43·5], to 418 000 deaths [389 000–441 000]),
and age-standardised death rates also rose 6·4% (3·3–9·3).
Global deaths due to Alzheimer’s disease and other
dementias increased by 38·2% (36·2–40·1), to 1·9 million
deaths (1·6 million to 2·2 million), which was largely
driven by population ageing, given that age-standardised
mortality decreased by 2·7% (1·7–3·7). Notably, both total
deaths and age-standardised death rates due to alcohol use
disorders signiﬁcantly dropped from 2005 to 2015, falling
by 12·6% (7·0–16·7), to 138 000 deaths (131 000–144 000),
and 29·2% (24·7–32·4), respectively. However, drug use
disorders claimed increasingly more lives, resulting in a
rise of 31·8% (20·4–39·4; rising to 170 000 deaths,
152 000–179 000) since 2005. Deaths due to opioid use
disorders accounted for 71·9% (69·5–73·3) of these drugrelated deaths in 2015, increasing by 29·6% (18·2–37·2) to
a total of 122 100 deaths (109 500–129 700) that year.
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Articles

All age deaths (thousands)

Age-standardised mortality rate (per 100 000)

2005

2015

Percentage change,
2005–15

2005

2015

Percentage change,
2005–15

All causes

53 618·5
(53 139·8 to 54 075·8)

55 792·9
(54 984·1 to 56 640·3)

4·1
(2·6 to 5·6)

1024·0
(1015·1 to 1032·6)

850·1
(838·3 to 862·4)

–17·0
(–18·1 to –15·8)

Communicable, maternal, neonatal,
and nutritional diseases (Group 1
causes)

14 023·9
(13 734·8 to 14 335·3)

11 263·6
(10 922·7 to 11 594·5)

–19·7
(–21·6 to –17·8)

226·2
(221·3 to 231·6)

159·3
(154·4 to 163·9)

–29·6
(–31·3 to –27·9)

3139·5
(2938·6 to 3469·8)

2305·2
(2092·7 to 2578·0)

–26·6
(–30·1 to –23·0)

51·6 (48·0 to 57·4)

31·9 (28·8 to 35·9)

–38·2
(–41·2 to –35·2)

Tuberculosis

1347·6
(1152·9 to 1658·7)

1112·6
(909·8 to 1392·8)

–17·4
(–24·4 to –11·3)

24·2 (20·8 to 29·9)

16·0 (13·1 to 20·1)

–33·8
(–39·6 to –28·7)

HIV/AIDS

1791·9
(1703·8 to 1886·6)

1192·6
(1130·8 to 1270·3)

–33·4
(–36·2 to –30·0)

27·4 (26·0 to 28·8)

15·8 (15·0 to 16·9)

–42·1
(–44·6 to –39·1)

–39·8
(–44·3 to –34·4)

5·4 (4·4 to 6·2)

2·8 (2·2 to 3·3)

–48·2
(–52·1 to –43·5)

21·9 (20·5 to 23·6)

13·0 (12·1 to 14·1)

–40·6
(–43·8 to –36·9)

HIV/AIDS and tuberculosis

HIV/AIDS—tuberculosis

351·8 (281·7 to 400·4)

211·7 (161·9 to 245·0)

HIV/AIDS resulting in other
diseases

1440·1
(1349·6 to 1546·7)

980·8
(914·7 to 1063·6)

–31·9
(–35·6 to –27·7)

Diarrhoea, lower respiratory, and
other common infectious diseases

5773·1
(5548·3 to 6004·8)

4959·8
(4711·6 to 5179·4)

–14·1
(–17·1 to –11·0)

1657·2
(1565·0 to 1756·1)

1312·1
(1233·6 to 1391·3)

–20·8
(–26·1 to –15·4)

28·1 (26·7 to 29·6)

19·1 (18·0 to 20·2)

–32·2
(–36·5 to –27·7)

Diarrhoeal diseases
Intestinal infectious diseases
Typhoid fever
Paratyphoid fever
Other intestinal infectious
diseases
Lower respiratory infections

99·3
(95·5 to 103·1)

73·2
(69·5 to 76·4)

–26·3
(–28·7 to –23·8)

208·6 (118·0 to 344·1)

178·5 (100·9 to 293·7)

–14·4
(–20·7 to –8·7)

3·0 (1·7 to 5·0)

2·4 (1·4 to 4·0)

–20·3
(–26·1 to –15·0)

172·9 (94·6 to 293·2)

148·8 (81·9 to 249·7)

–14·0
(–20·6 to –8·1)

2·5 (1·4 to 4·3)

2·0 (1·1 to 3·4)

–19·8
(–25·7 to –14·0)

33·9 (15·6 to 65·1)

29·2 (13·7 to 56·3)

–14·1
(–21·8 to –6·2)

0·5 (0·2 to 0·9)

0·4 (0·2 to 0·8)

–20·3
(–27·4 to –13·2)

1·8 (0·6 to 3·3)

0·6 (0·3 to 1·2)

–64·0
(–75·5 to –43·9)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–67·7
(–77·7 to –51·2)

51·7 (47·9 to 54·1)

41·6 (38·0 to 43·5)

–19·5
(–22·3 to –16·9)

2828·5
(2628·6 to 2965·8)

2736·7
(2500·3 to 2860·8)

–3·2
(–6·9 to 0·4)

Upper respiratory infections

3·8 (3·3 to 4·2)

3·1 (2·8 to 3·5)

–18·0
(–28·5 to –5·2)

0·1 (0·1 to 0·1)

0·0 (0·0 to 0·1)

–32·2
(–40·4 to –22·0)

Otitis media

3·9 (3·5 to 4·3)

3·2 (2·9 to 3·7)

–17·7
(–27·3 to –4·5)

0·1 (0·1 to 0·1)

0·0 (0·0 to 0·1)

–27·8
(–38·5 to –14·5)

Meningitis

407·7 (351·1 to 457·1)

379·2 (322·7 to 444·7)

–7·0
(–15·4 to 5·2)

6·3 (5·5 to 7·1)

5·2 (4·5 to 6·1)

–17·2
(–24·3 to –6·7)

Pneumococcal meningitis

112·1 (93·3 to 135·2)

112·9 (93·4 to 141·8)

0·7
(–8·7 to 13·8)

1·7 (1·5 to 2·1)

1·6 (1·3 to 1·9)

–10·8
(–18·4 to 0·7)

Haemophilus inﬂuenzae type b
meningitis

110·6 (88·3 to 135·8)

71·5 (56·7 to 91·8)

–35·4
(–43·6 to –24·7)

1·7 (1·3 to 2·0)

1·0 (0·8 to 1·3)

–41·1
(–48·3 to –31·4)

74·3 (58·7 to 91·8)

73·3 (58·0 to 93·2)

–1·3
(–13·1 to 15·4)

1·1 (0·9 to 1·4)

1·0 (0·8 to 1·3)

–11·6
(–21·8 to 3·0)

110·6 (94·9 to 128·6)

121·5 (101·8 to 144·2)

9·8
(1·1 to 22·0)

1·8 (1·5 to 2·1)

1·7 (1·4 to 2·0)

–4·6
(–11·8 to 5·9)

Encephalitis

147·0 (135·3 to 163·0)

149·5 (137·6 to 167·0)

1·7
(–4·7 to 8·1)

2·4 (2·2 to 2·7)

2·1 (1·9 to 2·4)

–11·7
(–17·1 to –6·4)

Diphtheria

5·6 (3·0 to 11·0)

–61·3
(–85·0 to –2·0)

0·1 (0·0 to 0·2)

0·0 (0·0 to 0·1)

–64·2
(–86·2 to –9·2)

Meningococcal meningitis
Other meningitis

Whooping cough

2·1 (1·1 to 4·7)

99·6 (36·8 to 226·3)

58·7 (20·3 to 126·6)

–41·0
(–77·9 to 65·1)

1·4 (0·5 to 3·3)

0·8 (0·3 to 1·7)

–45·1
(–79·4 to 53·8)

Tetanus

108·0 (90·9 to 151·1)

56·7 (48·2 to 80·0)

–47·5
(–54·6 to –39·0)

1·7 (1·4 to 2·4)

0·8 (0·7 to 1·1)

–53·2
(–59·7 to –45·9)

Measles

293·7 (110·6 to 611·4)

73·4 (26·1 to 161·4)

–75·0
(–84·5 to –58·8)

4·2 (1·6 to 8·8)

1·0 (0·4 to 2·2)

–76·7
(–85·5 to –61·6)

–33·5
(–44·4 to –19·2)

0·2 (0·2 to 0·2)

0·1 (0·1 to 0·1)

–45·8
(–54·7 to –34·7)

Varicella and herpes zoster

9·6 (8·5 to 11·0)

6·4 (5·4 to 7·8)

(Table 5 continues on next page)
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Articles

All age deaths (thousands)

Age-standardised mortality rate (per 100 000)

2005

2015

Percentage change,
2005–15

2005

1298·5
(1082·7 to 1509·1)

843·1
(669·9 to 1019·7)

–35·1
(–43·6 to –26·7)

19·5
(16·3 to 22·6)

2015

Percentage change,
2005–15

(Continued from previous page)
Neglected tropical diseases
and malaria
Malaria

1167·0 (952·1 to 1378·1)

730·5 (555·8 to 904·0)

–37·4
(–47·0 to –27·8)

17·4 (14·2 to 20·6)

11·5 (9·1 to 13·9)

–41·3
(–48·9 to –33·8)

9·9 (7·5 to 12·3)

–43·1
(–51·8 to –34·7)

Chagas disease

7·5 (7·2 to 7·8)

8·0 (7·5 to 8·6)

7·7
(0·1 to 15·9)

0·1 (0·1 to 0·2)

0·1 (0·1 to 0·1)

–16·5
(–22·4 to –10·3)

Leishmaniasis

23·1 (14·8 to 33·2)

24·2 (17·1 to 32·5)

4·9
(–8·5 to 21·5)

0·3 (0·2 to 0·5)

0·3 (0·2 to 0·4)

–7·2
(–18·7 to 7·1)

23·1 (14·8 to 33·2)

24·2 (17·1 to 32·5)

4·9
(–8·5 to 21·5)

0·3 (0·2 to 0·5)

0·3 (0·2 to 0·4)

–7·2
(–18·7 to 7·1)

14·2 (7·6 to 23·1)

3·5 (1·8 to 5·7)

–75·3
(–81·4 to –67·9)

0·2 (0·1 to 0·4)

0·0 (0·0 to 0·1)

–78·4
(–83·7 to –72·0)

Schistosomiasis

7·8 (7·0 to 8·9)

4·4 (3·8 to 4·9)

–44·2
(–52·7 to –35·6)

0·1 (0·1 to 0·2)

0·1 (0·1 to 0·1)

–55·8
(–62·7 to –48·8)

Cysticercosis

0·6 (0·5 to 0·7)

0·4 (0·3 to 0·5)

–37·0
(–43·5 to –28·0)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–47·7
(–53·1 to –40·2)

Cystic echinococcosis

1·8 (1·7 to 1·9)

1·2 (1·1 to 1·3)

–32·6
(–35·7 to –29·4)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–44·6
(–47·0 to –42·1)

12·3 (8·6 to 15·1)

18·4 (11·8 to 22·7)

48·7
(15·1 to 90·9)

0·2 (0·1 to 0·2)

0·3 (0·2 to 0·3)

34·0
(4·4 to 70·9)

6·3 (1·3 to 16·9)

5·1 (1·1 to 14·2)

–18·8
(–33·5 to –0·8)

0·1 (0·0 to 0·2)

0·1 (0·0 to 0·2)

–25·7
(–39·2 to –9·4)

32·1 (28·0 to 36·1)

17·4 (14·8 to 20·6)

–45·8
(–52·2 to –39·0)

0·5 (0·4 to 0·6)

0·2 (0·2 to 0·3)

–52·9
(–58·4 to –47·3)

Visceral leishmaniasis
African trypanosomiasis

Dengue
Yellow fever
Rabies
Intestinal nematode infections
Ascariasis
Ebola virus disease

Other neglected tropical diseases
Maternal disorders

3·8 (3·3 to 4·3)

2·7 (2·4 to 3·1)

–28·5
(–36·9 to –19·7)

0·1 (0·1 to 0·1)

0·0 (0·0 to 0·0)

–34·7
(–42·3 to –26·7)

3·8 (3·3 to 4·3)

2·7 (2·4 to 3·1)

–28·5
(–36·9 to –19·7)

0·1 (0·1 to 0·1)

0·0 (0·0 to 0·0)

–34·7
(–42·3 to –26·7)

0·0 (0·0 to 0·0)

5·5 (4·4 to 6·6)

32 659·1
(32 659·1 to
32 659·1)

0·0 (0·0 to 0·0)

0·1 (0·1 to 0·1)

28 636·1 (28 636·1
to 28 636·1)

21·9 (14·0 to 27·7)

21·8 (12·7 to 27·6)

–0·6
(–14·5 to 15·9)

0·4 (0·2 to 0·4)

0·3 (0·2 to 0·4)

–13·0
(–24·9 to 1·1)

–21·5
(–30·3 to –10·7)

5·1 (4·7 to 5·5)

3·6 (3·2 to 4·1)

–29·1
(–37·1 to –19·3)

350·8 (327·9 to 376·6)

275·3 (243·8 to 315·5)

Maternal haemorrhage

99·7 (87·6 to 113·0)

83·1 (67·0 to 101·5)

–16·6
(–28·8 to –3·2)

1·4 (1·3 to 1·6)

1·1 (0·9 to 1·3)

–25·0
(–35·9 to –12·9)

Maternal sepsis and other
maternal infections

24·7 (20·4 to 29·9)

17·9 (13·4 to 23·9)

–27·7
(–41·7 to –10·8)

0·4 (0·3 to 0·4)

0·2 (0·2 to 0·3)

–35·0
(–47·6 to –19·8)

Maternal hypertensive disorders

63·7 (54·9 to 74·3)

46·9 (37·1 to 59·6)

–26·4
(–36·7 to –13·1)

0·9 (0·8 to 1·1)

0·6 (0·5 to 0·8)

–32·9
(–42·5 to –20·9)

Maternal obstructed labour and
uterine rupture

26·9 (22·1 to 32·0)

23·1 (17·2 to 30·0)

–13·9
(–27·4 to 1·5)

0·4 (0·3 to 0·5)

0·3 (0·2 to 0·4)

–22·5
(–34·5 to –8·5)

Maternal abortion, miscarriage,
and ectopic pregnancy

41·2 (34·7 to 49·6)

31·7 (24·6 to 39·7)

–23·1
(–33·9 to –11·1)

0·6 (0·5 to 0·7)

0·4 (0·3 to 0·5)

–30·7
(–40·4 to –19·8)

Indirect maternal deaths

38·2 (31·6 to 45·4)

30·8 (23·1 to 40·5)

–19·4
(–32·4 to –1·9)

0·6 (0·5 to 0·7)

0·4 (0·3 to 0·5)

–27·1
(–38·8 to –11·1)

Late maternal deaths

7·9 (5·3 to 11·5)

6·7 (4·3 to 10·0)

–15·1
(–26·2 to –1·1)

0·1 (0·1 to 0·2)

0·1 (0·1 to 0·1)

–23·3
(–33·3 to –10·6)

Maternal deaths aggravated by
HIV/AIDS

2·8 (1·8 to 3·8)

2·3 (1·4 to 3·3)

–15·8
(–33·1 to 8·0)

0·0 (0·0 to 0·1)

0·0 (0·0 to 0·0)

–24·8
(–40·4 to –3·7)

45·7 (39·0 to 53·9)

32·7 (26·3 to 40·5)

–28·4
(–37·1 to –18·3)

0·7 (0·6 to 0·8)

0·4 (0·3 to 0·5)

–35·3
(–43·3 to –26·2)

Other maternal disorders

(Table 5 continues on next page)
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Articles

All age deaths (thousands)

Age-standardised mortality rate (per 100 000)

2005

2015

Percentage change,
2005–15

2005

2015

Percentage change,
2005–15

2653·5
(2583·4 to 2728·1)

2163·2
(2095·1 to 2232·5)

–18·5
(–20·4 to –16·4)

37·3
(36·4 to 38·4)

28·8
(27·9 to 29·7)

–22·8
(–24·6 to –20·9)

(Continued from previous page)
Neonatal disorders
Neonatal preterm birth
complications

1088·0
(1010·9 to 1217·7)

805·8 (736·2 to 898·6)

–25·9
(–31·3 to –20·6)

15·3 (14·2 to 17·1)

10·7 (9·8 to 12·0)

–29·8
(–34·9 to –24·8)

9·9 (8·9 to 11·0)

–20·5
(–27·8 to –12·8)

Neonatal encephalopathy (birth
asphyxia and trauma)

882·8 (800·7 to 974·3)

740·4 (667·6 to 829·2)

–16·1
(–23·8 to –8·0)

12·4 (11·3 to 13·7)

Neonatal sepsis and other
neonatal infections

352·3 (252·0 to 465·7)

351·7 (249·2 to 459·1)

–0·2
(–16·2 to 20·3)

5·0 (3·5 to 6·6)

4·7 (3·3 to 6·1)

–5·5
(–20·6 to 13·9)

–34·0
(–47·9 to –17·1)

1·0 (0·6 to 1·5)

0·6 (0·4 to 0·9)

–37·6
(–50·6 to –21·6)

Haemolytic disease and other
neonatal jaundice
Other neonatal disorders
Nutritional deﬁciencies
Protein-energy malnutrition
Iodine deﬁciency

68·3 (42·9 to 106·1)

45·1 (30·1 to 67·3)

262·0 (190·3 to 343·0)

220·2 (167·6 to 276·8)

–16·0
(–34·1 to 5·6)

3·7 (2·7 to 4·8)

2·9 (2·2 to 3·7)

–20·5
(–37·7 to –0·1)

460·8 (380·3 to 541·6)

405·7 (331·7 to 495·6)

–11·9
(–22·9 to 0·6)

7·8 (6·5 to 9·0)

5·9 (4·8 to 7·2)

–24·3
(–32·9 to –14·3)

379·7 (314·3 to 457·1)

323·2 (264·9 to 400·8)

–14·9
(–27·3 to –0·2)

6·4 (5·3 to 7·6)

4·7 (3·9 to 5·8)

–26·3
(–35·8 to –14·5)

2·1 (1·6 to 2·9)

2·0 (1·5 to 2·7)

–3·1
(–31·4 to 40·7)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–18·4
(–41·6 to 15·7)

Iron-deﬁciency anaemia

48·4 (31·9 to 63·1)

54·2 (35·1 to 72·9)

12·1
(–2·1 to 28·0)

0·8 (0·5 to 1·1)

0·8 (0·5 to 1·0)

–5·1
(–16·8 to 7·8)

Other nutritional deﬁciencies

30·7 (21·7 to 43·7)

26·3 (20·7 to 33·6)

–14·1
(–33·1 to 1·1)

0·6 (0·4 to 0·8)

0·4 (0·3 to 0·5)

–30·0
(–45·1 to –18·7)

Other communicable, maternal,
neonatal, and nutritional diseases
Sexually transmitted diseases
excluding HIV
Syphilis

347·7 (291·2 to 419·8)

311·3 (257·9 to 372·7)

–10·5
(–15·6 to –4·6)

5·6 (4·7 to 6·6)

4·4 (3·6 to 5·2)

–21·5
(–26·0 to –16·6)

135·5 (81·2 to 207·2)

108·0 (64·6 to 165·7)

–20·3
(–28·3 to –12·4)

2·0 (1·2 to 3·0)

1·5 (0·9 to 2·2)

–26·1
(–33·7 to –19·0)

134·1 (79·9 to 205·7)

106·8 (63·4 to 164·6)

–20·3
(–28·5 to –12·4)

1·9 (1·2 to 3·0)

1·4 (0·9 to 2·2)

–26·1
(–33·8 to –18·8)

Chlamydial infection

0·2 (0·1 to 0·2)

0·2 (0·1 to 0·2)

–5·3
(–17·0 to 10·6)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–23·5
(–32·9 to –11·3)

Gonococcal infection

0·8 (0·7 to 0·9)

0·7 (0·5 to 0·8)

–15·7
(–26·7 to –4·7)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–31·3
(–40·1 to –22·6)

Other sexually transmitted
diseases

0·4 (0·3 to 0·4)

0·3 (0·2 to 0·4)

–16·8
(–27·6 to –6·1)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–31·7
(–40·3 to –23·0)

–14·0
(–17·9 to –10·0)

2·1 (2·0 to 2·2)

1·5 (1·4 to 1·6)

–28·0
(–31·1 to –24·7)

Hepatitis

123·0 (118·6 to 127·6)

105·8 (100·7 to 110·8)

Acute hepatitis A

16·9 (10·9 to 23·1)

11·2 (6·9 to 15·9)

–34·0
(–43·5 to –24·2)

0·2 (0·2 to 0·3)

0·2 (0·1 to 0·2)

–39·4
(–47·9 to –30·4)

Hepatitis B

71·4 (62·0 to 80·1)

65·4 (56·4 to 73·7)

–8·4
(–14·1 to –2·2)

1·3 (1·1 to 1·4)

0·9 (0·8 to 1·1)

–26·4
(–30·9 to –21·6)

Hepatitis C

2·8 (0·6 to 6·4)

2·5 (0·5 to 5·9)

–9·8
(–24·4 to 8·6)

0·1 (0·0 to 0·1)

0·0 (0·0 to 0·1)

–29·6
(–41·0 to –15·1)

31·9 (23·0 to 42·3)

26·7 (18·5 to 36·6)

–16·4
(–26·1 to –6·6)

0·5 (0·4 to 0·7)

0·4 (0·3 to 0·5)

–26·3
(–34·3 to –17·9)

89·1 (61·3 to 102·3)

97·5 (61·3 to 112·9)

9·4
(–2·3 to 23·2)

1·5 (1·1 to 1·7)

1·4 (0·9 to 1·6)

–6·4
(–16·8 to 5·2)

Acute hepatitis E
Other infectious diseases
Non-communicable diseases
Neoplasms
Lip and oral cavity cancer

34 835·6
(34 441·3 to 35 277·1)

39 804·2
(39 210·8 to 40 452·2)

14·3
(12·6 to 16·0)

719·1
(711·9 to 727·3)

624·7
(615·8 to 634·5)

–13·1
(–14·3 to –11·9)

7492·8
(7378·4 to 7616·5)

8764·6
(8591·1 to 8945·6)

17·0
(14·8 to 19·3)

149·2
(147·1 to 151·7)

134·3
(131·6 to 137·0)

–10·0
(–11·6 to –8·3)

110·2 (107·6 to 112·9)

146·0 (141·6 to 150·6)

32·5
(28·5 to 37·0)

2·2 (2·1 to 2·2)

2·2 (2·1 to 2·3)

1·4
(–1·6 to 4·8)

Nasopharynx cancer

55·8 (45·9 to 58·8)

63·0 (51·1 to 67·0)

12·8
(5·1 to 19·4)

1·0 (0·8 to 1·1)

0·9 (0·7 to 1·0)

–10·9
(–16·8 to –5·7)

Other pharynx cancer

51·9 (50·5 to 53·2)

64·4 (61·6 to 67·1)

24·1
(18·4 to 29·7)

1·0 (1·0 to 1·0)

1·0 (0·9 to 1·0)

–5·0
(–9·3 to –0·6)
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(Continued from previous page)
Oesophageal cancer

459·3 (445·1 to 474·2)

439·0 (422·6 to 456·9)

–4·4
(–9·0 to 0·7)

9·2 (8·9 to 9·5)

6·7 (6·5 to 7·0)

–26·8
(–30·3 to –22·9)

Stomach cancer

824·5 (806·8 to 843·0)

818·9 (795·5 to 843·7)

–0·7
(–3·7 to 2·6)

16·7 (16·3 to 17·0)

12·7 (12·4 to 13·1)

–23·8
(–26·0 to –21·4)

Colon and rectum cancer

675·5 (664·9 to 688·2)

832·0 (811·7 to 854·5)

23·2
(20·6 to 26·0)

14·0 (13·8 to 14·2)

13·0 (12·7 to 13·4)

–6·7
(–8·7 to –4·6)

Liver cancer

726·7 (636·0 to 762·2)

810·5 (749·7 to 862·8)

11·5
(5·9 to 20·4)

13·9 (12·3 to 14·6)

12·1 (11·2 to 12·9)

–13·1
(–17·4 to –6·7)

Liver cancer due to hepatitis B

263·1 (224·4 to 282·5)

265·3 (241·0 to 290·5)

0·8
(–5·6 to 12·5)

4·8 (4·1 to 5·1)

3·8 (3·5 to 4·2)

–20·2
(–25·2 to –11·5)

Liver cancer due to hepatitis C

137·8 (126·1 to 146·3)

167·1 (153·9 to 177·9)

21·3
(17·3 to 26·2)

2·8 (2·6 to 3·0)

2·6 (2·4 to 2·8)

–7·4
(–10·4 to –3·8)

Liver cancer due to alcohol use

194·5 (168·8 to 208·3)

245·2 (225·1 to 266·6)

26·1
(18·5 to 37·1)

3·8 (3·3 to 4·1)

3·7 (3·4 to 4·0)

–3·1
(–8·6 to 4·8)

Liver cancer due to other causes

131·3 (114·1 to 141·6)

132·9 (119·8 to 144·4)

1·2
(–4·2 to 9·7)

2·5 (2·2 to 2·7)

2·0 (1·8 to 2·2)

–21·1
(–25·2 to –15·0)

Gallbladder and biliary tract cancer

124·5 (120·8 to 127·8)

140·5 (131·4 to 147·2)

12·9
(7·3 to 18·2)

2·6 (2·5 to 2·7)

2·2 (2·1 to 2·3)

–14·7
(–19·0 to –10·6)

Pancreatic cancer

314·6 (310·1 to 319·0)

411·6 (403·6 to 420·7)

30·8
(28·3 to 33·6)

6·5 (6·4 to 6·6)

6·4 (6·3 to 6·6)

–0·9
(–2·8 to 1·2)

93·1 (90·9 to 95·7)

105·9 (102·7 to 109·5)

13·8
(10·5 to 17·5)

1·8 (1·8 to 1·9)

1·6 (1·6 to 1·7)

–12·8
(–15·3 to –10·0)

20·1
(16·7 to 24·0)

29·0 (28·5 to 29·6)

26·6 (25·9 to 27·4)

–8·1
(–10·7 to –5·2)

Larynx cancer
Tracheal, bronchus, and lung
cancer

1434·5
(1406·5 to 1463·5)

1722·5
(1673·7 to 1772·7)

Malignant skin melanoma

47·0 (38·7 to 58·6)

59·8 (47·6 to 72·7)

27·2
(20·0 to 32·6)

0·9 (0·8 to 1·1)

0·9 (0·7 to 1·1)

–1·8
(–7·1 to 2·4)

Non-melanoma skin cancer

36·3 (35·4 to 37·1)

51·9 (49·9 to 53·8)

42·9
(37·4 to 47·8)

0·8 (0·7 to 0·8)

0·8 (0·8 to 0·9)

7·6
(3·4 to 11·1)

Squamous-cell carcinoma

36·3 (35·4 to 37·1)

51·9 (49·9 to 53·8)

42·9
(37·4 to 47·8)

0·8 (0·7 to 0·8)

0·8 (0·8 to 0·9)

7·6
(3·4 to 11·1)

Breast cancer

439·8 (418·8 to 461·9)

533·6 (502·2 to 553·1)

21·3
(14·9 to 27·2)

8·5 (8·1 to 8·9)

7·9 (7·5 to 8·2)

–6·8
(–11·5 to –2·5)

Cervical cancer

225·4 (213·9 to 237·8)

238·6 (225·3 to 252·4)

5·8
(–0·5 to 13·8)

4·2 (4·0 to 4·4)

3·5 (3·3 to 3·7)

–17·7
(–22·5 to –11·5)

Uterine cancer

81·8 (78·5 to 85·4)

89·9 (86·1 to 94·3)

10·0
(3·8 to 17·4)

1·6 (1·6 to 1·7)

1·4 (1·3 to 1·4)

–16·1
(–20·8 to –10·7)

Ovarian cancer

133·8 (130·8 to 138·6)

161·1 (156·5 to 166·5)

20·4
(16·5 to 24·4)

2·6 (2·6 to 2·7)

2·4 (2·3 to 2·5)

–7·9
(–10·8 to –4·9)

Prostate cancer

277·4 (230·8 to 348·9)

365·9 (303·5 to 459·6)

31·9
(28·2 to 35·4)

6·1 (5·1 to 7·7)

6·0 (5·0 to 7·6)

–1·7
(–4·5 to 0·8)

8·4
(1·3 to 14·4)

0·1 (0·1 to 0·1)

0·1 (0·1 to 0·1)

–8·9
(–14·7 to –3·9)

Testicular cancer

8·6 (8·3 to 9·1)

9·4 (8·8 to 9·9)

Kidney cancer

104·5 (102·4 to 106·9)

136·9 (133·0 to 141·3)

31·0
(27·0 to 34·6)

2·1 (2·1 to 2·1)

2·1 (2·0 to 2·2)

0·4
(–2·6 to 3·2)

Bladder cancer

150·6 (147·9 to 153·2)

188·0 (182·8 to 192·7)

24·8
(21·4 to 28·3)

3·2 (3·2 to 3·3)

3·0 (2·9 to 3·1)

–6·4
(–9·0 to –3·8)

Brain and nervous system cancer

190·4 (173·3 to 201·2)

228·8 (209·5 to 244·7)

20·1
(12·7 to 27·2)

3·5 (3·2 to 3·6)

3·3 (3·0 to 3·6)

–3·6
(–9·3 to 1·8)

Thyroid cancer

25·5 (24·4 to 27·6)

31·9 (28·9 to 33·2)

24·8
(14·8 to 31·0)

0·5 (0·5 to 0·6)

0·5 (0·5 to 0·5)

–4·8
(–12·2 to 0·0)

Mesothelioma

23·2 (22·7 to 23·8)

32·4 (31·2 to 33·4)

39·6
(34·4 to 44·3)

0·5 (0·5 to 0·5)

0·5 (0·5 to 0·5)

7·8
(3·6 to 11·6)

Hodgkin lymphoma

25·4 (22·7 to 29·7)

23·9 (21·8 to 29·0)

–6·0
(–10·6 to –1·3)

0·5 (0·4 to 0·5)

0·3 (0·3 to 0·4)

–23·9
(–27·7 to –20·1)

231·4 (195·7 to 243·8)

29·0
(18·1 to 35·2)

3·5 (3·1 to 3·7)

3·5 (3·0 to 3·7)

0·0
(–8·0 to 4·4)

Non-Hodgkin’s lymphoma

179·3 (160·6 to 191·6)

(Table 5 continues on next page)

www.thelancet.com Vol 388 October 8, 2016

1487

Articles

All age deaths (thousands)
2005

Age-standardised mortality rate (per 100 000)
2015

Percentage change,
2005–15

2005

2015

Percentage change,
2005–15
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Multiple myeloma

101·1 (97·7 to 104·1)

30·5
(26·3 to 34·5)

1·6 (1·6 to 1·6)

1·6 (1·5 to 1·6)

–1·3
(–4·4 to 1·7)

303·5 (297·3 to 311·8)

353·5 (344·6 to 363·1)

16·5
(13·5 to 19·6)

5·6 (5·5 to 5·7)

5·3 (5·1 to 5·4)

–5·7
(–7·9 to –3·3)

Acute lymphoid leukaemia

97·5 (90·4 to 108·0)

110·5 (101·2 to 118·4)

13·3
(7·1 to 19·0)

1·6 (1·5 to 1·8)

1·6 (1·4 to 1·7)

–3·0
(–8·1 to 1·7)

Chronic lymphoid leukaemia

51·5 (49·3 to 53·9)

60·7 (57·9 to 64·6)

17·9
(12·5 to 23·4)

1·1 (1·0 to 1·1)

1·0 (0·9 to 1·0)

–10·1
(–14·0 to –6·1)

119·0 (110·5 to 126·7)

147·1 (137·3 to 157·0)

23·5
(19·3 to 27·8)

2·2 (2·1 to 2·3)

2·2 (2·1 to 2·3)

–0·4
(–3·5 to 2·7)

35·4 (33·4 to 38·2)

35·2 (33·4 to 37·7)

–0·7
(–4·8 to 3·8)

0·7 (0·6 to 0·7)

0·5 (0·5 to 0·6)

–22·0
(–25·3 to –18·5)

292·1 (270·9 to 302·6)

372·2 (335·9 to 392·1)

27·4
(21·4 to 32·6)

5·5 (5·1 to 5·7)

5·5 (5·0 to 5·8)

1·2
(–3·6 to 5·3)

Leukaemia

Acute myeloid leukaemia
Chronic myeloid leukaemia
Other neoplasms
Cardiovascular diseases
Rheumatic heart disease

77·5 (75·6 to 79·7)

15 933·7
(15 732·1 to 16 161·6)
333·2 (313·1 to 349·5)

17 921·0
(17 590·5 to 18 276·8)
319·4 (297·3 to 337·3)

12·5
(10·6 to 14·4)
–4·1
(–8·2 to –0·1)

338·1
(333·8 to 342·9)
6·4 (6·0 to 6·7)

285·5
(280·2 to 291·2)
4·8 (4·5 to 5·1)

–15·6
(–16·9 to –14·2)
–24·7
(–27·9 to –21·6)

Ischaemic heart disease

7648·4
(7551·5 to 7774·3)

8917·0
(8751·6 to 9108·8)

16·6
(14·6 to 18·6)

163·1 (160·8 to
165·6)

142·1 (139·5 to
145·2)

–12·8
(–14·2 to –11·4)

Cerebrovascular disease

6020·9
(5920·2 to 6127·1)

6326·1
(6175·2 to 6492·9)

5·1
(2·7 to 7·5)

127·9
(125·8 to 130·1)

101·0
(98·6 to 103·6)

–21·0
(–22·8 to –19·2)

Ischaemic stroke

2760·8
(2682·7 to 2837·5)

2978·0
(2880·8 to 3068·8)

7·9
(5·2 to 10·6)

61·3 (59·5 to 62·9)

48·9 (47·3 to 50·4)

–20·2
(–22·1 to –18·1)

Haemorrhagic stroke

3260·1
(3169·2 to 3359·8)

3348·2
(3240·9 to 3500·1)

2·7
(–0·6 to 6·4)

66·7 (64·9 to 68·7)

52·1 (50·4 to 54·5)

–21·9
(–24·3 to –19·0)

15·4 (13·9 to 16·4)

–4·9
(–11·9 to –0·6)

Hypertensive heart disease

760·5 (711·9 to 823·7)

962·4 (873·6 to 1024·5)

26·5
(17·5 to 32·3)

16·2 (15·2 to 17·5)

Cardiomyopathy and myocarditis

328·8 (315·8 to 338·8)

353·7 (339·5 to 370·6)

7·6
(3·8 to 11·4)

6·4 (6·2 to 6·6)

5·4 (5·2 to 5·7)

–16·1
(–18·9 to –13·2)

Atrial ﬁbrillation and ﬂutter

142·8 (117·3 to 172·0)

195·3 (159·5 to 236·2)

36·8
(34·0 to 39·6)

3·4 (2·8 to 4·1)

3·3 (2·7 to 4·0)

–3·4
(–4·9 to –1·9)

Aortic aneurysm

134·8 (131·7 to 138·3)

168·2 (163·6 to 172·8)

24·8
(19·5 to 28·5)

2·9 (2·8 to 3·0)

2·7 (2·6 to 2·8)

–6·6
(–10·4 to –3·8)

Peripheral vascular disease

38·1 (36·7 to 39·6)

52·5 (49·7 to 55·7)

37·7
(30·1 to 46·5)

0·9 (0·8 to 0·9)

0·9 (0·8 to 0·9)

–0·3
(–5·9 to 6·3)

Endocarditis

68·8 (60·4 to 74·7)

84·9 (74·7 to 93·0)

23·4
(18·5 to 28·2)

1·4 (1·2 to 1·5)

1·3 (1·2 to 1·4)

–4·6
(–8·1 to –1·1)

541·4 (521·7 to 561·2)

18·4
(14·0 to 22·5)

9·6 (9·3 to 9·8)

8·6 (8·3 to 8·9)

–10·3
(–13·5 to –7·4)

Other cardiovascular and
circulatory diseases
Chronic respiratory diseases
Chronic obstructive pulmonary
disease
Pneumoconiosis

457·4 (446·7 to 470·6)
3709·1
(3631·6 to 3796·0)

3795·5
(3683·9 to 3910·4)

2·3
(–0·8 to 5·4)

79·0 (77·3 to 80·9)

61·0 (59·3 to 62·8)

–22·8
(–25·1 to –20·4)

3100·5
(2997·7 to 3194·9)

3188·3
(3083·8 to 3292·5)

2·8
(–0·6 to 6·9)

67·0 (64·8 to 69·0)

51·7 (50·0 to 53·4)

–22·9
(–25·4 to –20·0)

31·9 (28·4 to 36·3)

36·1 (31·5 to 40·7)

13·2
(6·4 to 22·4)

0·7 (0·6 to 0·8)

0·6 (0·5 to 0·7)

–14·4
(–19·5 to –7·7)

10·2 (9·4 to 11·4)

10·4 (9·4 to 11·7)

2·0
(–9·0 to 15·4)

0·2 (0·2 to 0·2)

0·2 (0·1 to 0·2)

–21·8
(–30·2 to –11·8)

Asbestosis

2·8 (2·0 to 3·2)

3·6 (2·5 to 4·2)

28·4
(17·6 to 39·5)

0·1 (0·0 to 0·1)

0·1 (0·0 to 0·1)

–2·1
(–10·2 to 6·2)

Coal workers pneumoconiosis

2·7 (2·4 to 3·0)

2·5 (2·2 to 2·9)

–7·3
(–21·5 to 6·4)

0·1 (0·1 to 0·1)

0·0 (0·0 to 0·0)

–29·9
(–40·4 to –19·6)

16·1 (13·3 to 19·7)

19·5 (15·8 to 23·2)

21·2
(11·0 to 33·5)

0·3 (0·3 to 0·4)

0·3 (0·3 to 0·4)

–9·4
(–16·9 to –0·2)

449·9 (362·1 to 518·0)

397·1 (363·0 to 438·7)

–11·7
(–21·2 to 3·4)

8·8 (7·1 to 10·2)

6·1 (5·6 to 6·7)

–31·3
(–38·9 to –19·4)

Silicosis

Other pneumoconiosis
Asthma
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Interstitial lung disease and
pulmonary sarcoidosis

80·4 (61·2 to 92·8)

121·8 (94·1 to 135·2)

51·5
(37·9 to 60·5)

1·7 (1·3 to 2·0)

2·0 (1·5 to 2·2)

14·1
(4·1 to 20·9)

Other chronic respiratory diseases

46·4 (33·9 to 55·6)

52·1 (38·0 to 61·0)

12·2
(1·4 to 23·0)

0·8 (0·6 to 1·0)

0·8 (0·6 to 0·9)

–5·9
(–13·8 to 2·5)

10·3
(7·0 to 13·7)

21·6 (20·9 to 22·8)

18·8 (18·0 to 19·9)

–13·1
(–15·6 to –10·5)

Cirrhosis and other chronic liver
diseases

1171·7
(1131·9 to 1236·7)

1292·1
(1239·9 to 1371·7)

Cirrhosis and other chronic liver
diseases due to hepatitis B

341·4 (316·2 to 374·1)

371·1 (341·6 to 410·0)

8·7
(4·7 to 12·7)

6·3 (5·9 to 6·9)

5·4 (5·0 to 6·0)

–14·6
(–17·5 to –11·6)

Cirrhosis and other chronic liver
diseases due to hepatitis C

287·4 (268·1 to 307·8)

325·6 (301·8 to 349·9)

13·3
(10·4 to 16·5)

5·4 (5·0 to 5·8)

4·8 (4·4 to 5·1)

–11·7
(–13·9 to –9·3)

Cirrhosis and other chronic liver
diseases due to alcohol use

310·1 (289·4 to 333·4)

347·9 (322·7 to 374·6)

12·2
(8·4 to 16·7)

5·6 (5·2 to 6·0)

5·0 (4·6 to 5·3)

–11·6
(–14·5 to –8·2)

Cirrhosis and other chronic liver
diseases due to other causes

232·8 (217·6 to 254·6)

247·5 (230·3 to 272·2)

6·3
(3·4 to 9·8)

4·3 (4·0 to 4·7)

3·6 (3·4 to 4·0)

–14·8
(–17·1 to –12·2)

8·1
(3·7 to 12·6)

22·0 (21·4 to 23·4)

18·5 (17·7 to 19·5)

–16·1
(–19·3 to –12·7)

–9·1
(–15·3 to 0·0)

5·8 (5·5 to 6·3)

4·1 (3·8 to 4·4)

–29·3
(–34·1 to –22·1)

Digestive diseases
Peptic ulcer disease

1113·2
(1081·1 to 1186·7)
294·3 (278·0 to 322·0)

1203·0
(1150·5 to 1270·0)
267·5 (249·4 to 290·0)

Gastritis and duodenitis

49·9 (40·2 to 60·9)

49·7 (41·8 to 60·1)

–0·5
(–10·9 to 12·4)

1·0 (0·8 to 1·2)

0·8 (0·6 to 0·9)

–23·0
(–31·0 to –12·9)

Appendicitis

49·9 (42·9 to 56·4)

50·1 (41·2 to 56·0)

0·5
(–9·0 to 10·7)

0·9 (0·8 to 1·0)

0·7 (0·6 to 0·8)

–17·0
(–24·5 to –9·0)

233·4 (210·7 to 272·0)

264·3 (242·4 to 307·4)

13·2
(7·7 to 19·7)

4·6 (4·1 to 5·3)

4·0 (3·7 to 4·7)

–11·4
(–15·5 to –6·6)

Inguinal, femoral, and abdominal
hernia

56·6 (40·0 to 63·8)

59·8 (41·1 to 69·2)

5·8
(–3·1 to 16·8)

1·1 (0·8 to 1·3)

0·9 (0·6 to 1·1)

–18·1
(–25·2 to –9·3)

Inﬂammatory bowel disease

42·6 (38·3 to 47·3)

47·4 (43·5 to 51·7)

11·2
(2·9 to 18·8)

0·9 (0·8 to 0·9)

0·7 (0·7 to 0·8)

–14·6
(–20·4 to –9·1)

Vascular intestinal disorders

84·3 (79·0 to 91·2)

105·8 (99·0 to 114·3)

25·6
(20·4 to 30·5)

1·8 (1·7 to 2·0)

1·7 (1·6 to 1·8)

–6·1
(–10·0 to –2·7)

Gallbladder and biliary diseases

96·4 (91·1 to 103·1)

111·7 (105·3 to 120·0)

15·9
(10·2 to 21·3)

2·0 (1·9 to 2·1)

1·8 (1·7 to 1·9)

–11·7
(–15·8 to –7·7)

109·6 (103·0 to 117·2)

132·7 (122·9 to 144·0)

21·1
(14·3 to 28·1)

2·0 (1·9 to 2·2)

1·9 (1·8 to 2·1)

–3·9
(–9·2 to 1·5)

96·3 (86·5 to 116·2)

114·0 (101·9 to 131·1)

18·3
(8·1 to 28·9)

2·0 (1·8 to 2·4)

1·8 (1·6 to 2·0)

–9·5
(–16·6 to –2·1)

Paralytic ileus and intestinal
obstruction

Pancreatitis
Other digestive diseases
Neurological disorders
Alzheimer’s disease and other
dementias

1671·0
(1445·9 to 1889·8)

2258·9
(1937·8 to 2574·4)

35·2
(33·2 to 37·2)

38·7 (33·1 to 44·1)

37·6 (32·2 to 43·0)

–2·7
(–3·7 to –1·6)

1380·8
(1152·7 to 1599·4)

1908·2
(1586·7 to 2229·1)

38·2
(36·2 to 40·1)

33·2 (27·6 to 38·7)

32·3 (26·9 to 37·8)

–2·7
(–3·7 to –1·7)

Parkinson’s disease

82·4 (80·0 to 85·6)

117·4 (113·9 to 121·3)

42·4
(37·3 to 46·9)

1·9 (1·8 to 2·0)

2·0 (1·9 to 2·0)

4·2
(0·5 to 7·6)

119·0 (111·9 to 127·6)

124·9 (119·3 to 131·0)

5·0
(–2·1 to 12·3)

1·9 (1·8 to 2·0)

1·7 (1·6 to 1·8)

–9·2
(–15·1 to –3·3)

Multiple sclerosis

16·5 (14·9 to 18·1)

18·9 (17·3 to 20·0)

14·8
(7·2 to 20·7)

0·3 (0·3 to 0·3)

0·3 (0·2 to 0·3)

–9·7
(–15·3 to –5·1)

Motor neuron disease

27·6 (26·8 to 28·8)

35·2 (33·9 to 36·7)

27·6
(20·6 to 31·1)

0·5 (0·5 to 0·6)

0·5 (0·5 to 0·6)

–1·2
(–6·5 to 1·6)

Other neurological disorders

44·8 (43·6 to 47·8)

54·3 (53·0 to 57·5)

21·3
(17·5 to 24·5)

0·8 (0·8 to 0·8)

0·8 (0·8 to 0·8)

–1·0
(–4·1 to 1·7)

6·2
(1·9 to 10·4)

5·1 (4·9 to 5·3)

4·5 (4·3 to 4·7)

–12·6
(–16·0 to –9·2)

16·9 (15·9 to 18·0)

–11·4
(–18·8 to –2·9)

0·3 (0·3 to 0·4)

0·2 (0·2 to 0·3)

–29·2
(–34·9 to –22·9)

137·5 (131·5 to 144·0)

–12·6
(–16·7 to –7·0)

2·7 (2·5 to 2·8)

1·9 (1·8 to 2·0)

–29·2
(–32·4 to –24·7)

Epilepsy

Mental and substance use disorders

305·9 (293·5 to 314·9)

Schizophrenia
Alcohol use disorders

19·1 (17·9 to 20·0)
157·4 (147·4 to 163·3)

324·9 (308·6 to 337·4)

(Table 5 continues on next page)
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Drug use disorders

128·8 (124·0 to 133·6)

169·9 (152·1 to 179·2)

31·8
(20·4 to 39·4)

2·1 (2·0 to 2·2)

2·3 (2·1 to 2·5)

11·5
(2·0 to 17·7)

Opioid use disorders

94·2 (90·5 to 99·7)

122·1 (109·5 to 129·7)

29·6
(18·2 to 37·2)

1·5 (1·5 to 1·6)

1·7 (1·5 to 1·8)

10·0
(0·5 to 16·5)

Cocaine use disorders

7·4 (5·0 to 7·9)

11·1 (8·5 to 12·2)

49·7
(33·6 to 75·4)

0·1 (0·1 to 0·1)

0·1 (0·1 to 0·2)

26·4
(12·9 to 48·0)

Amphetamine use disorders

7·3 (4·3 to 8·2)

12·2 (8·4 to 14·2)

67·5
(25·6 to 118·9)

0·1 (0·1 to 0·1)

0·2 (0·1 to 0·2)

42·3
(7·2 to 85·6)

19·9 (18·6 to 22·8)

24·5 (22·7 to 27·3)

23·0
(12·7 to 32·1)

0·3 (0·3 to 0·4)

0·3 (0·3 to 0·4)

2·6
(–5·6 to 9·5)

0·6 (0·4 to 0·8)

0·7 (0·5 to 0·9)

7·7
(0·8 to 17·3)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–4·4
(–10·2 to 3·5)

Anorexia nervosa

0·6 (0·4 to 0·7)

0·6 (0·4 to 0·8)

5·6
(–1·2 to 14·1)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–6·0
(–11·8 to 1·1)

Bulimia nervosa

0·0 (0·0 to 0·1)

0·1 (0·0 to 0·1)

33·2
(19·1 to 58·1)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

14·6
(3·3 to 34·2)

Other drug use disorders
Eating disorders

Diabetes, urogenital, blood, and
endocrine diseases
Diabetes mellitus
Acute glomerulonephritis
Chronic kidney disease

2635·3
(2534·5 to 2716·0)

3409·3
(3287·5 to 3516·5)

29·4
(26·1 to 32·7)

52·9 (51·0 to 54·3)

52·9 (51·0 to 54·5)

–0·1
(–2·3 to 2·3)

1150·2
(1120·9 to 1176·8)

1519·0
(1470·3 to 1576·0)

32·1
(27·7 to 36·3)

23·6 (23·0 to 24·2)

23·7 (23·0 to 24·6)

0·4
(–2·7 to 3·6)

–6·9
(–23·8 to 2·0)

0·2 (0·2 to 0·3)

0·2 (0·1 to 0·2)

31·7
(27·7 to 35·6)

19·0 (17·7 to 19·7)

19·2 (17·7 to 20·0)

1·2
(–1·9 to 4·0)

12·7 (9·9 to 14·4)
937·7 (866·2 to 970·8)

11·8 (7·8 to 13·3)
1234·9
(1131·7 to 1282·4)

–25·3
(–38·9 to –18·2)

Chronic kidney disease due to
diabetes mellitus

299·4 (278·7 to 314·2)

417·8 (388·7 to 441·4)

39·5
(35·4 to 43·5)

6·1 (5·7 to 6·4)

6·5 (6·1 to 6·9)

6·4
(3·3 to 9·3)

Chronic kidney disease due to
hypertension

408·5 (377·1 to 427·6)

549·5 (501·6 to 575·6)

34·5
(30·0 to 38·7)

8·4 (7·8 to 8·8)

8·7 (7·9 to 9·1)

2·4
(–0·9 to 5·5)

Chronic kidney disease due to
glomerulonephritis

205·6 (184·9 to 217·9)

237·7 (212·6 to 255·9)

15·6
(10·9 to 20·2)

4·0 (3·6 to 4·2)

3·6 (3·3 to 3·9)

–9·0
(–12·6 to –5·4)

Chronic kidney disease due to
other causes

24·2 (20·2 to 28·6)

30·0 (25·0 to 35·2)

23·9
(17·8 to 30·2)

0·5 (0·4 to 0·6)

0·5 (0·4 to 0·5)

–2·2
(–6·9 to 2·5)

201·1 (188·2 to 215·7)

261·7 (243·2 to 277·6)

30·1
(23·7 to 36·6)

4·2 (3·9 to 4·5)

4·1 (3·8 to 4·4)

–1·3
(–6·1 to 3·6)

149·8 (139·3 to 160·9)

196·4 (181·5 to 211·0)

31·1
(25·3 to 37·3)

3·2 (2·9 to 3·4)

3·1 (2·9 to 3·4)

–1·1
(–5·5 to 3·7)

Urinary diseases and male
infertility
Interstitial nephritis and urinary
tract infections
Urolithiasis

14·9 (12·5 to 18·1)

16·1 (14·0 to 20·3)

7·8
(0·0 to 21·2)

0·3 (0·3 to 0·4)

0·2 (0·2 to 0·3)

–16·5
(–22·6 to –5·8)

Other urinary diseases

36·4 (30·8 to 42·7)

49·2 (41·2 to 55·4)

35·1
(20·4 to 49·9)

0·7 (0·6 to 0·9)

0·8 (0·6 to 0·9)

4·2
(–7·1 to 15·3)

7·6 (6·1 to 8·6)

7·9 (5·9 to 9·2)

2·9
(–10·1 to 24·5)

0·1 (0·1 to 0·2)

0·1 (0·1 to 0·1)

–17·4
(–28·0 to –1·0)

Uterine ﬁbroids

2·1 (1·2 to 2·7)

2·3 (1·2 to 3·0)

9·5
(–12·5 to 34·7)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–13·3
(–30·5 to 5·8)

Polycystic ovarian syndrome

0·7 (0·2 to 1·3)

0·6 (0·2 to 1·0)

–17·9
(–37·0 to 10·1)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–30·9
(–47·0 to –7·9)

Endometriosis

0·0 (0·0 to 0·1)

0·1 (0·0 to 0·1)

24·2
(–0·6 to 59·4)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

5·7
(–15·2 to 35·4)

Genital prolapse

1·1 (0·6 to 1·8)

0·9 (0·6 to 1·5)

–19·5
(–36·0 to 12·9)

0·0 (0·0 to 0·0)

0·0 (0·0 to 0·0)

–39·0
(–51·1 to –15·9)

Other gynaecological diseases

3·6 (2·7 to 4·5)

4·0 (3·0 to 4·8)

9·9
(–5·8 to 34·4)

0·1 (0·0 to 0·1)

0·1 (0·0 to 0·1)

–10·0
(–23·1 to 9·9)

Gynaecological diseases

Haemoglobinopathies and
haemolytic anaemias
Thalassaemias

215·5 (173·5 to 274·0)

226·9 (177·2 to 306·2)

5·3
(–9·4 to 24·1)

3·6 (2·9 to 4·5)

3·2 (2·5 to 4·3)

–9·8
(–21·2 to 5·1)

19·7 (16·5 to 23·3)

16·8 (13·9 to 20·2)

–14·5
(–27·7 to 2·9)

0·3 (0·3 to 0·4)

0·2 (0·2 to 0·3)

–23·6
(–34·1 to –10·3)
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(Continued from previous page)
Sickle cell disorders

108·3 (78·5 to 159·8)

114·8 (78·3 to 183·2)

6·0
(–20·1 to 40·4)

1·6 (1·2 to 2·3)

1·6 (1·1 to 2·5)

–2·7
(–26·0 to 28·3)

Glucose-6-phosphate
dehydrogenase deﬁciency

27·5 (23·5 to 32·1)

33·0 (28·0 to 38·9)

19·9
(11·6 to 29·2)

0·4 (0·4 to 0·5)

0·5 (0·4 to 0·5)

1·2
(–5·9 to 8·7)

Other haemoglobinopathies
and haemolytic anaemias

60·0 (53·2 to 66·5)

62·3 (54·7 to 71·1)

3·9
(–3·4 to 10·2)

1·2 (1·1 to 1·3)

1·0 (0·9 to 1·1)

–19·6
(–25·6 to –15·0)

Endocrine, metabolic, blood, and
immune disorders

110·5 (108·1 to 113·5)

147·3 (142·5 to 151·7)

33·2
(28·0 to 37·2)

2·1 (2·1 to 2·2)

2·2 (2·2 to 2·3)

5·6
(1·7 to 8·7)

Musculoskeletal disorders

76·2 (69·2 to 80·5)

90·1 (82·5 to 94·6)

18·2
(10·8 to 24·3)

1·5 (1·4 to 1·6)

1·4 (1·3 to 1·5)

–8·3
(–13·5 to –3·8)

Rheumatoid arthritis

26·5 (23·2 to 29·3)

30·0 (27·0 to 34·6)

13·2
(5·0 to 23·5)

0·6 (0·5 to 0·6)

0·5 (0·4 to 0·5)

–14·0
(–20·0 to –6·4)

Other musculoskeletal disorders

49·7 (45·5 to 53·1)

60·1 (53·1 to 63·5)

20·9
(11·5 to 27·0)

1·0 (0·9 to 1·0)

0·9 (0·8 to 1·0)

–5·0
(–11·5 to –0·5)

Other non-communicable diseases
Congenital anomalies

726·6 (626·8 to 869·3)

744·6 (667·8 to 811·6)

2·5
(–10·6 to 11·7)

10·9 (9·4 to 13·0)

10·2 (9·2 to 11·1)

–6·5
(–17·7 to 1·5)

634·2 (535·9 to 773·4)

627·8 (567·3 to 694·4)

–1·0
(–15·4 to 9·0)

9·2 (7·8 to 11·2)

8·4 (7·6 to 9·3)

–8·0
(–21·1 to 1·1)

76·5 (56·7 to 107·0)

64·6 (47·9 to 83·4)

–15·5
(–34·9 to 4·4)

1·1 (0·8 to 1·5)

0·9 (0·6 to 1·1)

–20·5
(–38·8 to –1·7)

319·0 (267·4 to 378·1)

303·3 (268·8 to 335·4)

–4·9
(–18·9 to 6·5)

4·6 (3·9 to 5·4)

4·1 (3·6 to 4·5)

–11·4
(–24·4 to –0·9)

–59·0
(–66·4 to –50·1)

0·0 (0·0 to 0·1)

0·0 (0·0 to 0·0)

–61·3
(–68·3 to –52·9)

Neural tube defects
Congenital heart anomalies
Cleft lip and cleft palate

3·3 (2·6 to 3·8)

1·3 (1·1 to 1·7)

Down’s syndrome

26·6 (17·9 to 42·7)

26·5 (19·1 to 36·9)

–0·2
(–25·0 to 30·6)

0·4 (0·3 to 0·6)

0·4 (0·3 to 0·5)

–10·1
(–31·7 to 16·9)

Other chromosomal
abnormalities

20·6 (9·8 to 49·3)

22·7 (12·9 to 40·5)

10·3
(–21·8 to 41·0)

0·3 (0·1 to 0·7)

0·3 (0·2 to 0·5)

3·3
(–26·6 to 31·3)

Other congenital anomalies

188·3 (158·7 to 231·9)

209·4 (188·9 to 241·3)

11·2
(–3·7 to 24·5)

2·8 (2·3 to 3·4)

2·8 (2·6 to 3·3)

2·7
(–10·6 to 14·6)

Skin and subcutaneous diseases

71·6 (48·1 to 90·4)

97·6 (66·6 to 128·8)

36·2
(29·5 to 46·4)

1·5 (1·0 to 1·8)

1·5 (1·0 to 2·0)

3·7
(–1·6 to 12·5)

Cellulitis

12·6 (7·8 to 17·4)

16·9 (10·4 to 23·0)

34·2
(22·2 to 48·2)

0·3 (0·2 to 0·3)

0·3 (0·2 to 0·3)

3·5
(–5·5 to 14·1)

Pyoderma

30·9 (21·3 to 43·5)

44·1 (31·1 to 62·8)

42·7
(33·0 to 53·3)

0·6 (0·4 to 0·8)

0·7 (0·5 to 1·0)

12·5
(4·7 to 21·4)

Decubitus ulcer

25·1 (14·5 to 30·7)

32·4 (19·3 to 40·0)

29·3
(20·4 to 42·4)

0·6 (0·3 to 0·7)

0·5 (0·3 to 0·7)

–5·7
(–12·6 to 4·4)

Other skin and subcutaneous
diseases
Sudden infant death syndrome
Injuries

3·1 (2·2 to 4·2)

4·2 (3·0 to 5·8)

35·4
(26·9 to 46·0)

0·1 (0·0 to 0·1)

0·1 (0·0 to 0·1)

5·7
(–1·2 to 14·2)

20·8 (16·9 to 33·7)

19·2 (15·9 to 27·5)

–7·9
(–23·0 to 8·9)

0·3 (0·2 to 0·5)

0·3 (0·2 to 0·4)

–13·5
(–27·7 to 2·3)

4759·0
(4451·4 to 4893·1)

4725·1
(4398·5 to 4905·2)

–0·7
(–4·3 to 3·5)

Transport injuries

1494·1
(1444·8 to 1550·6)

1466·6
(1394·8 to 1536·5)

–1·8
(–7·4 to 3·3)

24·2 (23·4 to 25·0)

20·2 (19·3 to 21·2)

–16·2
(–20·8 to –11·8)

Road injuries

1392·5
(1341·0 to 1446·0)

1361·7
(1294·0 to 1428·1)

–2·2
(–7·8 to 2·6)

22·5 (21·7 to 23·3)

18·8 (17·9 to 19·7)

–16·4
(–21·1 to –12·3)

Pedestrian road injuries

78·6
(73·5 to 80·8)

66·2
(61·5 to 68·7)

–15·8
(–18·7 to –12·4)

581·4 (546·3 to 631·3)

560·6 (525·8 to 617·1)

–3·6
(–10·7 to 2·8)

9·6 (9·1 to 10·5)

7·8 (7·4 to 8·6)

–18·6
(–24·6 to –13·2)

63·4 (58·7 to 68·9)

58·7 (54·4 to 64·4)

–7·5
(–15·2 to 1·2)

1·0 (1·0 to 1·1)

0·8 (0·8 to 0·9)

–21·9
(–28·5 to –14·6)

Motorcyclist road injuries

245·7 (215·2 to 263·8)

257·1 (230·6 to 290·9)

4·6
(–4·7 to 16·5)

3·8 (3·4 to 4·1)

3·5 (3·1 to 3·9)

–8·9
(–17·0 to 1·6)

Motor vehicle road injuries

483·1 (445·9 to 536·6)

464·2 (417·8 to 508·3)

–3·9
(–9·3 to 2·1)

7·7 (7·1 to 8·5)

6·4 (5·7 to 7·0)

–17·2
(–21·8 to –12·1)

Cyclist road injuries

(Table 5 continues on next page)
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Articles

All age deaths (thousands)
2005

Age-standardised mortality rate (per 100 000)
2015

Percentage change,
2005–15

2005

2015

Percentage change,
2005–15

(Continued from previous page)
Other road injuries

18·9 (13·1 to 22·5)

21·1 (14·0 to 24·8)

11·3
(–5·4 to 34·9)

0·3 (0·2 to 0·4)

0·3 (0·2 to 0·3)

–4·5
(–18·7 to 14·7)

Other transport injuries

101·5 (93·2 to 114·0)

104·9 (90·5 to 127·2)

3·3
(–6·4 to 14·7)

1·7 (1·5 to 1·9)

1·4 (1·2 to 1·8)

–12·6
(–20·7 to –3·2)

32·3 (29·1 to 33·6)

26·5 (23·6 to 28·0)

–17·8
(–20·4 to –13·4)

Unintentional injuries

1887·3
(1701·0 to 1969·6)

1838·7
(1634·6 to 1939·1)

–2·6
(–5·7 to 3·2)

Falls

436·1 (402·3 to 451·2)

527·2 (467·8 to 554·5)

20·9
(14·6 to 27·2)

8·6 (7·9 to 8·9)

8·1 (7·2 to 8·5)

–5·5
(–10·1 to –0·8)

Drowning

403·1 (349·2 to 424·7)

323·8 (285·8 to 347·5)

–19·7
(–23·6 to –14·2)

6·3 (5·4 to 6·6)

4·5 (4·0 to 4·8)

–28·5
(–31·8 to –23·8)

Fire, heat, and hot substances

195·2 (161·4 to 209·0)

176·0 (145·1 to 189·6)

–9·9
(–14·8 to –2·5)

3·3 (2·7 to 3·5)

2·5 (2·1 to 2·7)

–23·5
(–27·7 to –17·7)

Poisonings

100·8 (71·4 to 117·4)

86·4 (58·6 to 101·0)

–14·3
(–24·1 to –1·1)

1·6 (1·2 to 1·9)

1·2 (0·8 to 1·4)

–26·7
(–34·3 to –16·2)

Exposure to mechanical forces

202·6 (175·4 to 214·0)

200·6 (157·6 to 216·7)

–1·0
(–11·7 to 7·0)

3·3 (2·8 to 3·5)

2·8 (2·2 to 3·0)

–15·1
(–24·1 to –8·9)

Unintentional ﬁrearm injuries

32·7 (23·8 to 35·6)

32·0 (23·3 to 35·1)

–2·1
(–7·1 to 3·3)

0·5 (0·4 to 0·6)

0·5 (0·3 to 0·5)

–17·0
(–20·9 to –12·7)

Unintentional suﬀocation

34·9 (27·1 to 39·4)

35·6 (25·6 to 40·3)

2·0
(–11·6 to 15·8)

0·6 (0·4 to 0·6)

0·5 (0·4 to 0·6)

–9·2
(–21·2 to 2·5)

135·0 (113·9 to 144·3)

133·0 (101·1 to 145·1)

–1·5
(–13·6 to 8·5)

2·2 (1·9 to 2·3)

1·9 (1·4 to 2·0)

–16·2
(–26·2 to –8·3)

97·3 (74·1 to 107·8)

99·8 (77·3 to 109·0)

2·5
(–2·6 to 9·3)

1·7 (1·4 to 1·9)

1·5 (1·1 to 1·6)

–15·6
(–19·2 to –11·4)

104·4 (67·1 to 114·9)

94·0 (55·8 to 132·3)

–9·9
(–19·7 to 18·4)

1·7 (1·1 to 1·9)

1·3 (0·8 to 1·8)

–22·5
(–31·0 to 1·6)

Venomous animal contact

88·2 (54·1 to 98·6)

79·6 (44·2 to 115·9)

–9·8
(–21·0 to 20·5)

1·4 (0·9 to 1·6)

1·1 (0·6 to 1·6)

–22·3
(–32·1 to 3·7)

Non-venomous animal contact

16·2 (13·1 to 18·7)

14·4 (11·4 to 16·4)

–10·8
(–19·7 to 10·9)

0·3 (0·2 to 0·3)

0·2 (0·2 to 0·2)

–23·5
(–30·6 to –5·8)

Other exposure to mechanical
forces
Adverse eﬀects of medical
treatment
Animal contact

(Table 5 continues on next page)

Injuries
In 2015, transport injuries caused 1·5 million deaths
(95% UI 1·4 million to 1·5 million), unintentional injuries
resulted in 1·8 million (1·6 million to 1·9 million), and
intentional injuries, including self-harm and interpersonal
violence, led to 1·2 million (1·1 million to 1·3 million).
Although total deaths did not signiﬁcantly change between
2005 and 2015, age-standardised death rates fell by 16·2%
(11·8–20·8) for transport injuries, 17·8% (13·4–20·4) for
unintentional injuries, and 16·3% (12·6–20·1) for
intentional injuries. Age-standardised death rates for road
injuries and most types of road injuries, including
pedestrian, cyclist, and motor vehicle injuries, signiﬁcantly
decreased from 2005 to 2015. Notably, deaths due to falls
increased by 20·9% (14·6–27·2) between 2005 and 2015
(to 527 000 deaths, 468 000–555 000), which probably
reﬂects global shifts in ageing rather than a rise in injury
risk given that age-standardised death rates fell by 5·5%
(0·8–10·1). For drowning, there were signiﬁcant
reductions in both total deaths (decreased by 19·7%
[14·2–23·6], to 324 000 deaths [286 000–347 000]) and agestandardised death rates (decreased by 28·5%, 23·8–31·8).
1492

Total deaths due to self-harm and interpersonal violence
remained relatively unchanged since 2005, but agestandardised deaths fell by 16·3% (11·2–21·5) and 16·4%
(13·1–19·1), respectively. Assault by ﬁrearms, which
accounted for 42·4% (40·4–43·9) of all interpersonal
violence deaths, claimed 173 100 lives (149 300–183 200) in
2015, and in contrast with all other causes of interpersonal
violence, total deaths signiﬁcantly increased since 2005
(rose by 6·3%, 2·4–11·0).
Mortality trends due to natural disasters and war were
highly irregular (ﬁgure 11). By decade, the numbers of
war deaths were higher in the 1970s and 1980s, then fell
in the 1990s and in the ﬁrst decade of the 21st century.
Conversely, between 2010 and 2015, mortality due to war
(collective violence and legal intervention) increased,
rising to 171 300 (88 100–251 100) in 2015. More than
40·6% (34·8–45·1) of these deaths occurred in Syria and
Yemen (70 000 deaths, 33 000–107 000). These numbers
of war fatalities remain much lower than those recorded
in 1993 and 1994, when more than 626 000 lives were lost
to the Rwandan genocide, the Iraq civil war, ongoing
armed conﬂict in Bosnia and Herzegovina, and other
www.thelancet.com Vol 388 October 8, 2016

Articles

All age deaths (thousands)
2005

Age-standardised mortality rate (per 100 000)
2015

Percentage change,
2005–15

2005

2015

Percentage change,
2005–15

(Continued from previous page)
Foreign body

145·7 (118·7 to 175·9)

151·6 (132·6 to 169·8)

4·1
(–4·7 to 13·6)

2·5 (2·1 to 3·0)

2·2 (1·9 to 2·4)

–12·3
(–18·4 to –6·1)

116·6 (93·0 to 148·1)

124·0 (105·5 to 143·2)

6·3
(–4·9 to 15·7)

2·0 (1·7 to 2·5)

1·8 (1·5 to 2·1)

–10·8
(–18·5 to –4·6)

29·0 (18·1 to 43·2)

27·6 (20·3 to 34·4)

–5·0
(–22·7 to 11·2)

0·5 (0·3 to 0·7)

0·4 (0·3 to 0·5)

–18·8
(–34·3 to –6·2)

Environmental heat and cold
exposure

53·4 (39·9 to 57·2)

45·2 (33·5 to 49·5)

–15·4
(–21·1 to –9·1)

0·9 (0·7 to 1·0)

0·7 (0·5 to 0·7)

–31·3
(–35·8 to –26·6)

Other unintentional injuries

148·8 (141·4 to 157·7)

134·2 (124·8 to 147·8)

–9·8
(–16·7 to –1·6)

2·4 (2·3 to 2·5)

1·9 (1·7 to 2·0)

–22·3
(–28·2 to –15·4)

–1·3
(–5·7 to 3·0)

20·3 (18·2 to 20·9)

17·0 (15·5 to 17·7)

–16·3
(–20·1 to –12·6)

Pulmonary aspiration and
foreign body in airway
Foreign body in other body part

Self-harm and interpersonal
violence

1253·0
(1125·6 to 1288·8)

1236·7
(1130·1 to 1287·9)

Self-harm

827·6 (725·4 to 855·5)

828·1 (745·8 to 868·7)

0·1
(–6·2 to 6·1)

13·7 (12·0 to 14·2)

11·5 (10·3 to 12·1)

–16·3
(–21·5 to –11·2)

Interpersonal violence

425·3 (388·7 to 439·6)

408·6 (370·5 to 431·5)

–3·9
(–7·0 to –0·1)

6·5 (6·0 to 6·8)

5·5 (5·0 to 5·8)

–16·4
(–19·1 to –13·1)

Assault by ﬁrearm

162·9 (142·8 to 168·8)

173·1 (149·3 to 183·2)

6·3
(2·4 to 11·0)

2·4 (2·1 to 2·5)

2·3 (2·0 to 2·4)

–6·0
(–9·4 to –1·8)

Assault by sharp object

104·4 (97·5 to 110·7)

–14·3
(–18·8 to –9·1)

1·6 (1·5 to 1·7)

1·2 (1·1 to 1·3)

–25·6
(–29·4 to –21·2)

Assault by other means

158·0 (143·1 to 167·5)

145·9 (129·6 to 159·7)

–7·6
(–12·6 to –1·5)

2·5 (2·3 to 2·6)

2·0 (1·8 to 2·2)

–20·6
(–24·8 to –15·4)

Forces of nature, war, and legal
intervention

124·7 (82·5 to 166·5)

183·1 (100·0 to 263·8)

46·8
(–14·2 to 120·5)

1·9 (1·3 to 2·6)

2·4 (1·3 to 3·5)

27·4
(–25·5 to 90·7)

Exposure to forces of nature

90·8 (53·0 to 128·0)

11·8 (7·2 to 16·4)

–87·0
(–87·9 to –86·1)

1·4 (0·8 to 2·0)

0·2 (0·1 to 0·2)

–88·5
(–89·3 to –87·6)

Collective violence and legal
intervention

33·8 (25·5 to 43·0)

171·3 (88·1 to 251·1)

406·0
(236·0 to 524·5)

0·5 (0·4 to 0·7)

2·3 (1·2 to 3·3)

347·5
(192·4 to 455·8)

89·5 (83·3 to 97·3)

Data in parentheses are 95% uncertainty intervals.

Table 5: Global deaths in 2005 and 2015 for all ages and both sexes combined and age-standardised death rates, with percentage change between 2005 and 2015 for 249 causes

occurrences of collective violence; nonetheless, the rising
number of casualties in the Middle East represents the
largest increase in war deaths since 1995. Because of
deaths in Afghanistan, Iraq, Syria, and Yemen, war
deaths have increased during 2014–15. Between 2004 and
2010, natural disasters claimed thousands of lives,
including 226 000 from the Indonesian earthquake and
tsunami in 2004; 74 700 from earthquakes in India and
Pakistan, as well as 1870 from Hurricane Katrina in the
USA in 2005; 87 900 from an earthquake in China and
138 000 from a cyclone in Myanmar in 2008; and 223 000
from the earthquake in Haiti in 2010. In 2015, natural
disasters caused 11 800 deaths (7160–16 400), mainly due
to the Nepal earthquake and ﬂoods in India.
In general, age-standardised death rates for males and
females by cause are highly correlated at the global level
(ﬁgure 12). For most causes, male age-standardised
death rates are higher than for females. Death rates are
notably higher in males for many cancers including
tracheal, bronchus, and lung, liver, oesophageal, bladder,
and larynx cancer, and mesothelioma. Male agestandardised death rates are also higher for many
www.thelancet.com Vol 388 October 8, 2016

injuries including road injuries, self-harm, falls, and
interpersonal violence. For a small number of causes,
female age-standardised rates are higher than for males,
including breast cancer, rheumatic heart disease,
gallbladder and biliary cancer, whooping cough,
rheumatoid arthritis, thyroid cancer, and multiple
sclerosis, and other musculoskeletal disorders.

Decomposition analysis of changes in global mortality
Drivers of global changes in mortality—population
growth, ageing, and changes to age-standardised rates of
cause-speciﬁc mortality—varied substantially by cause
from 2005 to 2015 (ﬁgure 13). Among the leading 30 causes
of death worldwide, changes in total death tolls ranged
from a reduction of 37·4% (95% UI 27·8–47·0) for malaria
to an increase of 38·2% (36·2–40·1) for Alzheimer’s
disease and other dementias. Population growth accounted
for increases in numbers of deaths across all 30 causes, but
its contribution ranged from less than 9% for several types
of cancer, including lung cancer and liver cancer, to 22·9%
for malaria. In fact, for malaria, as well as a subset of other
Group 1 causes (ie, preterm birth complications, neonatal
1493
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Figure 11: Global deaths due to fatal discontinuities by cause group for each year, 1980–2015
Numbers shown are total deaths. Fatal discontinuities are events that lead to abrupt changes in deaths in a geography. The causes for these fatal discontinuities
include wars, natural disasters, industrial accidents, large transport accidents, epidemics, famines, or other injuries.

encephalopathy, and meningitis), population growth was
the only factor that hindered further reductions in
mortality. Population ageing led to increasing mortality for
most causes, but its relative contribution ranged from less
than 4% for interpersonal violence and diarrhoeal diseases
to 29·6% for Alzheimer’s disease and other dementias.
Shifts in population age structures also accounted for
more than 23% of increased mortality due to cardiovascular
disease (ischaemic heart disease and stroke), 24·2% for
COPD, and at least 20% for several types of cancer (eg,
pancreatic cancer and oesophageal cancer). Conversely, for
some causes, namely neonatal conditions and causes that
largely aﬀect children, such as malaria, population ageing
contributed to decreasing levels of mortality. Except for
pancreatic cancer, changes in age-speciﬁc and causespeciﬁc rates of death drove reductions in deaths due to
the 28 other leading causes. Declines attributable to
changes in age-speciﬁc and cause-speciﬁc mortality rates
markedly diﬀered, with several causes experiencing
reductions of more than 40% (eg, malaria [58·2%],
HIV/AIDS [54·8%], tuberculosis [41·9%], and diarrhoeal
diseases [41·0%]) and others showing much smaller
decreases (eg, chronic kidney disease [2·4%] and diabetes
[3·1%]). Notably, patterns were less distinct for most
injuries because population growth and shifts in agespeciﬁc and cause-speciﬁc mortality rates had relatively
similar contributions to changes in deaths due to road
injuries, self-harm, and interpersonal violence. Falls were
the exception, with a combination of population growth
and ageing mainly driving its rising death toll.

Global YLLs
From 2005 to 2015, changes in the relative ranks of YLLs,
emphasised the increasing complexity of global mortality
1494

patterns (ﬁgure 14). The top three causes of YLLs—
ischaemic heart disease, stroke (which includes both
ischaemic and haemorrhagic stroke), and lower
respiratory infections—all saw reductions in agestandardised rates between 2005 and 2015, but changed
minimally in rankings. In 2005, the causes ranked fourth
to eighth were all communicable diseases (HIV/AIDS
[ fourth], diarrhoeal diseases [sixth], and malaria
[seventh]) or neonatal disorders (preterm birth
complications [ﬁfth] and neonatal encephalopathy
[eighth]). By 2015, both total and age-standardised rates
of YLLs had signiﬁcantly decreased for all of these causes,
but their relative rankings did not substantially change;
the exceptions were HIV/AIDS, which fell to seventh,
and malaria, which dropped to ninth. Road injuries,
COPD, and congenital anomalies, ranked as ninth, tenth,
and 11th leading causes of YLLs in 2005, remained largely
the same in terms of ranks in 2015, with only road
injuries moving up by one spot to rank eighth. YLLs due
to road injuries fell signiﬁcantly between 2005 and 2015,
both in terms of total YLLs, which decreased by 8·1%
(95% UI 3·3–13·3), and age-standardised rates, which
decreased by 18·5% (14·3–23·1). Among the top
ten leading causes, premature mortality due to malaria
decreased the most, with total YLLs falling by 40·1%
(29·4–50·2) and age-standardised rates dropping 44·7%
(34·9–54·1).
More pronounced shifts in YLL ranks and percentage
changes between 2005 and 2015 occurred beyond the
leading 11 causes, particularly for several NCDs. Total
YLLs due to diabetes rose 25·4% (95% UI 20·4–30·0)
and diabetes advanced from being ranked 18th to 15th.
Similar increases occurred for chronic kidney disease
(18·4% [13·8–23·1] for total YLLs and rising from 21st to
www.thelancet.com Vol 388 October 8, 2016
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Figure 12: Global age-standardised death rates for males versus females, by GBD cause Level 3, 1990 and 2015
The y-axis and x-axis are shown on a log scale to enable comparisons between males and females spanning a wide range of values. Black lines show where death rates are identical for males and
females. Causes that only aﬀect one sex, including maternal disorders, chlamydia, cervical, uterine, ovarian, prostate, testicular cancers, and gynaecological diseases are not shown. GBD=Global Burden
of Disease. COPD=chronic obstructive pulmonary disease. C=cancer.

17th) and Alzheimer’s disease and other dementias
(30·5% [28·6–32·4] for total YLLs and increasing from
30th to 25th). Several types of cancer, including colon
and rectum cancer, breast cancer, pancreatic cancer, and
brain cancer, showed signiﬁcant increases in total YLLs
and relative ranks by 2015; however, none of these
cancers had signiﬁcant increases in age-standardised
rates of YLLs. Among NCDs, only asthma (ranked 32nd
in 2005 and 37th in 2015) and rheumatic heart disease
(ranked 41st in 2005 and 43rd in 2015) had signiﬁcant
reductions for both total YLLs and age-standardised
rates. By contrast, larger declines for total YLLs
and age-standardised rates occurred for several
leading Group 1 causes, including tuberculosis
(20·5% [14·9–26·0] and 33·7% [29·1–38·3], respectively);
protein-energy malnutrition (22·9% [4·8–38·1] and
29·4% [13·0–43·0], respectively); and most notably,
measles (75·0% [58·9–84·4] and 76·7% [61·8–85·5],
respectively). In general, changes in total YLLs and agestandardised rates due to injuries suggested reduced
levels of premature mortality; the main exception was
early deaths due to war, which climbed from the
92nd leading cause of YLLs in 2005 to 38th in 2015, and
increased more than 350% for total YLLs and agestandardised rates of early death. Additional comparisons
for changes in YLLs across diﬀerent years between 1990
and 2015 can be explored online.
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Causes of child death
Globally, under-5 deaths decreased by 27·2% (95% UI
25·2–29·0) between 2005 and 2015, reaching 5·8 million
deaths (95% UI 5·6 million to 6·0 million). Group 1
causes, which include communicable, maternal, neonatal,
and nutritional conditions, led to 80·8% (79·5–82·3;
4·7 million deaths, 4·6 million to 4·8 million) of under-5
deaths, NCDs caused 13·8% (12·6–14·9; 804 000 deaths,
733 000–868 000), and injuries accounted for 5·4%
(4·6–6·0; 313 000 deaths, 265 000–348 000) of deaths. Of
the selected causes shown in table 6, neonatal disorders,
which can aﬀect children beyond the neonatal period
(ie, infants younger than 1 month), caused 37·2%
(36·0–38·3) of under-5 deaths, equating to 2·2 million
deaths (2·1 million to 2·2 million) in 2015; these
causes included preterm birth complications, neonatal
encephalopathy, neonatal sepsis, and other neonatal
disorders. 62 Group 1 causes of under-5 deaths were
lower respiratory infections (12·1% [11·2–13·1],
703 000 deaths [651 000–763 000]); diarrhoeal diseases
(8·5% [7·7–9·5], 499 000 deaths [447 000–558 000]);
malaria (8·1% [5·7–10·7], 474 000 deaths [333 000–624 000]);
nutritional deﬁciencies (3·3% [2·6–4·3], 193 000 deaths
[147 000–248 000]); and meningitis (3·0% [2·3–3·9],
173 000 deaths [137 000–229 000]). Congenital anomalies,
which include congenital heart anomalies, led to 8·5%
(7·7–9·5) of under-5 deaths in 2015 (497 000 deaths,
1495
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Figure 13: Global decomposition of changes in leading 30 causes of death, 2005 to 2015
Changes due to population growth, population ageing, and changes in age-speciﬁc mortality rates are shown. Causes are reported in descending order by total
number of deaths for all ages and both sexes combined in 2015. The black circle shows the overall median percentage change in global deaths from 2005 to 2015.
Causes with increases in overall death rates have a circle to the right of the zero, whereas a circle to the left of the zero denotes causes with decreases in overall death
rates. The contributions of population growth, ageing, and change in age-speciﬁc death rates sum to the total change in numbers of deaths.

444 000–555 000), and other NCDs, such as sudden infant
death syndrome, accounted for 9·0% (8·1–9·9) of under-5
deaths that year (522 000 deaths, 470 000–580 000).
Neonatal deaths, which accounted for 45·0%
(44·9–45·2) of total under-5 deaths in 2015, decreased by
20·3% (95% UI 18·7–21·8), falling from 3·3 million
(3·2 million to 3·3 million) in 2005 to 2·6 million
(2·6 million to 2·7 million) in 2015. Neonatal
causes, mainly preterm complications and neonatal
encephalopathy, accounted for 77·5% (76·0–79·5) of
deaths among neonates (766 000 deaths, 700 000–854 000),
followed by neonatal sepsis, congenital anomalies, and
lower respiratory infections. Tetanus had the largest
reduction in neonatal deaths between 2005 and 2015,
falling 57·7% (50·0–64·2) to 19 900 deaths (17 000–23 400),
followed by malaria, which fell by 55·9% (41·1–67·8) to
13 900 deaths (8 930–19 800). Smaller improvements were
achieved in the reduction of neonatal deaths from sepsis
and congenital anomalies.
Among children aged 1–59 months, total deaths fell by
32·1% (95% UI 29·7–34·2) from 2005 to 2015, with
1·5 million (1·2 million to 1·8 million) fewer children in
this age group dying in 2015. Lower respiratory infections,
diarrhoeal diseases, and malaria caused 57·0% (49·7–64·6)
of deaths among children aged 1–59 months, leading to a
total of 1·8 million deaths (1·6 million to 2·1 million).
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Other leading causes of death for this age group included
congenital anomalies (254 000 deaths, 224 000–297 000),
nutritional deﬁciencies (193 000 deaths, 147 000–248 000),
and meningitis (147 000 deaths, 117 000–196 000). Deaths
due to measles fell by 75·1% (59·6–84·5), the largest
reduction among this age group, to 62 600 deaths
(22 400–136 000), followed by tetanus, which fell by 55·2%
(39·3–66·4) to 5560 deaths (4140–7760), and HIV/AIDS,
which fell by 51·9% (49·6–54·2), to 88 900 deaths
(84 300–93 700). Nearly all of these leading causes of death
showed some form of reduction from 2005 to 2015;
neonatal sepsis and congenital anomalies were exceptions,
both of which had, albeit not signiﬁcant, increases in
deaths since 2005.

Lower respiratory infections and diarrhoea by
pathogens
In 2015, we estimated that 1·3 million deaths (95% UI
1·2 million to 1·4 million) were caused by diarrhoeal
diseases, including 499 000 (447 000–558 000) in children
younger than 5 years, representing 8·6% (7·7–9·5) of all
deaths in this age group. Reductions in under-5 deaths
due to diarrhoeal diseases exceeded the rate of change for
all other age groups. Rotaviral enteritis (rotavirus) was
the leading cause of diarrhoeal death in children younger
than 5 years globally (29·3% [24·6–35·9%], 146 500 deaths
www.thelancet.com Vol 388 October 8, 2016
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Leading causes
1990

%
Median
change all-age
%
change

Leading causes
2005

1 Lower respiratory infections

1 Ischaemic heart disease

2 Neonatal preterm birth complications

2 Lower respiratory infections

3 Diarrhoeal diseases

3 Cerebrovascular disease

4 Ischaemic heart disease

Agestandardised %
change

Median
%
change all-age
%
change

Leading causes
2015

Agestandardised %
change

25·8

2·3

–12·6

1 Ischaemic heart disease

–10·2

–2·5

–14·8

–37·3

–49·0

–37·5

2 Cerebrovascular disease

–0·9

–12·4

–23·0

21·2

–1·4

–13·3

3 Lower respiratory infections

–23·9

–32·7

–31·1

4 HIV/AIDS

597·5

467·3

458·7

4 Neonatal preterm birth complications

–25·9

–34·5

–29·8

5 Cerebrovascular disease

5 Neonatal preterm birth complications

–39·4

–50·7

–37·4

5 Diarrhoeal diseases

–29·2

–37·4

–35·8

6 Neonatal encephalopathy

6 Diarrhoeal diseases

–38·5

–50·0

–40·4

6 Neonatal encephalopathy

–16·1

–25·8

–20·5

–33·9

–41·5

–41·4

–8·1

–18·7

–18·5

7 Malaria

7 Malaria

21·1

–1·5

19·1

7 HIV/AIDS

8 Measles

8 Neonatal encephalopathy

–3·5

–21·6

–0·3

8 Road injuries

9 Road injuries

11·0

–9·7

–7·8

–40·1

–47·0

–44·7

–4·6

–22·4

–30·1

10 COPD

–3·0

–14·2

–25·0

–2·3

–13·5

–8·3

–29·7

–33·7

9 Congenital anomalies

9 Malaria

10 Road injuries

10 COPD

11 Tuberculosis

11 Congenital anomalies

–17·6

–33·0

–16·8

11 Congenital anomalies

12 COPD

12 Tuberculosis

–16·0

–31·7

–36·5

12 Tuberculosis

–20·5

13 Drowning

13 Self-harm

14·8

–6·6

–10·8

13 Lung cancer

14·3

1·1

–11·5

14 Protein-energy malnutrition

14 Lung cancer

31·5

7·0

–6·2

14 Self-harm

–4·4

–15·4

–17·1

15 Meningitis

15 Neonatal sepsis

7·0

–13·0

10·5

15 Diabetes

25·4

10·9

–2·1

16 Self-harm

16 Meningitis

–25·2

–39·2

–27·7

16 Neonatal sepsis

–0·2

–11·7

–5·5

17 Other neonatal disorders

17 Measles

–65·1

–71·6

–64·6

17 Chronic kidney disease

18·4

4·7

–3·9

18 Neonatal sepsis

18 Diabetes

61·1

31·0

16·2

18 Meningitis

–11·8

–22·0

–18·9

19 Tetanus

19 Drowning

–38·2

–49·7

–42·9

19 Interpersonal violence

–6·1

–17·0

–16·2

20 Lung cancer

20 Protein-energy malnutrition

–38·5

–50·0

–38·7

20 Liver cancer

21 Interpersonal violence

21 Chronic kidney disease

36·9

11·4

5·3

22 Intestinal infectious diseases

22 Other neonatal disorders

–25·4

–39·3

–23·0

22 Protein-energy malnutrition

23 Stomach cancer

23 Interpersonal violence

16·3

–5·4

–5·1

23 Drowning

24 STDs

24 Liver cancer

32·7

7·9

–4·9

24 Stomach cancer

25 Chronic kidney disease

25 Stomach cancer

3·2

–16·1

–26·5

26 Asthma

26 Intestinal infectious diseases

–16·8

–32·3

27 Diabetes

27 Hypertensive heart disease

28 Liver cancer

28 Colorectal cancer

29 HIV/AIDS

29 Falls

30 Whooping cough

30 Alzheimer’s disease

31 Hypertensive heart disease

32 Asthma

37 Asthma

32 Falls

33 Breast cancer

44 STDs

40 Colorectal cancer

34 STDs

56 Measles

44 Breast cancer

46 Whooping cough

61 Whooping cough

45 Alzheimer’s disease

52 Tetanus

75 Tetanus

4·6

–7·5

–16·9

–16·0

–25·7

–20·5

–22·9

–31·8

–29·4

–26·4

–34·9

–32·4

–6·9

–17·7

–27·3

25 Alzheimer’s disease

30·5

15·5

–5·1

–23·4

26 Hypertensive heart disease

17·1

3·6

–8·9

27 Colorectal cancer

17·4

3·8

–8·9

7·4

–5·0

–8·8

7·6

–12·5

–24·2

32·9

8·1

–6·3

0·8

–18·1

–16·6

47·5

19·9

–3·7

21 Other neonatal disorders

28 Falls
29 Breast cancer
30 Intestinal infectious diseases

17·2

3·7

–7·5

–16·1

–25·8

–20·9

Communicable, maternal, neonatal,
and nutritional
Non-communicable
Injuries

Figure 14: Leading 30 Level 3 causes of global YLLs for both sexes combined for 1990, 2005, and 2015, with percent change in number of YLLs, and all-age and age-standardised rates
Causes are connected by lines between time periods. For the time periods 1990 to 2005 and 2005 to 2015, three measures of change are shown: percent change in the number of YLLs, percent change
in the all-age YLL rate, and percent change in the age-standardised YLL rate. Statistically signiﬁcant changes are shown in bold. YLLs=years of life lost. COPD=chronic obstructive pulmonary disease.
STDs=sexually transmitted diseases excluding HIV. An interactive version of this ﬁgure is available online at http://vizhub.healthdata.org/gbd-compare.

[118 000–183 500]) in 2015 followed by cryptosporidiosis
(Cryptosporidium; 12·1% [2·8–26·9], 60 400 deaths
[13 700–134 500]) and shigellosis (Shigella; 11·0%
[5·5–18·7], 54 900 deaths [27 000–94 700]). Rotavirus was
also the leading cause of mortality due to diarrhoea in all
ages (15·2% [12·9–18·1], 199 200 deaths [165 500–241 200]),
followed by Shigella (12·5% [6·4–21·2], 164 300 deaths
[85 000–278 700]) and other Salmonella infections (6·9%
[2·7–13·9], 90 300 deaths [34 100–183 100]; table 7).
Adenovirus was an important cause of mortality due to
diarrhoea in children younger than 5 years, accounting
for nearly 10% of such deaths in this age group (9·2
[3·3–19·7], 46 000 deaths [16 200–97 700]). Mortality due
to Clostridium diﬃcile was the lowest among all diarrhoea
causes, but was a major cause of diarrhoea mortality in
high-income countries. Moreover, it was the only cause
www.thelancet.com Vol 388 October 8, 2016

for which the attributable fraction increased from 2005 to
2015 (increased by 36·3%, 11·3–65·6). During this same
time period, the only attributable fraction to signiﬁcantly
decrease was for rotavirus (decreased by 14·1%,
6·3–20·5; table 7).
We estimated that 2·7 million (95% UI 2·5 million to
2·9 million) deaths occurred in 2015 due to lower
respiratory infections, of which 704 000 (651 000–763 000)
occurred among children younger than 5 years,
representing 12·1% of deaths in this age group. From
2005 to 2015, the number of deaths due to lower respiratory
infections decreased by 3·25% (−0·45 to 6·94) globally in
all age groups, but decreased by 36·9% (31·6–42·0) in
children younger than 5 years. Pneumococcal pneumonia
and H inﬂuenzae type b together accounted for nearly 65%
of deaths due to lower respiratory infections in children
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Neonates age <1 month

Children age 1–59 months

Under-5 totals

2015 (thousands)

Percentage
change, 2005–15

2015 (thousands) Percentage
change, 2005–15

2015
(thousands)

Percentage
change,
2005–15

All causes

2621·5
(2562·0–2680·8)

–20·3
(–21·8 to –18·7)

3199·4
(3093·9–3309·8)

–32·1
(–34·2 to –29·7)

5820·9
(5673·0–5965·2)

–27·2
(–29·0 to –25·2)

Communicable, maternal,
neonatal, and nutritional diseases

2331·6
(2272·8–2394·0)

–21·6
(–23·2 to –19·9)

2371·7
(2267·7–2473·5)

–37·1
(–39·9 to –34·4)

4703·4
–30·3
(4569·9–4845·5) (–32·4 to –28·1)

88·9
(84·3–93·7)

–51·9
(–54·2 to –49·6)

88·9
(84·3–93·7)

–51·9
(–54·2 to –49·6)

454·9
(404·4–510·2)

–33·9
(–42·4 to –23·4)

498·9
(447·5–557·6)

–34·3
(–42·3 to –24·9)

42·2
(22·5–73·2)

–20·0
(–29·8 to –8·9)

42·2
(22·5–73·2)

–20·0
(–29·8 to –8·9)

HIV/AIDS
Diarrhoeal diseases
Intestinal infectious diseases

··
44·0
(38·6–50·6)
··

··
–38·5
(–46·3 to –29·1)
··

Lower respiratory infections

152·9
(140·4–166·6)

–35·9
(–40·8 to –30·7)

551·0
(502·2–600·5)

–37·1
(–43·0 to –30·9)

703·9
(651·4–763·0)

–36·9
(–42·0 to –31·6)

Meningitis

25·8
(18·3–35·9)

–15·6
(–31·9 to 9·3)

147·3
(117·1–196·0)

–17·9
(–32·0 to 4·9)

173·1
(137·1–228·9)

–17·6 (–31·0
to 4·0)

54·5
(18·8–117·0)

–41·0
(–77·8 to 63·5)

54·5
(18·8–117·0)

–41·0
(–77·8 to 63·5)

5·6
(4·1–7·8)

–55·2
(–66·4 to –39·3)

25·5
(21·8–30·9)

–57·2
(–63·8 to –49·1)

62·6
(22·4–135·8)

–75·1
(–84·5 to –59·6)

62·6
(22·4–135·8)

–75·1
(–84·5 to –59·6)

Whooping cough

··

Tetanus

19·9
(17·0–23·5)

Measles

··

··
–57·7
(–64·2 to –50·0)
··

Malaria

13·9
(8·9–19·8)

–55·9
(–67·8 to –41·1)

460·2
(324·1–604·9)

–42·3
(–54·1 to –29·0)

474·1
(333·3–623·7)

–42·8 (–54·6
to –29·4)

Neonatal preterm birth
complications

765·9
(700·0–854·3)

–25·9
(–31·5 to –20·5)

39·9
(32·7–48·3)

–25·9
(–39·3 to –8·4)

805·8
(736·2–898·6)

–25·9
(–31·3 to –20·6)

Neonatal encephalopathy (birth
asphyxia and trauma)

707·8
(638·4–789·7)

–16·3
(–23·8 to –8·0)

32·6
(24·8–43·0)

–11·9
(–34·0 to 16·4)

740·4
(667·6–829·2)

–16·1
(–23·8 to –8·0)

Neonatal sepsis and other
neonatal infections

336·3
(237·4–441·5)

–0·5
(–16·9 to 20·7)

15·4
(10·0–20·6)

7·8
(–18·0 to 40·6)

351·7
(249·2–459·1)

–0·2
(–16·2 to 20·3)

Other neonatal disorders

180·0
(133·9–229·4)

–16·4
(–35·1 to 6·2)

40·3
(29·2–52·3)

–14·1
(–39·2 to 19·9)

220·2
(167·6–276·8)

–16·0
(–34·1 to 5·6)

192·8
(147·2–248·1)

–24·3
(–40·4 to –4·1)

192·8
(147·2–248·1)

–24·3
(–40·4 to –4·1)

Nutritional deﬁciencies

··

··

Syphilis

31·5
(17·5–49·2)

–28·4
(–34·5 to –21·5)

59·0
(32·9–95·7)

–16·5
(–28·7 to –5·4)

90·5
(50·6–144·5)

–21·1
(–30·4 to –12·5)

Other communicable diseases

53·6
(39·3–75·5)

–30·9
(–44·1 to –16·4)

124·7
(108·2–141·5)

–21·7
(–30·2 to –10·3)

178·3
(151·7–211·3)

–24·7
(–32·3 to –16·2)

267·4
(234·3–290·8)

–7·1
(–18·4 to 0·8)

537·2
(488·1–592·6)

–8·0
(–18·0 to 2·9)

804·5
(733·8–868·9)

–7·7
(–17·3 to 1·0)

Congenital anomalies

242·6
(213·6–263·6)

–6·0
(–18·4 to 2·5)

254·0
(223·6–297·4)

–0·4
(–17·2 to 13·7)

496·6
(444·4–554·6)

–3·2
(–17·8 to 7·6)

Sudden infant death syndrome

1·9
(1·6–2·6)

–9·7
(–25·5 to 4·9)

17·3
(14·2–24·9)

–7·7
(–23·1 to 9·7)

19·2
(15·9–27·5)

–7·9
(–23·0 to 8·9)

Other non-communicable
diseases

22·9
(17·3–37·3)

–17·3
(–29·3 to 3·8)

265·9
(232·7–315·0)

–14·3
(–25·5 to 1·6)

288·8
(251·6–348·9)

–14·6
(–25·3 to –0·1)

22·5
(17·0–25·9)

–13·9
(–23·1 to –2·7)

290·5
(247·2–323·4)

–17·5
(–25·9 to –5·0)

313·0
(265·2–348·4)

–17·3
(–25·3 to –5·2)

Road injuries

2·4
(1·7–3·4)

–27·8
(–49·9 to 2·4)

47·1
(40·9–54·2)

–16·0
(–30·0 to 4·1)

49·5
(43·0–56·8)

–16·7
(–30·1 to 2·5)

Drowning

1·4
(0·9–1·9)

–20·3
(–44·4 to 16·9)

54·7
(43·4–64·3)

–37·1
(–47·0 to –23·9)

56·1
(44·4–65·7)

–36·8
(–46·6 to –23·8)

Other injuries

18·7
(14·0–21·7)

–11·2
(–20·8 to 1·6)

188·7
(155·8–216·0)

–9·8
(–20·2 to 6·2)

207·4
(170·2–236·6)

–9·9
(–19·9 to 5·3)

Non-communicable diseases

Injuries

Data in parenthesis are 95% uncertainty intervals. The selected causes are the major causes of death within each Level 1 group that accounted for deaths in children younger
than 5 years. Neonates were deﬁned as children younger than 1 month. Childhood was deﬁned as ages 1–59 months.

Table 6: Selected causes of global child deaths for both sexes combined in 2005 and 2015, with percentage change between 2005 and 2015
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younger than 5 years (table 7). The attributable fraction of
deaths due to lower respiratory infection caused by
pneumococcal pneumonia was highest in children
younger than 5 years (55·8%, 32·5–75·0) and all ages
(55·4%, 31·5–79·1). The percentage of under-5 deaths due
to H inﬂuenzae type b decreased by 60·7% (56·8–65·7),
from 13·4% (−0·8 to 24·7) in 2005 to 8·3% (−0·5 to 15·9)
in 2015, with 58 700 deaths (−3130 to 115 000) recorded in
2015. Respiratory syncytial virus (5·2% [2·9–8·6],
36 400 deaths [20 400–61 500]) and inﬂuenza (1·4%
[0·8–2·4], 10 200 deaths [5700–16 800]) together accounted
for less than 10% of deaths due to lower respiratory
infections in children younger than 5 years, and the
remaining 29% of such deaths in this age group remain
unattributed.

Expected changes in disease proﬁle with higher SDI
Figure 15 shows the changes in patterns of premature
mortality as they relate to age-standardised rates of
YLLs, population age structure, and total YLLs per
100 000 population. With increasing SDI, age-standardised YLL rates narrowed (ﬁgure 15A), from a total of
98 742 YLLs per 100 000 for males and 96 381 YLLs
per 100 000 for females at low SDI, to a low of 9172 YLLs
per 100 000 and 6239 YLLs per 100 000, respectively, at
high SDI. The cause composition of YLLs substantially
shifted as well. At lower SDI, premature mortality
was largely due to communicable diseases that
disproportionately aﬀect children, such as diarrhoeal
disease and lower respiratory infections, measles, and
meningitis, but with increasing SDI, YLLs due to these
causes markedly decreased. Age-standardised YLL rates
due to HIV/AIDS and tuberculosis, neglected tropical
diseases and malaria, neonatal disorders, and maternal
disorders also rapidly decreased as SDI increased.
Nonetheless, the gains achieved for neglected tropical
diseases and malaria with rising SDI were somewhat
attenuated because the rates of premature mortality due
to dengue and Chagas disease increased. For a subset of
NCDs, several causes had reductions in age-standardised
YLL rates amid improving SDI, including chronic
respiratory diseases; digestive diseases; diabetes,
urogenital, blood, and endocrine diseases; and
unintentional injuries. However, for other causes, the
relationship between increasing SDI and premature
mortality was less obvious. Age-standardised YLL rates
due to cardiovascular disease gradually increased for
both sexes until SDI reached 0·40, after which rates
declined slowly until an SDI of 0·7, and more rapidly
thereafter. For cancers, age-standardised rates of YLLs
rose steadily between SDI levels of 0·60 and 0·72, and
then largely plateaued. Notably, changes in agestandardised YLL rates and SDI aﬀected the relative ratio
of early death by sex for a subset of causes. Cancers, for
example, began to exact a larger toll for males than
females at SDI levels of about 0·40; this was mainly
associated with rising mortality due to lung cancer.
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A similar trend occurred for cardiovascular disease, with
the age-standardised YLL rates of males exceeding those
of females beyond an SDI of 0·27. Injuries generally
caused higher rates of age-standardised YLLs among
males than females across all levels of SDI, but the
largest imbalance occurred between SDI levels of 0·35
and 0·72.
Increases in SDI had sizeable implications for
population age structure (ﬁgure 15B), and in combination
with age-standardised rates of cause-speciﬁc YLLs, these
factors shape the magnitude—and types—of early deaths
worldwide (ﬁgure 15C). At the lowest levels of SDI (where
SDI equals 1), 49·8% of the population was younger than
15 years and 0·23% was older than 80 years, whereas
11·3% were younger than 15 years and 9·3% were older
than 80 years at the highest levels of SDI (where SDI
equals 100). Diﬀerences by sex with increasing SDI were
minimal, except for in the oldest age groups starting
from SDI of 0·40. At highest SDI, the 80 years and older
age group consisted of far more females (10·9%) than
males (6·2%). Below an SDI of 0·50, Group 1 causes,
especially infectious diseases such as diarrhoeal diseases
and lower respiratory infections, accounted for most
premature mortality (as much as 72·5%, or roughly
141 513 YLLs per 100 000). Between SDI levels of 0·32 and
0·58, premature mortality from communicable causes,
nutritional deﬁciencies, and maternal disorders sharply
decreased, whereas YLLs per 100 000 due to NCDs and
injuries remained relatively unchanged or slowly
increased; notably, as SDI increased, early death due to
neonatal disorders decreased at a much slower pace than
did other Group 1 causes. At SDI of 0·50 and above,
NCDs and injuries accounted for a larger portion of total
YLLs per 100 000 than did communicable, maternal,
neonatal, and nutritional causes. With further
improvements in SDI, YLLs per 100 000 generally
plateaued—or even increased for some causes—as
population age structures began to shift faster than the
falls in age-standardised rates of death. The stark contrast
between the absolute and relative causes of YLLs
per 100 000 for SDI levels lower than 0·40 and higher
than 0·60 accentuates the complex disease proﬁle of the
remaining levels of SDI: relatively high levels of
premature mortality due to a broad mixture of causes,
ranging from neonatal disorders to cardiovascular
disease.

Attribution of change in life expectancy to changes in
major causes of death
Figure 16 shows changes in life expectancy from 2005 to
2015, as attributable to changes in Level 2 causes of death,
for each country, territory, and subnational geography. In
2015, Andorra had the highest life expectancy at birth for
males (81·2 years, 95% UI 80·8–81·6) and females
(88·4 years, 88·1–88·7), whereas Lesotho experienced the
lowest life expectancy at birth for both sexes (44·1 years,
38·6–51·8 for males and 50·4 years, 43·6–58·5 for
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Children younger than 5 years
2005

All ages
2015

Percentage
change, 2005–15

2005

2015

Percentage
change, 2005–15

Deaths
(thousands)

Population
attributable
fractions (%)

Deaths
(thousands)

Population
attributable
fractions (%)

–38·4
(–49·9 to –24·3)

98·7
(70·7 to 130·3)

6·0
(4·3 to 7·7)

68·4
(50·4 to 87·1)

5·2
(3·8 to 6·6)

–30·7
(–38·9 to –21·1)

7·7
(2·5 to 16·6)

–35·9
(–76·9 to 76·3)

116·8
7·0
(44·3 to 241·9) (2·7 to 14·5)

90·3
(34·1 to 183·1)

6·9
(2·7 to 13·9)

–22·7
(–71·8 to 116·1)

54·9
(27·0 to 94·7)

11·0
(5·5 to 18·7)

–33·8
(–68·3 to 40·9)

195·4
11·8
(101·5 to 328·5) (6·2 to 19·6)

164·3
12·5
(85·0 to 278·7) (6·4 to 21·2)

–15·9
(–59·2 to 77·4)

2·0
(0·1 to 5·4)

11·3
(0·7 to 32·0)

2·3
(0·1 to 6·2)

–26·0
(–85·5 to 283·4)

16·0
(0·6 to 44·6)

12·0
(0·6 to 34·1)

–25·1
(–83·8 to 249·8)

Deaths
(thousands)

Population
attributable
fractions (%)

Deaths
(thousands)

Population
attributable
fractions (%)

Cholera

46·8
(32·2 to 64·5)

6·2
(4·3 to 8·4)

28·8
(20·6 to 39·7)

5·8
(4·1 to 7·9)

Other Salmonella
infections

60·1
(18·6 to 131·3)

7·9
(2·5 to 17·6)

38·5
(12·2 to 84·2)

Shigellosis

83·0
10·9
(42·8 to 147·3) (5·7 to 18·9)

Diarrhoea

Enteropathogenic 15·2
(0·7 to 41·7)
Escherichia coli
infection

1·0
(0·0 to 2·6)

0·9
(0·0 to 2·6)

Enterotoxigenic
Escherichia coli
infection

38·2
(15·7 to 72·5)

5·0
(2·1 to 9·3)

23·6
(9·6 to 44·3)

4·7
(2·0 to 8·9)

–38·1
(–74·0 to 42·7)

91·8
5·5
(40·3 to 167·0) (2·5 to 10·1)

74·1
5·6
(29·9 to 137·9) (2·3 to 10·4)

–19·3
(–66·5 to 91·2)

Campylobacter
enteritis

46·1
(10·5 to 94·1)

6·1
(1·4 to 12·4)

30·9
(8·3 to 62·5)

6·2
(1·7 to 12·5)

–32·9
(–68·2 to 48·8)

52·7
(11·1 to 111·0)

3·2
(0·7 to 6·8)

37·5
(6·3 to 81·6)

2·9
(0·5 to 6·2)

–28·9
(–69·8 to 67·0)

Amoebiasis

26·1
3·4
(–37·8 to 173·9) (–4·9 to 22·3)

15·5
3·1
–40·8
(–32·4 to 102·4) (–6·3 to 20·7) (–467·1 to 881·9

79·7
(4·9 to 316·8)

4·8
(0·3 to 18·8)

67·9
(5·6 to 236·7)

5·2
(0·4 to 18·1)

–14·8
(–90·9 to 837·6)

Cryptosporidiosis

78·7
10·3
(21·2 to 179·0) (2·9 to 22·8)

60·4
(13·7 to 134·5)

83·0
(14·5 to 201·5)

5·0
(0·9 to 11·8)

64·8
(11·1 to 154·2)

4·9
(0·8 to 11·6)

–21·9
(–81·6 to 208·8)

146·5
29·3
–43·6
(118·0 to 183·5) (24·6 to 35·9) (–52·1 to –33·0)

336·1
(281·3 to
403·7)

20·3
(17·4 to
24·0)

199·2
(165·5 to
241·2)

–40·7
15·2
(12·9 to 18·1) (–48·0 to –32·3)

34·2
(29·3 to 41·5)

Rotaviral enteritis 259·7
(211·2 to
323·5)

12·1
(2·8 to 26·9)

–23·2
(–80·6 to 188·8)

Aeromonas

11·8
1·5
(–72·2 to 90·6) (–9·5 to 11·8)

7·3
(–48·3 to 59·1)

1·4
–37·9
(–9·7 to 12·0) (–96·0 to 287·7)

67·8
4·1
(–10·4 to 189·9) (–0·6 to 11·4)

56·8
(–4·0 to 151·3)

4·3
(–0·3 to 11·6)

–16·2
(–112·7 to 475·3)

Clostridium
diﬃcile

0·9
(0·8 to 1·1)

0·1
(0·1 to 0·1)

0·8
(0·7 to 0·9)

0·2
(0·1 to 0·2)

–10·5
(–24·0 to 2·3

6·7
(5·9 to 7·7)

0·4
(0·3 to 0·5)

9·4
(7·9 to 11·5)

0·7
(0·6 to 0·9)

40·1
(29·6 to 49·9)

Norovirus

20·7
(5·0 to 46·3)

2·7
(0·7 to 6·3)

14·8
(4·2 to 33·7)

3·0
(0·8 to 6·7)

–28·5
(–71·9 to 86·3)

36·3
(5·6 to 82·5)

2·2
(0·3 to 5·0)

29·7
(4·8 to 67·6)

2·3
(0·4 to 5·2)

–18·3
(–70·8 to 131·3)

Adenovirus

68·5
(24·8 to 141·9)

9·0
(3·3 to 18·6)

46·0
(16·2 to 97·7)

9·2
(3·3 to 19·7)

–32·8
(–77·2 to 90·1)

95·2
5·7
(35·4 to 191·4) (2·1 to 11·6)

70·2
5·4
(25·4 to 145·4) (2·0 to 10·9)

–26·2
(–74·5 to 110·8)

1·4
(0·8 to 2·4)

–37·8
(–44·2 to –31·7)

81·3
2·9
(56·3 to 116·8) (1·9 to 4·2)

83·1
(55·7 to 122·1)

3·0
(2·0 to 4·4)

2·3
(–4·4 to 8·7)

Lower respiratory infections
Inﬂuenza

16·3
(9·6 to 26·0)

1·5
(0·8 to 2·4)

10·2
(5·7 to 16·8)

Pneumococcal
pneumonia

642·0
(386·2 to
848·6)

57·6
(35·5 to 74·1)

393·0
55·8
–38·8
(228·4 to 532·3) (32·5 to 75·0) (–45·7 to –32·1)

1692·3
(1061·1 to
2245·6)

59·8
(37·7 to 79·2)

1517·4
(857·9 to
2183·8)

55·4
–10·3
(31·5 to 79·1) (–22·4 to –0·8)

Haemophilus
inﬂuenzae type b

149·5
13·4
(–8·9 to 277·9) (–0·8 to 24·7)

58·7
(–3·1 to 114·5)

8·3
–60·7
(–0·5 to 15·9) (–65·7 to –56·8)

149·5
(–8·9 to 277·9)

5·3
(–0·3 to 9·9)

58·7
(–3·1 to 114·5)

2·1
(–0·1 to 4·2)

–60·7
(–65·7 to –56·8)

Respiratory
syncytial virus

58·4
(33·2 to 97·6)

36·4
(20·4 to 61·5)

5·2
(2·9 to 8·6)

95·8
3·4
(61·5 to 142·6) (2·2 to 5·1)

82·0
(53·9 to 117·6)

3·0
(2·0 to 4·3)

–14·3
(–23·1 to –5·2)

5·2
(3·0 to 8·7)

–37·8
(–44·4 to –30·6)

Data in parentheses are 95% uncertainty intervals. Numbers for each cause represent the reduction in deaths that is estimated to occur if a pathogen were eliminated. Numbers should not be summed across
pathogens because of interactions between pathogens.

Table 7: Global counterfactual deaths and population attributable fractions for diarrhoea and lower respiratory infection pathogens for 2005 and 2015, with percentage change between
2005 and 2015

females). Overall, several countries in sub-Saharan Africa
had the largest gains in longevity since 2005. By 2015,
Zimbabwe had the fastest progress for both sexes, with life
expectancy increasing by 11·7 years (5·5–18·3) to 56·3 years
(51·1–62·6) for males and 17·0 years (10·1–23·3) to
62·5 years (56·3–68·3) for females. Furthermore, female
life expectancy increased by more than 10 years for eight
countries in sub-Saharan Africa (South Africa, Ethiopia,
Botswana, Zambia, Swaziland, Namibia, Zimbabwe, and
1500

Malawi); this progress was largely attributable to marked
reductions in mortality from HIV/AIDS. Death rates due to
HIV/AIDs peaked from 2003 to 2005 for many of these
countries, after which sizeable gains in prolonged life
occurred through to 2015. For some countries, including
Laos, decreases in death rates from various communicable
diseases, such as diarrhoeal diseases and lower respiratory
infections, were related to improved life expectancy,
whereas several countries in central and eastern Europe
www.thelancet.com Vol 388 October 8, 2016
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Figure 15: Expected relationship between age-standardised YLL rates per 100 000 people for the 21 GBD Level 2 causes and SDI (A), the expected relationship between population
and SDI (B), and the expected relationship between all-age YLL rates per 100 000 people for the 21 GBD Level 2 causes and SDI (C), by sex
The stacked curves in A and C represent the average relationship between SDI and each cause of YLLs observed across all geographies over the time period 1980 to 2015. In each ﬁgure, the y-axis spans
from the lowest SDI up to the highest SDI. To the left of the midline are male rates, and the female rates are to the right; higher rates are further from the midline. GBD=Global Burden of Disease.
SDI=Socio-demographic Index. YLL=years of life lost.

recorded gains in longevity that were mainly associated
with relative reductions in cardiovascular disease deaths.
Nonetheless, seven countries and territories had higher
life expectancies for both sexes combined (nine for males
only, four for females only) in 2005 than in 2015 and
many others had minimal progress due to rising
numbers of war-related causalities. By 2015, average life
expectancy for both sexes fell by 1·3 years (−0·3 to 2·8)
in Libya, 1·1 years (−0·2 to 2·4) in Dominica, and
7·3 years (1·8–12·1) in Syria; however, these reductions
were far more pronounced among males in these
countries, with male life expectancy reduced by 11·3 years
(3·7–17·4) in Syria, 2·5 years (0·2–4·9) in Libya, and
1·6 years (−0·3 to 3·6) in Dominica. For Syria and Libya,
rising mortality due to war was the main driver of such
losses in longevity, whereas NCDs, including cancers
and cardiovascular disease, led to reduced male life
expectancy in Dominica. Six other geographies also had
www.thelancet.com Vol 388 October 8, 2016

decreases in male life expectancy since 2005, with losses
of 0·9 years (−0·6 to 2·5) in Jamaica, 1·6 years
(−1·2 to 4·2) in Guam, 0·5 years (−2·4 to 3·2) in
Palestine, 0·4 years (–1·3 to 2·0) in the Northern Mariana
Islands, 0·6 years (−0·7 to 2·0) in the Virgin Islands, and
0·5 years (−1·2 to 2·1) in Venezuela. Increased mortality
from cancers, cardiovascular disease, diabetes, and
chronic kidney disease was associated with reduced life
expectancy among males in Jamaica and Guam, whereas
increased death rates due to interpersonal violence
largely contributed to reduced longevity for males in
Venezuela. For several countries and territories, overall
life expectancy increased from 2005 to 2015, but
heightened mortality due to natural disasters,
interpersonal violence, and war oﬀset gains achieved
against other causes of death since 2005. In Yemen, for
example, male and female life expectancy rose by
1·0 years and 1·9 years, respectively, yet rising war-related
1501
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deaths resulted in reductions in life expectancy of
1·5 years for males and 1·0 years for females, attenuating
further improvement in life expectancy. Similar results
emerged for other countries in which war has claimed
increasingly more lives, including Afghanistan, Iraq,
Somalia, and South Sudan. The 2015 earthquake in Nepal
largely contributed to the 0·7 years lost for females and
0·8 years for males; nonetheless, overall life expectancy
improved by 2·1 years (−0·4 to 4·6) and 2·4 years
(0·0–4·6) for males and females in Nepal, respectively—
gains mainly attributable to reductions in mortality from
diarrhoeal diseases and lower respiratory infections.
Inequalities in life expectancy by sex generally
increased over time. In 2005, the diﬀerence between
male and female life expectancy was 5·0 years (65·7 years,
95% UI 65·5–65·9 for males and 70·7 years, 70·5–71·0
for females), which widened to 5·8 years in 2015
(69·0 years, 68·3–69·4 for males and 74·8 years,
74·4–75·2 for females). For several countries, including
Russia, Estonia, and Latvia, diﬀerences between male
and female life expectancy narrowed more rapidly; these
gains could be attributed to reduced mortality due to
cardiovascular diseases, cancer, and injuries. Yet,
inequalities in life expectancy grew in many countries
and territories, often driven by uneven progress in health
by sex and increasing male deaths due to a subset of
NCDs. For example, Georgia recorded a widening gap
between male and female life expectancy, rising from
8·6 years (7·7–9·6) in 2005 to 10·2 years (8·9–11·4) in
2015. In other places (eg, Syria), rising mortality from
interpersonal violence or war disproportionately aﬀected
males.

Leading causes of YLLs and deviations from expected
levels based on SDI
Distinct, yet notably varied, patterns emerged across and
within GBD regions when we compared observed YLLs
due to leading causes with the levels of premature
mortality expected on the basis of SDI. Figure 17 shows
the ratios of observed and expected YLLs for the
ten leading causes by geography in 2015, colour coded by
the magnitude of diﬀerences between observed and
expected YLLs.
Globally, ischaemic heart disease and stroke were the
leading two causes of premature mortality in 2015;
119 countries and territories also had ischaemic heart
disease or stroke as the leading cause of YLLs that year.
Three geographical regions featured countries that
largely diverged from this trend: Latin America and the
Caribbean, where interpersonal violence or lower
respiratory infections frequently accounted for the most
YLLs; north Africa and the Middle East, where war was
the primary cause of early death in several countries;
and sub-Saharan Africa, where HIV/AIDS or malaria
was the leading cause of YLLs in 28 countries.
Furthermore, lung cancer consistently ranked among
the top three causes of YLLs in high-income countries;
1502

road injuries were a major cause of early death in Latin
American countries; and neonatal disorders were
frequently among leading ﬁve causes of YLLs in south
Asia and sub-Saharan Africa.
Of the ten leading causes of premature mortality
globally, lower respiratory infections resulted in the
most countries (122) recording observed YLLs lower
than those expected on the basis of SDI. This ﬁnding
was particularly prevalent in east Asia, where China and
North Korea had YLL ratios less than 0·40. Other leading
causes for which observed YLLs were much lower than
expected included stroke in Andean Latin America and
neonatal preterm birth complications in Oceania. By
contrast, HIV/AIDS led to the highest discrepancies for
observed and expected YLLs, particularly aﬀecting
southern sub-Saharan Africa. Diarrhoeal diseases,
particularly in southern sub-Saharan Africa, and
neonatal encephalopathy due to birth asphyxia and
trauma, particularly in southern Asia, also resulted in
large diﬀerences for observed and expected YLLs.

Regional, country, territory, and selected subnational
results
For many high-income countries, observed YLLs due to
stroke—a cause consistently among the leading three
causes of early death—fell below the levels expected on
the basis of SDI in 2015. Spain, France, Malta, and Israel
had particularly low ratios for observed versus expected
YLLs from stroke, all falling below 0·45; 26 countries,
including Portugal, Argentina, and Uruguay had ratios
lower than 0·80. A subset of countries, including Japan,
South Korea, and Chile, also had lower observed YLLs
from ischaemic heart disease than expected on the basis
of SDI. Early death due to drug use disorders exceeded
expected levels in the USA (5·71), Scotland (5·08), and
Norway (3·44), and a similar pattern was found for YLLs
due to alcohol use disorders in Denmark (10·50) and
Finland (9·61). Within the GBD high-income superregion, Brunei, Greenland, and the USA had some of the
largest deviations between observed and expected YLLs
across causes. Within the UK, observed YLLs from selfharm and stroke were often substantially lower than
expected for most regions, whereas observed levels of
premature mortality due to COPD were higher than
expected.
Throughout Latin America and the Caribbean,
observed YLLs due to interpersonal violence far exceeded
those expected on the basis of SDI, with 19 countries
and territories recording ratios higher than 3·00.
Furthermore, interpersonal violence ranked as the ﬁrst
or second leading cause of early death for seven of
11 countries in central and Tropical Latin America. For
these two geographical regions, discrepancies between
observed and expected YLLs from interpersonal violence
were highest in Venezuela (9·91) and Brazil (4·88),
respectively. Observed YLLs were also higher than
expected for diabetes, especially in the Caribbean;
www.thelancet.com Vol 388 October 8, 2016
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−0·0

Liberia

+5·2

−0·2

Malawi

+13·7

−0·1

Burundi

+7·5

−0·0
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−0·0

Singapore

+1·9

−0·0
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+1·8

−0·0
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−0·0
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+1·6

−0·1
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+2·3

−0·0
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+1·8

−0·0
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+2·4

−0·0

Finland

+2·1

−0·0

Northern Ireland (UK)
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+1·2
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Jordan

+1·8
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+2·0
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+3·7
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+2·6
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+1·3

−0·0
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+0·8

−0·0
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+2·9

−0·0
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+2·7

−0·0
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+1·8

−0·1

+6·3

−0·0

+1·3

−0·4
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+1·9

−0·1
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+1·8

−0·1
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+4·4

−0·0
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+3·9

−0·0
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+1·3
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Egypt
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Figure 16: Attribution of changes in life expectancy at birth to changes in major groups of causes of death, 2005 to 2015
Changes are shown for countries and territories (and subnational units in the UK) for females (A) and males (B). Locations are ordered by decreasing life expectancy at birth in 2015. Blue lines show life
expectancy at birth in 2005 and black lines show life expectancy at birth in 2015. Causes to the left of the 2005 life expectancy values reﬂect causes that contributed to reductions in life expectancy
from 2005 to 2015. Causes to the right of the 2005 life expectancy values contributed to increases in life expectancy from 2005 to 2015.
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chronic kidney disease, particularly in Mexico (3·22);
and prostate cancer for several Caribbean islands and
territories. Although ischaemic heart disease was a
leading cause of early death for many Latin American
countries, several had ratios of observed and expected
YLLs lower than 0·60, including Peru (0·33), Panama
(0·50), and Colombia (0·51). Similar results were found
for stroke (eg, a ratio of 0·26 for Costa Rica); road injuries
(eg, Honduras [0·37] and Cuba [0·48]); and for preterm
birth complications (Haiti [0·43] and Guatemala [0·32]).
In 2015, leading causes of early death, as well as
their observed and expected levels, were markedly
heterogeneous in southeast and east Asia and Oceania.
For many countries and territories, lower respiratory
infections ranked among the ten leading causes of
premature mortality, but observed YLLs fell below the
levels expected on the basis of SDI (eg, 0·22 in the
Maldives, 0·34 in China, and 0·46 in the Solomon
Islands). For others, such as Malaysia and Laos, observed
YLLs due to lower respiratory infections were higher than
expected. Within the region, 18 countries and territories
had ischaemic heart disease as their leading cause of
YLLs in 2015, but their ratios of observed versus expected
YLLs ranged from less than 0·50 in Thailand to more
than 4·00 in Guam. Particularly in Oceania, observed
levels of YLLs due to diabetes and chronic kidney disease
consistently exceeded expected YLLs, and premature
mortality due to liver cancer was higher than expected in
Taiwan (province of China), Thailand, China, North
Korea, Vietnam, and Tonga. Observed YLLs due to
communicable diseases were at least twice as high as
expected for some countries, including measles in Papua
New Guinea (3·61) and tuberculosis in Indonesia (6·53)
and the Philippines (4·11). At the same time, several
countries and territories recorded cause-speciﬁc YLLs
that were substantially lower than expected, such as
preterm birth complications in Papua New Guinea (0·35);
road injuries in Sri Lanka (0·47) and Samoa (0·31); and
self-harm in Malaysia (0·52) and China (0·51).
Patterns of early death in south Asia reﬂect the region’s
diversity of countries and their relative stages of
development. Although lower respiratory infections,
diarrhoeal diseases, and congenital anomalies remained
among the leading causes of premature mortality
throughout south Asia, observed levels of YLLs were
generally lower than those expected on the basis of SDI.
However, for most countries in south Asia, observed
YLLs due to neonatal encephalopathy were more than
twice as high as expected (eg, 2·94 in Pakistan and
2·13 in India). Notably, observed YLLs from intestinal
infections, such as typhoid fever, were above expected
levels in Bangladesh (6·07). Observed levels of YLLs
exceeded expected levels for a subset of NCDs, including
ischaemic heart disease in Pakistan (1·81), and COPD in
India (2·44). In 2015, an earthquake claimed more than
8700 lives in Nepal, and since the occurrence of
earthquakes has minimal linkages to SDI, the ratio for
www.thelancet.com Vol 388 October 8, 2016

observed and expected YLLs was extremely high for
natural disasters. At the same time, Nepal and Bangladesh
had substantially fewer than expected YLLs due to
preterm birth complications (0·25 and 0·40, respectively).
Observed levels of early death from stroke were also
lower than expected in Bhutan (0·49) and Nepal (0·49).
In central Europe, eastern Europe, and central Asia,
except for a subset of causes and countries, observed
YLLs generally met or exceeded the levels expected on
the basis of SDI. YLL ratios due to ischaemic heart
disease and hypertensive heart disease were more
than 2·00 for 17 countries, and observed premature
mortality due to cardiomyopathy and myocarditis was at
least three times higher than expected levels in Russia
(10·86), Latvia (7·93), and Bosnia and Herzegovina
(5·65). Alcohol and drug use disorders were among the
ten leading causes of early death throughout the region,
and observed levels often exceeded expected YLLs (eg,
24·53 for drug use disorders in the Ukraine and 17·95 for
alcohol use disorders in Russia). Early death from
cirrhosis due to alcohol use was more common than
expected in several countries, including Moldova (4·24)
and Hungary (3·40), whereas levels of YLLs due to
interpersonal violence far exceeded expected levels in
Russia (12·78) and Kazakhstan (5·65). Group 1 causes
often led to higher levels of observed YLLs than expected
in central Asia, such as neonatal encephalopathy in
Azerbaijan (8·26) and lower respiratory infections in
Turkmenistan (6·81). Notably, several countries had
much lower than expected observed YLLs due to road
injuries, including Albania (0·38) and Macedonia (0·47).
In north Africa and the Middle East, large discrepancies
occurred between observed YLLs and those expected on
the basis of SDI, underscoring the region’s rapid
development and inequalities in wealth. Furthermore,
because of the region’s escalating rates of war-related
mortality, which is not strictly related to SDI, ratios of
observed versus expected YLLs from war were extremely
high. The United Arab Emirates (UAE) and Afghanistan
had the most causes for which observed levels of YLLs
exceeded expected YLLs; these causes ranged from
ischaemic heart disease to interpersonal violence for
Afghanistan, and included chronic kidney disease, COPD,
diabetes, and road injuries for the UAE. Many countries
in the region recorded substantially lower YLLs than
expected for several causes: 13 had ratios less than 0·60
for lower respiratory infections, including Iraq (0·40) and
Palestine (0·25); eight countries had ratios less than 0·60
for stroke, including Lebanon (0·45) and Turkey (0·42);
and six had ratios less than 0·60 for preterm birth
complications, including Egypt (0·47) and Syria (0·19).
For every country in sub-Saharan Africa, the leading
cause of early death was one of four communicable
diseases—HIV/AIDS, malaria, lower respiratory
infection, or diarrhoeal diseases—yet patterns in
observed and expected levels of YLLs strikingly diﬀered
within the continent. In southern sub-Saharan Africa,
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LRI
(6·81)
LRI
(2·62)
Violence
(4·23)
IHD
(0·62)
IHD
(0·51)
Road injuries
(0·65)
IHD
(0·61)
Violence
(4·74)
IHD
(1·02)
CKD
(3·22)
IHD
(0·46)
Violence
(4·74)
IHD
(0·91)
IHD
(0·42)
IHD
(0·55)
Road injuries
(0·98)
IHD
(0·33)
Stroke
(0·89)
Stroke
(1·33)
Stroke
(1·27)
Diabetes
(4·62)
Violence
(3·66)
Stroke
(1·12)
Stroke
(0·63)
Diabetes
(3·95)
Stroke
(0·74)
Stroke
(1·26)
HIV
(2·21)
LRI
(0·72)

3
LRI
(2·08)
Lung C
(1·32)
Stroke
(1·33)
Road injuries
(1·08)
Self-harm
(2·16)
LRI
(1·21)
Self-harm
(3·03)
NN preterm
(0·64)
Stroke
(2·36)
Stroke
(1·17)
Road injuries
(0·84)
Road injuries
(0·73)
Road injuries
(0·6)
Congenital
(0·91)
CKD
(2·27)
Diarrhoea
(0·88)
Stroke
(0·89)
Diabetes
(2·7)
LRI
(0·38)
Road injuries
(0·86)
Road injuries
(1·19)
Road injuries
(0·68)
Stroke
(0·66)
IHD
(0·48)
Road injuries
(0·56)
LRI
(0·84)
Diabetes
(7·24)
Violence
(14·42)
Stroke
(0·81)
IHD
(0·73)
Lung C
(1·05)
Lung C
(1·15)
Stroke
(0·78)
Road injuries
(0·93)
LRI
(2·31)
Stroke
(1·56)
IHD
(1·19)

4
NN encephalitis
(2·25)
Diabetes
(2·26)
NN encephalitis
(8·26)
Lung C
(0·97)
Road injuries
(1·55)
NN preterm
(0·94)
LRI
(2·24)
Stroke
(0·92)
Congenital
(2·06)
NN encephalitis
(2·74)
Stroke
(0·59)
CKD
(2·16)
Congenital
(0·88)
CKD
(1·28)
Road injuries
(0·78)
IHD
(0·49)
Congenital
(1·02)
Violence
(3·2)
Congenital
(0·65)
Congenital
(1·05)
Stroke
(0·58)
Stroke
(0·42)
NN encephalitis
(1·2)
Violence
(2·2)
Congenital
(0·63)
HIV
(1·06)
LRI
(1·68)
HIV
(2·6)
LRI
(1·4)
LRI
(0·96)
HIV
(2·67)
LRI
(0·95)
LRI
(1·51)
NN preterm
(1·13)
Diabetes
(5·05)
Diabetes
(3·27)
Diarrhoea
(0·71)

5
NN preterm
(0·97)
Congenital
(1·32)
NN preterm
(2·45)
HTN HD
(4·08)
NN preterm
(3·31)
NN encephalitis
(1·64)
Liver C
(10·66)
Diarrhoea
(1·04)
NN preterm
(2·99)
HTN HD
(6·01)
LRI
(0·78)
Congenital
(0·96)
Stroke
(0·37)
Violence
(1·61)
LRI
(0·63)
Congenital
(0·65)
NN preterm
(0·39)
Road injuries
(0·78)
Road injuries
(0·38)
LRI
(1·15)
Congenital
(0·94)
Congenital
(0·66)
Road injuries
(0·6)
CKD
(1·8)
Stroke
(0·31)
Road injuries
(0·88)
CKD
(2·8)
Diabetes
(4·85)
Breast C
(1·72)
Road injuries
(0·73)
Diabetes
(6·09)
Self-harm
(0·78)
CKD
(2·83)
HIV
(0·71)
CKD
(2·93)
Self-harm
(2·37)
Stroke
(1·11)

6
Congenital
(0·9)
LRI
(0·73)
Congenital
(1·22)
COPD
(1·25)
LRI
(1·88)
Congenital
(0·92)
NN encephalitis
(3·5)
Congenital
(0·7)
NN encephalitis
(6·34)
Road injuries
(0·59)
Diabetes
(1·34)
Diabetes
(1·72)
LRI
(0·62)
Stroke
(0·26)
Congenital
(0·78)
Road injuries
(0·49)
LRI
(0·32)
Congenital
(1·09)
Violence
(1·23)
Stroke
(0·51)
NN preterm
(1·07)
CKD
(1·27)
NN sepsis
(3·07)
Congenital
(0·78)
NN sepsis
(3·21)
Congenital
(1·1)
NN preterm
(3·6)
LRI
(1·85)
Prostate C
(3·93)
Diabetes
(2·44)
Road injuries
(2·17)
Alzheimer's
(1·12)
Road injuries
(0·85)
Congenital
(0·91)
Road injuries
(0·78)
LRI
(1·03)
Congenital
(1·3)

7
Road injuries
(0·69)
Road injuries
(0·63)
Lung C
(0·84)
Diabetes
(1·44)
Congenital
(1·38)
Road injuries
(0·67)
Road injuries
(1·07)
NN encephalitis
(0·81)
Road injuries
(0·66)
Self-harm
(0·9)
Congenital
(0·85)
LRI
(0·71)
COPD
(0·79)
Self-harm
(0·61)
Diabetes
(0·86)
Diabetes
(1·33)
Road injuries
(0·37)
LRI
(0·67)
Stroke
(0·35)
HIV
(0·63)
LRI
(0·91)
NN preterm
(0·51)
NN preterm
(0·52)
Stroke
(0·46)
NN preterm
(0·45)
Diabetes
(2·05)
HIV
(1·06)
HTN HD
(11·61)
CKD
(1·63)
Stroke
(0·7)
Colorect C
(1·08)
COPD
(0·94)
NN preterm
(1·86)
LRI
(0·83)
Congenital
(0·89)
Road injuries
(0·82)
Road injuries
(1·01)

8
Self-harm
(1·1)
COPD
(1·08)
Diabetes
(1·9)
LRI
(0·57)
COPD
(2·93)
Self-harm
(1·11)
Congenital
(1·13)
Hemog
(7·16)
Self-harm
(0·7)
Congenital
(0·55)
CKD
(1·44)
Stroke
(0·43)
Self-harm
(0·53)
Stomach C
(0·77)
Alcohol
(7·62)
NN preterm
(0·32)
Diarrhoea
(0·62)
Stroke
(0·41)
Diabetes
(0·75)
CKD
(1·71)
CKD
(1·84)
NN encephalitis
(0·92)
CKD
(1·41)
Diabetes
(1·31)
CKD
(0·9)
NN preterm
(0·68)
Congenital
(1·23)
Road injuries
(1·39)
Colorect C
(1·02)
NN preterm
(0·52)
Breast C
(1·66)
Colorect C
(0·75)
Congenital
(1·17)
Violence
(2·24)
NN preterm
(1·07)
Violence
(2·85)
NN encephalitis
(0·79)

9
10
HTN HD
COPD
(3·58)
(1·24)
Breast C
Stomach C
(1·37)
(0·79)
Road injuries Stomach C
(0·52)
(0·96)
Stomach C
Breast C
(0·84)
(1·16)
Violence
Lung C
(5·65)
(1·08)
COPD
Cirr hep B
(1·27)
(5·14)
NN preterm
Violence
(0·9)
(1·67)
Other NN
Drowning
(1·11)
(1·09)
Cirr hep B
Other cirr
(8·71)
(12·2)
NN preterm
Drowning
(0·43)
(1·6)
NN preterm
HIV
(0·56)
(0·3)
NN preterm
Self-harm
(0·57)
(0·57)
NN preterm
CKD
(0·47)
(0·71)
Alzheimer's
COPD
(0·94)
(0·56)
Self-harm
Stroke
(0·95)
(0·3)
CKD
PEM
(1·44)
(2·35)
HIV
Diabetes
(0·22)
(0·61)
NN preterm
Cirr alcohol
(0·69)
(3·0)
NN preterm
Self-harm
(0·28)
(0·71)
Diabetes
NN preterm
(1·56)
(0·8)
Diabetes
Self-harm
(1·65)
(0·81)
NN sepsis
Violence
(2·64)
(1·11)
Congenital
Self-harm
(0·57)
(0·86)
NN preterm
Self-harm
(0·6)
(0·64)
F Body
NN encephalitis
(2·83)
(0·94)
Diarrhoea
Violence
(0·8)
(2·2)
Prostate C
Violence
(4·63)
(4·46)
CKD
Breast C
(2·89)
(1·81)
Congenital
Violence
(1·4)
(4·33)
Congenital
CKD
(0·6)
(1·62)
LRI
Prostate C
(0·96)
(4·07)
Road injuries
CKD
(0·48)
(0·93)
Violence
Prostate C
(3·48)
(5·3)
NN sepsis
Diabetes
(5·3)
(1·0)
Violence
HIV
(2·38)
(0·57)
NN preterm
Congenital
(0·89)
(0·81)
NN preterm
Other NN
(0·43)
(1·73)

(Figure 17 continues on next page)
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Jamaica
Puerto Rico
Saint Lucia
Saint Vincent and
the Grenadines
Suriname
Trinidad and Tobago
Virgin Islands
Tropical Latin America
Brazil
Paraguay
Southeast, east Asia,
and Oceania
East Asia
China
North Korea
Taiwan (province of China)
Southeast Asia
Cambodia
Indonesia
Laos
Malaysia
Maldives
Mauritius
Myanmar
Philippines
Sri Lanka
Seychelles
Thailand
Timor-Leste
Vietnam
Oceania
American Samoa
Federated States of Micronesia
Fiji
Guam
Kiribati
Marshall Islands
Northern Mariana Islands

1
Stroke
(0·94)
IHD
(1·37)
Stroke
(0·95)
IHD
(1·05)
IHD
(0·79)
IHD
(1·96)
IHD
(2·72)
IHD
(0·69)
IHD
(0·69)
IHD
(0·67)
Stroke
(1·22)
Stroke
(1·2)
Stroke
(1·2)
Stroke
(1·58)
IHD
(0·69)
Stroke
(1·28)
IHD
(1·08)
Stroke
(1·76)
LRI
(1·35)
IHD
(1·29)
IHD
(0·51)
IHD
(0·99)
Stroke
(1·14)
IHD
(1·15)
IHD
(0·76)
IHD
(0·87)
IHD
(0·45)
LRI
(0·58)
Stroke
(1·16)
LRI
(1·07)
IHD
(1·16)
IHD
(1·63)
Diabetes
(11·92)
IHD
(4·42)
Stroke
(2·23)
IHD
(1·69)
IHD
(1·44)

2
Diabetes
(3·41)
Diabetes
(8·54)
IHD
(0·59)
Diabetes
(5·78)
Stroke
(1·16)
Diabetes
(14·95)
Stroke
(1·28)
Violence
(4·77)
Violence
(4·88)
Road injuries
(0·94)
IHD
(0·62)
IHD
(0·56)
IHD
(0·55)
IHD
(0·65)
Liver C
(3·67)
IHD
(0·79)
LRI
(0·64)
IHD
(0·97)
NN preterm
(1·24)
LRI
(2·41)
Congenital
(0·64)
Diabetes
(6·46)
LRI
(0·83)
LRI
(1·45)
Self-harm
(2·13)
LRI
(2·33)
Stroke
(0·66)
NN preterm
(0·57)
IHD
(0·42)
IHD
(2·14)
Diabetes
(4·56)
Stroke
(1·41)
IHD
(2·05)
Stroke
(2·08)
IHD
(1·52)
Diabetes
(3·81)
Stroke
(1·64)

3
Violence
(4·25)
Violence
(27·38)
Diabetes
(3·79)
Stroke
(1·07)
NN preterm
(1·83)
Stroke
(1·43)
Violence
(34·9)
Stroke
(0·73)
Stroke
(0·73)
Stroke
(0·8)
Road injuries
(0·79)
Road injuries
(0·82)
Road injuries
(0·82)
COPD
(1·67)
Stroke
(0·86)
LRI
(0·91)
Stroke
(1·03)
TB
(6·53)
IHD
(1·17)
Stroke
(0·98)
Stroke
(0·34)
CKD
(4·29)
TB
(2·11)
Stroke
(1·29)
Stroke
(0·57)
HTN HD
(9·18)
LRI
(1·73)
Congenital
(0·77)
Road injuries
(0·73)
Stroke
(1·86)
Stroke
(0·98)
Diabetes
(3·03)
LRI
(2·39)
Self-harm
(1·46)
LRI
(0·68)
Stroke
(1·49)
Self-harm
(0·64)

4
IHD
(0·45)
LRI
(1·32)
LRI
(1·28)
Violence
(5·04)
Self-harm
(1·98)
Violence
(15·41)
Diabetes
(7·53)
Road injuries
(0·99)
Road injuries
(0·99)
Congenital
(0·82)
COPD
(1·22)
COPD
(1·34)
Lung C
(1·39)
Road injuries
(0·91)
Lung C
(0·93)
Road injuries
(0·71)
NN preterm
(0·63)
Diabetes
(1·91)
Stroke
(1·11)
Road injuries
(1·19)
Self-harm
(0·69)
Stroke
(0·79)
IHD
(0·46)
Congenital
(0·82)
Diabetes
(1·55)
Stroke
(0·66)
Road injuries
(1·27)
IHD
(0·7)
Lung C
(1·91)
Diabetes
(4·86)
CKD
(2·84)
LRI
(0·73)
Stroke
(1·29)
Lung C
(1·59)
Diabetes
(4·82)
CKD
(3·34)
Road injuries
(1·09)

5
NN preterm
(1·4)
Stroke
(0·71)
Violence
(3·93)
LRI
(1·43)
HIV
(0·91)
Road injuries
(1·56)
Prostate C
(5·43)
LRI
(0·69)
LRI
(0·7)
NN preterm
(0·6)
Lung C
(1·26)
Lung C
(1·38)
COPD
(1·34)
Liver C
(4·43)
Diabetes
(4·17)
TB
(3·48)
Road injuries
(0·66)
Road injuries
(0·74)
Congenital
(1·12)
Lung C
(0·69)
Drowning
(1·14)
LRI
(0·77)
NN encephalitis
(1·08)
NN preterm
(0·56)
Asthma
(4·93)
CKD
(3·07)
Liver C
(4·02)
Stroke
(0·65)
LRI
(0·46)
COPD
(3·62)
LRI
(0·84)
CKD
(2·24)
CKD
(4·0)
Diabetes
(7·7)
NN preterm
(0·51)
LRI
(0·78)
Diabetes
(6·08)

6
CKD
(1·57)
CKD
(2·8)
CKD
(1·71)
HIV
(0·89)
Road injuries
(0·91)
HIV
(1·66)
CKD
(3·01)
Diabetes
(1·04)
Diabetes
(1·03)
Violence
(1·95)
Liver C
(2·82)
Liver C
(3·21)
Liver C
(3·18)
Lung C
(2·13)
Road injuries
(1·57)
Diabetes
(1·33)
Congenital
(0·74)
NN preterm
(0·74)
Road injuries
(0·91)
Self-harm
(0·52)
LRI
(0·22)
Road injuries
(0·53)
Road injuries
(0·49)
TB
(4·11)
LRI
(0·61)
Road injuries
(0·66)
HIV
(0·67)
Measles
(3·17)
Congenital
(0·76)
Road injuries
(0·93)
Congenital
(0·36)
Self-harm
(1·42)
NN preterm
(1·18)
LRI
(2·35)
TB
(2·13)
NN preterm
(0·43)
CKD
(4·58)

7
HIV
(0·56)
Road injuries
(1·62)
Road injuries
(0·62)
NN preterm
(1·93)
LRI
(1·25)
Self-harm
(0·92)
Lung C
(0·79)
COPD
(0·93)
COPD
(0·95)
LRI
(0·57)
LRI
(0·55)
Stomach C
(1·28)
Stomach C
(1·27)
Stomach C
(2·46)
Self-harm
(0·75)
NN preterm
(0·59)
HIV
(0·36)
LRI
(0·69)
Diarrhoea
(0·79)
Diabetes
(1·49)
CKD
(0·59)
Self-harm
(0·71)
NN preterm
(0·46)
Violence
(2·0)
Road injuries
(0·47)
Drowning
(3·44)
Lung C
(1·1)
NN encephalitis
(0·43)
Diabetes
(0·62)
NN preterm
(0·39)
Endocrine
(4·52)
Road injuries
(0·46)
Congenital
(1·09)
CKD
(4·92)
Violence
(2·72)
Self-harm
(1·41)
Drowning
(3·74)

8
Congenital
(0·86)
COPD
(1·61)
Congenital
(0·93)
CKD
(2·09)
Diabetes
(2·07)
Congenital
(2·15)
Colorect C
(1·25)
Congenital
(0·71)
Congenital
(0·7)
Diabetes
(1·34)
Congenital
(0·66)
LRI
(0·34)
LRI
(0·34)
LRI
(0·38)
LRI
(0·97)
Congenital
(0·68)
TB
(1·03)
Diarrhoea
(3·13)
NN encephalitis
(0·77)
HIV
(0·42)
NN encephalitis
(0·4)
HTN HD
(2·41)
Congenital
(0·8)
NN sepsis
(3·24)
CKD
(0·92)
Congenital
(0·83)
CKD
(1·62)
Diarrhoea
(0·28)
Liver C
(2·29)
Asthma
(5·21)
COPD
(1·51)
COPD
(1·2)
Self-harm
(1·21)
Road injuries
(2·23)
NN encephalitis
(0·75)
Road injuries
(0·49)
LRI
(1·83)

9
LRI
(0·7)
Alzheimer's
(0·84)
NN preterm
(1·26)
Congenital
(0·94)
Congenital
(1·16)
CKD
(3·08)
HTN HD
(8·02)
HIV
(0·32)
HIV
(0·32)
CKD
(1·22)
Stomach C
(1·09)
Congenital
(0·65)
Congenital
(0·65)
Self-harm
(1·04)
Colorect C
(0·9)
CKD
(1·14)
Self-harm
(1·12)
NN encephalitis
(1·25)
Drowning
(1·84)
Congenital
(0·57)
Road injuries
(0·17)
Congenital
(0·84)
COPD
(0·99)
CKD
(1·61)
Congenital
(0·53)
Self-harm
(0·55)
Self-harm
(1·14)
Other NN
(0·92)
TB
(1·61)
CKD
(2·8)
Drowning
(1·56)
Congenital
(0·4)
Asthma
(7·61)
Congenital
(2·29)
PEM
(2·75)
Congenital
(0·46)
Lung C
(1·17)

10
Lung C
(0·72)
Colorect C
(0·82)
Prostate C
(3·4)
Road injuries
(0·55)
CKD
(1·83)
LRI
(1·33)
LRI
(0·96)
NN preterm
(0·53)
NN preterm
(0·52)
NN encephalitis
(0·58)
Diabetes
(0·59)
Self-harm
(0·52)
Self-harm
(0·51)
Congenital
(0·78)
CKD
(1·39)
NN encephalitis
(0·83)
NN encephalitis
(0·46)
Congenital
(0·6)
Self-harm
(1·31)
CKD
(1·29)
NN preterm
(0·18)
NN preterm
(1·07)
HIV
(0·33)
Diabetes
(1·12)
COPD
(0·64)
Diabetes
(1·21)
Diabetes
(1·15)
Drowning
(1·41)
Drowning
(1·42)
Diarrhoea
(0·44)
Road injuries
(0·35)
Drowning
(1·14)
Other cardio
(4·83)
COPD
(2·56)
Self-harm
(1·87)
Drowning
(1·43)
Violence
(3·41)

(Figure 17 continues on next page)
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1
2
LRI
IHD
(1·03)
(1·92)
IHD
Diabetes
Samoa
(1·0)
(2·72)
IHD
Stroke
Solomon Islands
(2·1)
(1·71)
IHD
Diabetes
Tonga
(0·97)
(2·99)
IHD
Stroke
Vanuatu
(1·97)
(1·85)
IHD
War
North Africa and Middle East
(1·2)
(2001·28)
IHD
War
North Africa and Middle East
(1·2)
(2001·28)
War
LRI
Afghanistan
(2145·26)
(0·7)
IHD
NN preterm
Algeria
(0·67)
(0·75)
IHD
Diabetes
Bahrain
(0·81)
(4·21)
IHD
Congenital
Egypt
(1·39)
(1·32)
IHD
Road injuries
Iran
(1·3)
(1·75)
War
IHD
Iraq
(5558·67)
(1·92)
Congenital
IHD
Jordan
(1·1)
(0·7)
IHD
Congenital
Kuwait
(1·98)
(2·02)
IHD
Stroke
Lebanon
(1·07)
(0·45)
War
IHD
Libya
(6283·28)
(0·96)
IHD
NN preterm
Morocco
(0·62)
(0·56)
IHD
NN preterm
Palestine
(1·36)
(0·68)
Road injuries
IHD
Oman
(1·65)
(0·8)
Road injuries
IHD
Qatar
(1·58)
(0·63)
IHD
Road injuries
Saudi Arabia
(0·85)
(1·29)
NN preterm
Congenital
Sudan
(1·22)
(1·59)
War
IHD
Syria
(26105·82)
(1·39)
IHD
Stroke
Tunisia
(0·46)
(0·62)
IHD
Congenital
Turkey
(0·56)
(1·0)
IHD
Road injuries
United Arab Emirates
(2·73)
(3·54)
War
NN preterm
Yemen
(2398·83)
(1·05)
IHD
NN encephalitis
South Asia
(1·23)
(2·2)
IHD
NN encephalitis
South Asia
(1·23)
(2·2)
Stroke
IHD
Bangladesh
(1·2)
(0·95)
NN preterm
IHD
Bhutan
(1·29)
(0·77)
IHD
NN preterm
India
(1·2)
(1·28)
LRI
IHD
Nepal
(0·58)
(0·92)
NN encephalitis
IHD
Pakistan
(2·94)
(1·81)
Malaria
HIV
Sub-Saharan Africa
(5·39)
(2·64)
HIV
LRI
Southern sub-Saharan Africa
(13·33)
(1·83)
Papua New Guinea

3
Stroke
(1·74)
Stroke
(0·87)
Diabetes
(4·38)
LRI
(0·74)
LRI
(0·89)
NN preterm
(0·79)
NN preterm
(0·79)
IHD
(4·49)
Stroke
(0·72)
Road injuries
(0·58)
Stroke
(1·08)
Stroke
(0·78)
Congenital
(1·23)
Road injuries
(0·68)
Road injuries
(1·43)
Congenital
(0·97)
Road injuries
(0·83)
Stroke
(0·51)
Congenital
(0·84)
Other cardio
(5·29)
Congenital
(1·16)
Congenital
(1·26)
IHD
(1·66)
Stroke
(0·91)
Diabetes
(1·33)
Stroke
(0·42)
Stroke
(2·25)
IHD
(2·11)
NN preterm
(1·09)
NN preterm
(1·09)
NN encephalitis
(1·54)
NN encephalitis
(1·92)
NN encephalitis
(2·13)
NN encephalitis
(1·35)
NN preterm
(0·85)
LRI
(0·65)
TB
(11·22)

4
COPD
(3·83)
CKD
(2·09)
LRI
(0·46)
Stroke
(0·77)
Diabetes
(3·2)
Congenital
(1·21)
Congenital
(1·21)
Congenital
(1·6)
Road injuries
(0·68)
Congenital
(0·84)
LRI
(0·78)
Congenital
(1·05)
NN preterm
(0·7)
NN preterm
(0·69)
NN preterm
(2·89)
Lung C
(0·78)
Congenital
(1·08)
Diabetes
(1·41)
Road injuries
(0·49)
Congenital
(0·67)
Self-harm
(0·27)
NN preterm
(1·08)
LRI
(0·52)
Congenital
(0·76)
Road injuries
(0·59)
Lung C
(1·2)
CKD
(3·87)
Congenital
(1·37)
LRI
(0·75)
LRI
(0·75)
LRI
(0·52)
LRI
(0·52)
LRI
(0·82)
Disaster
(3932·26)
LRI
(0·62)
Diarrhoea
(0·67)
Diarrhoea
(4·01)

5
Diabetes
(3·52)
LRI
(0·54)
CKD
(3·1)
NN preterm
(0·48)
NN preterm
(0·52)
Road injuries
(0·98)
Road injuries
(0·98)
Stroke
(2·22)
Congenital
(0·91)
Self-harm
(0·37)
Cirr hep C
(7·38)
NN preterm
(0·95)
Stroke
(1·18)
LRI
(0·58)
Stroke
(0·77)
Diabetes
(1·39)
Stroke
(0·75)
Road injuries
(0·6)
Stroke
(0·71)
Diabetes
(2·06)
Diabetes
(2·48)
Stroke
(0·57)
Road injuries
(1·58)
LRI
(0·33)
Congenital
(0·79)
NN preterm
(0·85)
COPD
(4·24)
Road injuries
(1·55)
Diarrhoea
(1·07)
Diarrhoea
(1·07)
Drowning
(2·59)
COPD
(1·25)
COPD
(2·44)
TB
(1·39)
Diarrhoea
(0·85)
NN sepsis
(2·39)
Road injuries
(1·48)

6
Road injuries
(0·96)
Self-harm
(0·94)
NN preterm
(0·3)
Road injuries
(0·46)
Road injuries
(0·62)
Stroke
(0·87)
Stroke
(0·87)
NN preterm
(0·76)
Diabetes
(0·85)
CKD
(1·54)
NN preterm
(0·47)
HTN HD
(3·19)
NN sepsis
(2·44)
Stroke
(0·45)
LRI
(1·21)
Road injuries
(0·43)
Other transport
(11·51)
Congenital
(0·75)
LRI
(0·26)
LRI
(0·79)
NN preterm
(1·59)
LRI
(0·66)
Diarrhoea
(0·51)
Road injuries
(0·36)
Lung C
(1·23)
Road injuries
(0·51)
Diabetes
(3·39)
LRI
(0·38)
Stroke
(0·84)
Stroke
(0·84)
COPD
(1·34)
Stroke
(0·49)
Diarrhoea
(1·33)
COPD
(1·56)
Stroke
(0·88)
NN encephalitis
(0·83)
Violence
(4·96)

7
Diarrhoea
(0·42)
Road injuries
(0·31)
COPD
(1·67)
Congenital
(0·47)
Self-harm
(1·68)
LRI
(0·52)
LRI
(0·52)
Road injuries
(2·41)
LRI
(0·31)
Stroke
(0·33)
Road injuries
(0·47)
Other cardio
(2·86)
Road injuries
(0·67)
Diabetes
(1·18)
Self-harm
(0·17)
Colorect C
(0·85)
NN preterm
(0·61)
LRI
(0·27)
CKD
(1·32)
Stroke
(0·47)
Stroke
(0·45)
CKD
(1·42)
Stroke
(1·08)
NN preterm
(0·19)
NN preterm
(0·59)
COPD
(0·79)
Self-harm
(0·22)
Stroke
(1·19)
COPD
(2·17)
COPD
(2·17)
NN preterm
(0·4)
TB
(1·38)
Stroke
(0·8)
Stroke
(0·49)
TB
(1·38)
NN preterm
(0·49)
IHD
(0·79)

8
Asthma
(4·94)
Congenital
(0·35)
Road injuries
(0·63)
COPD
(0·92)
CKD
(1·94)
Diabetes
(0·97)
Diabetes
(0·97)
Oth Unint
(11·93)
NN sepsis
(1·57)
LRI
(0·57)
CKD
(1·29)
LRI
(0·55)
LRI
(0·4)
CKD
(1·07)
CKD
(1·3)
Alzheimer's
(1·17)
LRI
(0·38)
NN encephalitis
(0·42)
NN sepsis
(0·93)
NN preterm
(0·51)
Falls
(1·17)
NN sepsis
(3·78)
NN encephalitis
(0·3)
NN encephalitis
(0·33)
LRI
(0·42)
Alzheimer's
(1·38)
Falls
(2·15)
Diarrhoea
(0·28)
TB
(2·06)
TB
(2·06)
Road injuries
(0·48)
Congenital
(0·64)
TB
(2·51)
Diarrhoea
(0·38)
Meningitis
(1·44)
Congenital
(0·92)
Diabetes
(3·41)

9
10
NN preterm
Measles
(0·35)
(3·61)
COPD
Endocrine
(0·75)
(2·64)
Self-harm
Drowning
(1·64)
(1·6)
Meningitis
Liver C
(2·29)
(3·27)
COPD
Drowning
(1·48)
(1·78)
Diarrhoea
CKD
(0·33)
(1·02)
Diarrhoea
CKD
(0·33)
(1·02)
Diarrhoea
Violence
(0·23)
(4·04)
CKD
NN encephalitis
(0·79)
(0·49)
Breast C
NN preterm
(0·98)
(0·58)
Diabetes
CMP
(0·92)
(4·07)
Self-harm
Diabetes
(0·51)
(0·87)
Violence
Diabetes
(2·27)
(1·48)
NN sepsis NN encephalitis
(1·72)
(0·48)
Breast C
Diabetes
(0·73)
(1·4)
Breast C
CKD
(1·09)
(0·84)
CKD
Lung C
(1·01)
(1·02)
Lung C
CKD
(1·48)
(0·8)
NN encephalitis Violence
(0·29)
(0·81)
Other NN
Self-harm
(1·73)
(0·21)
Mech
Breast C
(1·21)
(1·17)
Self-harm
Falls
(0·22)
(1·04)
Other NN
HIV
(0·89)
(0·26)
Asthma
Alzheimer's
(1·54)
(1·33)
CKD
Alzheimer's
(0·72)
(1·16)
Diabetes
LRI
(0·65)
(0·32)
Congenital
Med treat
(1·18)
(12·7)
Other NN NN encephalitis
(0·79)
(0·25)
Road injuries Congenital
(0·65)
(0·65)
Road injuries Congenital
(0·65)
(0·65)
Congenital Intestinal infect
(0·62)
(6·07)
Intestinal infect Diarrhoea
(13·13)
(0·6)
Road injuries Self-harm
(0·69)
(1·27)
Road injuries NN preterm
(0·63)
(0·25)
Congenital
Other NN
(0·59)
(1·46)
PEM
Meningitis
(1·26)
(1·09)
NN preterm
Stroke
(0·88)
(0·98)

(Figure 17 continues on next page)
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Botswana
Lesotho
Namibia
South Africa
Swaziland
Zimbabwe
Western sub-Saharan Africa
Benin
Burkina Faso
Cameroon
Cape Verde
Chad
CÔte d’Ivoire
The Gambia
Ghana
Guinea
Guinea-Bissau
Liberia
Mali
Mauritania
Niger
Nigeria
São Tomé Príncipe
Senegal
Sierra Leone
Togo
Eastern sub-Saharan Africa
Burundi
Comoros
Djibouti
Eritrea
Ethiopia
Kenya
Madagascar
Malawi
Mozambique
Rwanda

1
HIV
(12·98)
HIV
(18·72)
HIV
(7·97)
HIV
(15·18)
HIV
(19·98)
HIV
(9·02)
Malaria
(9·36)
Malaria
(12·07)
Malaria
(5·47)
HIV
(3·79)
LRI
(0·64)
Diarrhoea
(1·23)
Malaria
(34·35)
LRI
(0·36)
Malaria
(78·2)
Malaria
(7·55)
LRI
(0·85)
LRI
(0·46)
Malaria
(6·63)
LRI
(0·61)
Malaria
(1·4)
Malaria
(108·21)
LRI
(0·68)
Diarrhoea
(0·51)
Malaria
(15·38)
Malaria
(19·06)
HIV
(2·51)
LRI
(0·43)
LRI
(0·5)
LRI
(1·11)
Diarrhoea
(0·82)
LRI
(0·43)
HIV
(3·56)
LRI
(0·71)
HIV
(4·96)
HIV
(7·75)
LRI
(0·79)

2
TB
(15·84)
Diarrhoea
(3·71)
LRI
(1·39)
Violence
(7·41)
LRI
(2·6)
Diarrhoea
(2·49)
Diarrhoea
(0·96)
LRI
(0·7)
LRI
(0·52)
Malaria
(76·49)
Stroke
(0·88)
LRI
(0·95)
HIV
(2·67)
NN sepsis
(2·23)
LRI
(0·99)
LRI
(0·69)
Diarrhoea
(0·89)
Malaria
(3·04)
Diarrhoea
(0·39)
NN sepsis
(3·54)
Diarrhoea
(0·54)
Diarrhoea
(2·18)
NN sepsis
(2·33)
LRI
(0·42)
LRI
(0·9)
HIV
(2·17)
LRI
(0·57)
Diarrhoea
(0·39)
Diarrhoea
(0·4)
Diarrhoea
(1·06)
LRI
(0·67)
Diarrhoea
(0·35)
Diarrhoea
(1·08)
Diarrhoea
(0·72)
Malaria
(5·36)
Malaria
(4·38)
HIV
(1·11)

3
4
LRI
IHD
(1·76)
(0·96)
LRI
TB
(1·88)
(10·58)
Diarrhoea
TB
(3·74)
(8·54)
LRI
Road injuries
(2·66)
(1·82)
Diarrhoea Road injuries
(7·38)
(2·1)
LRI
NN encephalitis
(1·07)
(1·58)
HIV
LRI
(0·73)
(1·76)
Diarrhoea
NN sepsis
(0·46)
(2·64)
Diarrhoea
NN sepsis
(0·44)
(1·77)
LRI
NN sepsis
(1·18)
(4·63)
IHD
HIV
(0·51)
(0·5)
Malaria
HIV
(4·11)
(1·88)
LRI
NN sepsis
(0·93)
(4·37)
Diarrhoea
HIV
(0·28)
(0·94)
NN sepsis
HIV
(5·51)
(1·16)
Diarrhoea
NN sepsis
(0·35)
(2·23)
HIV
Meningitis
(2·51)
(1·82)
Diarrhoea
HIV
(0·42)
(1·24)
PEM
NN preterm
(1·51)
(0·87)
Diarrhoea
NN preterm
(0·51)
(0·5)
LRI
Meningitis
(0·39)
(1·1)
HIV
LRI
(2·08)
(1·01)
Stroke
Congenital
(1·01)
(0·81)
NN sepsis
NN preterm
(2·04)
(0·38)
Hemog
Diarrhoea
(10·14)
(0·6)
LRI
Diarrhoea
(0·68)
(0·52)
Diarrhoea
Malaria
(0·52)
(2·32)
Malaria
NN preterm
(1·24)
(0·54)
NN preterm Congenital
(0·43)
(0·93)
HIV
Congenital
(1·01)
(1·28)
PEM
Congenital
(1·56)
(0·97)
TB
Congenital
(1·19)
(0·97)
LRI
NN encephalitis
(0·76)
(0·91)
NN preterm
PEM
(0·52)
(2·09)
LRI
Diarrhoea
(0·6)
(0·51)
LRI
Diarrhoea
(0·31)
(0·28)
Congenital
Diarrhoea
(1·25)
(0·4)

5
Road injuries
(1·11)
NN preterm
(1·13)
NN preterm
(0·78)
TB
(19·05)
TB
(14·18)
NN preterm
(0·6)
NN sepsis
(3·6)
NN preterm
(0·53)
Meningitis
(1·0)
Diarrhoea
(1·07)
NN preterm
(0·51)
NN sepsis
(2·61)
Diarrhoea
(0·67)
NN preterm
(0·38)
NN preterm
(0·5)
NN preterm
(0·62)
NN sepsis
(2·87)
NN sepsis
(1·98)
NN sepsis
(2·49)
NN encephalitis
(0·78)
PEM
(0·52)
NN sepsis
(5·4)
Diarrhoea
(0·38)
TB
(1·24)
Ebola
(98778·13)
NN sepsis
(3·19)
Congenital
(1·04)
Congenital
(1·01)
NN encephalitis
(0·61)
NN preterm
(0·52)
TB
(1·29)
NN encephalitis
(0·68)
NN preterm
(0·46)
Stroke
(1·22)
NN preterm
(0·49)
NN encephalitis
(0·71)
NN preterm
(0·5)

6
Diarrhoea
(4·35)
Road injuries
(1·77)
Road injuries
(1·0)
IHD
(0·81)
IHD
(1·22)
TB
(4·41)
NN encephalitis
(0·98)
NN encephalitis
(0·77)
NN encephalitis
(0·7)
NN encephalitis
(0·97)
Congenital
(0·82)
PEM
(1·7)
NN preterm
(0·69)
NN encephalitis
(0·5)
Stroke
(1·06)
NN encephalitis
(0·85)
Malaria
(2·72)
NN preterm
(0·48)
LRI
(0·29)
Congenital
(0·89)
NN preterm
(0·52)
NN encephalitis
(1·25)
NN encephalitis
(0·57)
NN encephalitis
(0·57)
NN sepsis
(2·98)
NN preterm
(0·55)
NN encephalitis
(0·7)
PEM
(0·89)
NN sepsis
(1·53)
Stroke
(0·84)
NN preterm
(0·43)
HIV
(0·82)
Congenital
(0·83)
Congenital
(0·85)
NN encephalitis
(0·72)
Congenital
(0·98)
NN encephalitis
(0·74)

7
Diabetes
(3·2)
Other NN
(5·18)
Other NN
(3·71)
Diabetes
(4·21)
Stroke
(1·46)
NN sepsis
(2·32)
NN preterm
(0·53)
Meningitis
(1·21)
PEM
(0·86)
NN preterm
(0·54)
Violence
(1·74)
NN preterm
(0·64)
NN encephalitis
(0·99)
Congenital
(0·64)
Congenital
(0·82)
HIV
(1·09)
NN preterm
(0·71)
NN encephalitis
(0·67)
NN encephalitis
(0·92)
STD
(2·35)
NN sepsis
(1·02)
NN preterm
(0·49)
NN preterm
(0·27)
Congenital
(0·76)
NN preterm
(0·66)
NN encephalitis
(0·86)
NN preterm
(0·42)
NN encephalitis
(0·6)
TB
(0·88)
IHD
(0·7)
Meningitis
(0·91)
NN preterm
(0·36)
Malaria
(2·45)
Malaria
(3·45)
Congenital
(1·0)
NN sepsis
(1·33)
NN sepsis
(2·02)

8
Stroke
(1·13)
Violence
(4·68)
IHD
(0·69)
Stroke
(0·96)
Other NN
(3·85)
PEM
(3·89)
Meningitis
(1·45)
PEM
(1·46)
Congenital
(0·88)
Congenital
(1·07)
NN sepsis
(2·48)
Meningitis
(1·48)
Congenital
(0·95)
Meningitis
(0·66)
IHD
(0·78)
Meningitis
(0·95)
PEM
(1·82)
TB
(1·09)
Meningitis
(0·95)
Meningitis
(0·88)
NN encephalitis
(0·53)
Hemog
(10·17)
IHD
(0·66)
Meningitis
(0·95)
NN encephalitis
(1·01)
Congenital
(0·8)
NN sepsis
(1·49)
TB
(0·98)
Stroke
(0·61)
TB
(1·62)
NN encephalitis
(0·54)
NN sepsis
(1·42)
Meningitis
(1·05)
NN sepsis
(1·72)
PEM
(1·14)
NN preterm
(0·37)
PEM
(1·78)

9
Self-harm
(1·96)
IHD
(1·27)
NN encephalitis
(1·11)
Diarrhoea
(10·14)
NN preterm
(0·76)
Road injuries
(0·69)
PEM
(1·54)
Congenital
(0·81)
NN preterm
(0·36)
Meningitis
(1·93)
NN encephalitis
(0·81)
NN encephalitis
(0·73)
Stroke
(0·97)
PEM
(0·76)
NN encephalitis
(0·79)
Hemog
(3·57)
STD
(3·53)
Ebola
(59835·47)
HIV
(1·08)
Stroke
(0·52)
Congenital
(0·59)
Congenital
(0·92)
CKD
(2·28)
Malaria
(1·89)
Meningitis
(1·62)
Hemog
(4·09)
PEM
(1·05)
HIV
(0·89)
STD
(1·7)
Measles
(7·35)
Stroke
(0·98)
Meningitis
(0·74)
NN sepsis
(1·24)
IHD
(0·88)
Meningitis
(0·96)
TB
(0·93)
Road injuries
(0·99)

10
NN preterm
(0·58)
Stroke
(1·39)
Stroke
(0·72)
NN preterm
(1·21)
Diabetes
(3·58)
Stroke
(0·97)
Congenital
(0·87)
Stroke
(0·88)
TB
(0·74)
PEM
(2·89)
Self-harm
(1·11)
Congenital
(0·91)
Meningitis
(1·16)
Liver C
(6·57)
PEM
(3·46)
PEM
(0·88)
NN encephalitis
(0·85)
Meningitis
(0·77)
Congenital
(0·82)
PEM
(1·27)
TB
(0·56)
Meningitis
(2·2)
PEM
(1·52)
Stroke
(0·81)
HIV
(1·14)
Stroke
(0·84)
Meningitis
(0·89)
NN sepsis
(1·03)
Meningitis
(0·62)
PEM
(2·99)
NN sepsis
(1·25)
STD
(1·78)
PEM
(1·22)
NN encephalitis
(0·44)
NN sepsis
(1·32)
Stroke
(0·85)
Meningitis
(1·06)

(Figure 17 continues on next page)
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Somalia
South Sudan
Tanzania
Uganda
Zambia
Central sub-Saharan Africa
Angola
Central African Republic
Congo (Brazzaville)
DR Congo
Equatorial Guinea
Gabon

1
Diarrhoea
(0·68)
Diarrhoea
(0·92)
HIV
(2·5)
HIV
(2·76)
HIV
(6·21)
Malaria
(3·57)
LRI
(0·96)
Malaria
(7·46)
HIV
(3·26)
Malaria
(2·78)
Malaria
(1084·28)
HIV
(2·69)

2
LRI
(0·65)
LRI
(0·72)
LRI
(0·79)
LRI
(0·6)
LRI
(0·96)
LRI
(0·55)
Malaria
(27·12)
HIV
(4·28)
Malaria
(108·62)
LRI
(0·46)
HIV
(3·62)
Malaria
(879·85)

3
PEM
(0·83)
HIV
(1·94)
Congenital
(1·42)
Malaria
(9·44)
Malaria
(41·28)
HIV
(1·54)
Diarrhoea
(0·64)
LRI
(0·96)
LRI
(0·98)
Diarrhoea
(0·27)
LRI
(1·88)
LRI
(1·63)

4
TB
(1·2)
Malaria
(2·24)
Malaria
(11·54)
Diarrhoea
(0·47)
Diarrhoea
(1·18)
Diarrhoea
(0·33)
HIV
(1·32)
Diarrhoea
(0·68)
Congenital
(1·05)
HIV
(1·3)
NN sepsis
(6·1)
Congenital
(1·26)

5
NN preterm
(0·64)
PEM
(1·37)
Diarrhoea
(0·49)
NN encephalitis
(0·87)
Congenital
(1·06)
PEM
(1·06)
NN sepsis
(2·85)
TB
(1·87)
NN sepsis
(3·15)
PEM
(0·88)
Congenital
(1·45)
NN sepsis
(5·65)

6
Malaria
(0·33)
Meningitis
(1·18)
NN encephalitis
(0·68)
Congenital
(1·13)
NN encephalitis
(0·74)
NN preterm
(0·46)
Congenital
(1·1)
NN preterm
(0·73)
Stroke
(1·23)
NN preterm
(0·47)
NN preterm
(0·76)
Stroke
(1·06)

7
Meningitis
(0·59)
NN preterm
(0·54)
NN sepsis
(2·06)
NN preterm
(0·47)
Meningitis
(1·95)
NN sepsis
(1·62)
NN preterm
(0·39)
Stroke
(1·6)
IHD
(0·89)
NN encephalitis
(0·63)
Road injuries
(1·06)
IHD
(0·66)

8
Congenital
(0·8)
TB
(1·11)
NN preterm
(0·34)
Meningitis
(1·46)
NN preterm
(0·34)
Congenital
(0·89)
PEM
(2·66)
PEM
(1·74)
NN encephalitis
(0·82)
NN sepsis
(1·3)
NN encephalitis
(1·23)
Road injuries
(0·93)

9
War
(329·44)
Congenital
(0·85)
PEM
(1·87)
NN sepsis
(1·87)
NN sepsis
(1·91)
NN encephalitis
(0·64)
Road injuries
(1·43)
Road injuries
(2·03)
NN preterm
(0·43)
Congenital
(0·8)
Other NN
(2·77)
NN preterm
(0·66)

(0·0–0·56)

(0·56–0·71)

(0·71–0·84)

(0·84–0·98)

(0·98–1·17)

(1·17–1·43)

(1·43–2·01)

(2·01–3·27)

>3·27

10
NN encephalitis
(0·52)
War
(441·01)
Meningitis
(1·06)
Hemog
(4·48)
IHD
(1·05)
TB
(1·03)
Meningitis
(1·63)
NN sepsis
(2·17)
Diarrhoea
(0·79)
TB
(0·91)
Meningitis
(4·35)
NN encephalitis
(1·23)

Colour
key

Figure 17: Leading ten causes of YLLs with the ratio of observed YLLs to YLLs expected on the basis of SDI in 2015, by location
The ratio of observed YLLs to YLLs expected based on SDI is provided in parentheses for each cause, and cells are colour coded by ratio ranges (calculated to place a
roughly equal number of cells into each bin). Shades of blue represent much lower observed YLLs than expected levels based on SDI, whereas red shows that observed
YLLs exceed expected levels. SDI=Socio-demographic Index. YLL=years of life lost. IHD=ischaemic heart disease. LRI=lower respiratory infection. NN enceph=neonatal
encephalitis. COPD=chronic obstructive pulmonary disease. Congenital=congenital disorders. C=cancer. Alzheimer=Alzheimer’s disease and other dementias.
HTN HD=hypertensive heart disease. Cirr hepB=cirrhosis due to hepatitis B. NN preterm=neonatal preterm birth complications. CKD=chronic kidney disease.
TB=tuberculosis. Intestinal infect=intestinal infectious disease. NN sepsis=neonatal sepsis. Endocrine=endocrine, metabolic, blood, and immune disorders. Other
cardio=other cardiovascular diseases. CMP=cardiomyopathies. Haemog=haemoglobinopathies and haemolytic anaemias. Cirr alcohol=cirrhosis due to alcohol use.
Violence=interpersonal violence. Alcohol=alcohol use disorders. Other cirr=cirrhosis due to other causes. Cirr hepC=cirrhosis due to hepatitis C. Drugs=drug use
disorders. F Body=pulmonary aspiration and foreign body in airway. PEM=protein-energy malnutrition. Mech=exposure to mechanical forces. Other transport=other
transport injuries. Med treat=adverse eﬀects of medical treatment. Leish=leishmaniasis. Other NN=other neonatal disorders. Iron=iron-deﬁciency anaemia.
Whooping=whooping cough.

HIV/AIDS was the leading cause of premature mortality
and resulted in exceedingly more YLLs than expected
given SDI; Namibia, with a YLL ratio for HIV/AIDS
of 7·97, was the lowest among these countries, whereas
Swaziland had the highest ratio (19·98). Early death due
to tuberculosis also surpassed expected levels, especially
in South Africa (19·05), as did observed YLLs due to
violence (eg, 7·41 in South Africa). Observed YLLs due to
preterm birth complications were somewhat lower than
expected in southern sub-Saharan Africa (eg, 0·58 in
Botswana), but such levels were largely surpassed by
countries in western and eastern sub-Saharan Africa. In
2015, 13 countries in western sub-Saharan Africa and
14 countries in eastern sub-Saharan Africa had YLL ratios
lower than 0·60 for preterm birth complications.
In western sub-Saharan Africa, observed premature
mortality due to malaria was at least twice as high as
expected in 13 of 19 countries in the region, with the
highest YLL ratios in Nigeria (108·21) and Ghana (78·2).
Neonatal sepsis caused more YLLs than expected based
on SDI in several western sub-Saharan African countries,
including Ghana (5·51). Despite the fact that the Ebola
virus disease epidemic claimed more lives in 2014 than
in 2015, Ebola virus disease remained among the leading
1520

cause of YLLs in Sierra Leone and Liberia. Although still
among the leading causes of early death in western
sub-Saharan Africa, YLLs due to lower respiratory
infections and diarrhoeal diseases were much lower than
expected for most countries, with YLL ratios as low as
0·29 in Mali and 0·28 in The Gambia, respectively.
Similar trends emerged for eastern sub-Saharan Africa,
although the toll of HIV/AIDS was generally higher;
observed levels of premature mortality due to HIV/AIDS
were at least ﬁve times higher than expected in Zambia
(6·21) and Mozambique (7·75). Within eastern subSaharan Africa, eight of 15 countries had YLL ratios less
than 0·60 for YLLs due to diarrhoeal diseases (eg,
Rwanda [0·40] and Uganda [0·47]), emphasising the
region’s rising SDI. Furthermore, every country in
eastern sub-Saharan Africa had observed YLLs due to
preterm birth complications that were below expected
levels, including Ethiopia (0·36) and Kenya (0·46).
Nonetheless, YLL ratios for malaria were quite high for
several countries, particularly Zambia (41·28) and
Tanzania (11·54). Among countries in central subSaharan Africa, malaria resulted in many more YLLs
than expected based on SDI, with Angola, Congo
(Brazzaville), Equatorial Guinea, and Gabon reporting
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ratios that exceeded 20·00. Neonatal sepsis consistently
caused more early deaths than expected within the
region. Observed YLLs due to preterm birth complications
fell below expected levels in Angola (0·39), Congo
(Brazzaville; 0·43), and the Democratic Republic of the
Congo (0·47). Notably, the Democratic Republic of the
Congo, which had the world’s sixth-highest death toll due
to diarrhoeal diseases in 2015, had far fewer YLLs due to
diarrhoea than expected (0·27).

Discussion
Main ﬁndings
Over the past 35 years, global life expectancy, agestandardised death rates, and age-standardised YLL rates
have all substantially improved year on year, with the
single exception of 1994 (high mortality from the
Rwandan genocide, the Iraq civil war, and ongoing
armed conﬂict in Bosnia and Herzegovina that year was
enough to change the trend in global life expectancy).
During 2005–15, life expectancy increased in 188 of
195 countries and territories and those increases were
faster than expected on the basis of SDI improvements
in 120 countries and territories. Such gains were mainly
driven by marked reductions in mortality due to HIV/
AIDS, malaria, infectious diseases such as lower
respiratory infections and diarrhoea, neonatal disorders,
cardiovascular disease, and cancers. Running counter to
the general improvement, age-standardised death rates
for 13 causes increased signiﬁcantly in the past decade.
In addition to these causes with increases, for some
leading causes of death such as diabetes and chronic
kidney disease, age-standardised death rates have
stagnated globally and increased in some countries.
Since 2011, global deaths from war have risen massively
due to conﬂicts in Syria, Yemen, and Libya. Furthermore,
gains in life expectancy were reversed for a subset of
countries, with Syrian men bearing the largest toll (a
12·1 year reduction in life expectancy from 2010 to 2015).
Our analysis of the average relationships between age,
sex, and cause-speciﬁc mortality and SDI suggest that
the epidemiological transition does not aﬀect all causes
uniformly. Not all causes of death or YLLs improve
as SDI increases. In fact, some causes such as
cardiovascular disease and a subset of cancer types,
initially tend to increase with rising SDI and then decline.
This inverted U pattern might be related to changes in
risk factors that initially increase disease incidence and
then, with rising SDI, risk factor management and
disease treatment might act to reduce age-speciﬁc
mortality. The change in death numbers and population
rates with the epidemiological transition was driven by
both expected changes in age-speciﬁc rates and the
highly regular shifts in population age structure that
occur with rising SDI. Previous attempts to characterise
the shifts in disease pattern with development56–58 have
not been as comprehensive and have not been based on a
comprehensive database such as that provided by GBD.
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Across causes and within geographical regions, we found
huge country-level heterogeneities when observed levels
of premature mortality were compared with those
expected on the basis of SDI. The average patterns of agespeciﬁc mortality associated with a given level of SDI are
a useful starting point for benchmarking a country’s
mortality pattern, but many other factors, including
public health programmes, access to medical care, and
inequalities could account for deviations from the pattern
expected on the basis of SDI alone.
Nearly 40 years ago, Samuel Preston observed a shifting
relationship between life expectancy and income per
capita;58 in a series of subsequent analyses, the crucial
role of technological change has been supported by this
changing relationship.58–61 With global life expectancy or
other mortality metrics improving faster than expected
on the basis of SDI, this general trend was tempered by
stagnant or increasing mortality rates due to a subset of
causes such as diabetes, cardiovascular disease, and
some types of cancer. The overall shift in life expectancy
masked larger gains for children and minimal progress
for older adults compared with that expected on the basis
of SDI. In fact, ﬁgures 10C and 10D show that global
progress has been much less impressive for the
probability of death from ages 15–50 years than for
children and that progress in reducing the probability of
death from ages 50–70 years only seems to be noticeable
at high levels of SDI. In the younger adult age groups,
temporal patterns over the past 25 years were profoundly
shaped by the unfolding of the HIV epidemic in eastern
and southern sub-Saharan Africa and roll-out of ART
and PMTCT and the rise and subsequent fall in adult
mortality in eastern Europe and central Asia. This is an
important diﬀerence from previous notions of the
inevitability of technological shifts driving up levels of
health faster than expected on the basis of income and
education alone.58–62 This ﬁnding comes at a time when
two very diﬀerent views of the future of health can be
envisioned: rising threats such as climate change, food
insecurity, water shortages, pandemics, human security,
continued increases in obesity, or antimicrobial
resistance that could undermine past health gains; and
the realisation of the huge potential of new medical and
public health breakthroughs driven by genomics,
nanotechnology, and other technical developments.63–68
Future health scenario construction will crucially depend
on how the balance of these forces is played out.
The analysis of trends in numbers of global deaths by
cause broken down into changes due to population
growth, population ageing, and changes in agestandardised death rates highlights the critical
importance of ageing in changing the mixture of causes
of death and disease that health systems will have to
manage. Likewise, the marked diﬀerence in patterns
between age-standardised rates to crude rates of YLLs
shows how ageing ampliﬁes the speed of the shifts from
communicable, maternal, neonatal, and nutritional
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diseases to NCDs. The combination of demographic and
epidemiological change can also lead to extremely rapid
changes in disease proﬁles in some countries. China is a
clear example of having an accelerated change in disease
proﬁles: from 1990 to 2015, the percentage of YLLs due to
NCDs increased from 50·0% (48·5–53·0) to 77·3%
(76·5–78·1). The potential rapidity of these changes
presents challenges to many ministries of health in
terms of human resources for health planning and policy
formulation. Understanding where this potential is
about to unfold will be aided by systematic demographic
and epidemiological forecasts grounded in the patterns
recorded in GBD.

Communicable diseases
Although our methods for the assessment of HIV/AIDS
mortality changed substantially from GBD 2013, our
general ﬁndings at the global level have remained similar
across iterations of GBD.11 With the global epidemic of
HIV/AIDS mortality peaking in 2005, at 1·8 million
deaths (95% UI 1·7 million to 1·9 million), deaths due to
HIV/AIDS had decreased by 2015, dropping to 1·2 million
(1·1 million to 1·3 million). Yet despite major progress,
especially amid the scale-up of ART and PMTCT in
sub-Saharan Africa, HIV/AIDS remains the leading
cause of YLLs in 16 countries and among top ﬁve causes
of mortality in 38 countries. Large numbers of individuals
continue to die from HIV/AIDS each year in eastern and
southern sub-Saharan Africa, where many countries still
experience large-scale epidemics, even with the rapid
scale-up of ART. We estimate that 17·8% (13·6–20·6) of
these HIV/AIDS deaths in 2015 were due to tuberculosis
in HIV-positive people, but little data exist for the
immediate causes of other HIV/AIDS deaths. Continued
high death rates in sub-Saharan Africa highlight the
critical importance of improved quality of care and early
initiation of therapy, irrespective of disease progression.69
In the face of calls for the end of HIV/AIDS by 2030,
more rapid progress is urgently needed.70–73 Stagnating
development assistance for health for HIV/AIDS
programmes ampliﬁes the challenge of reducing
HIV/AIDS mortality.74,75
Our results suggest a notable decrease in malaria
mortality in sub-Saharan Africa since 2003, consistent
with documented reductions in incidence and
prevalence, as well as observed increases in eﬀective
treatment and preventive interventions.76 We found that
malaria mortality peaked in 2003, which is slightly
earlier than reported in previous GBD estimates.
However, the timing of peak malaria mortality varied
across countries (eg, 2005 in Angola and 2000 in
Uganda), which might reﬂect a combination of factors.
Estimates presented here for sub-Saharan Africa are
based on an estimation method that maps from all
untreated cases to mortality and will be reﬁned in further
iterations of GBD (eg, the introduction of an intermediate
step of severe malaria).
1522

The population attributable fraction of diarrhoeal
aetiologies increased for most aetiologies compared with
GBD 2013. This is mainly because of two factors. First,
we used the new TAC diagnostic for the detection of
pathogens in GEMS compared with the conventional
laboratory diagnostic methods used in GBD 2013. The
TAC method is more sensitive and speciﬁc than the
conventional methods, such as bacterial culture or
ELISA, which tends to increase the odds ratios used in
the attributable fraction estimation by correcting for
the pathogen misclassiﬁcation.77,78 Second, we used a
correction factor to adjust for false negatives and false
positives of the prevalence of pathogens in patients with
diarrhoea and to make it comparable with the odds ratios
from the TAC diagnostic method. We corrected our
modelled prevalence estimates for the imperfect
sensitivity and speciﬁcity of the laboratory diagnostic
results compared with TAC because most studies
reported diarrhoea based on previous diagnostics.
Therefore, the correction for the prevalence of the
pathogens widened our uncertainty of the ﬁnal estimates.
Although qPCR is a well established diagnostic for
diarrhoeal pathogens, the application of TAC remains a
novel approach and further testing of the appropriate
cutoﬀs for continuous measures of pathogen presence is
needed.
The attributable fractions for Aeromonas, amoebiasis
(Entamoeba histolytica), and H inﬂuenzae type b were not
signiﬁcant in children younger than 5 years at the global
level. Indeed, this is biologically implausible given that
these pathogens do not have a protective eﬀect against
mortality. The odds ratios of diarrhoea given the presence
of Aeromonas and amoebiasis were not signiﬁcant in
children aged 0–1 years and 1–2 years but were signiﬁcant
in the 2–5-year age group, highlighting that these
pathogens might not be signiﬁcant contributors across
all age groups. The attributable fraction for H inﬂuenzae
type b is based on a meta-analysis of randomised
controlled trials of vaccine eﬃcacy where the CI of the
pooled estimate was not statistically signiﬁcant. This is a
potential limitation and future analyses could use
alternative meta-analytical methods, such as log-log
meta-analysis or imposition of a non-negative population
attributable fraction prior, to prevent negative population
attributable fraction estimates.
Our estimation of the fraction of deaths due to lower
respiratory infection attributable to pneumococcal
pneumonia relies on data from vaccine eﬃcacy studies
that show a decrease in all pneumonia and among
invasive (bacteraemic) pneumococcal disease in children
and adults. However, at least one study that used a urine
antigen test in elderly adults found that the relative
vaccine eﬃcacy of pneumococcal conjugate vaccine
against invasive pneumococcal disease was 66% greater
than against pneumococcal pneumonia.49 For GBD 2015,
we corrected the estimated pneumococcal conjugate
vaccine eﬃcacy against invasive pneumococcal disease
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by this ratio in both child and adult age groups. This is a
change in our GBD 2015 methods, although no studies
have used this diagnostic test to detect non-invasive
pneumococcal pneumonia in children. To reﬂect the
uncertainty of this adjustment, we used a uniform
distribution around the point estimate of the ratio. This
adjustment contributed to an increase in our estimates of
pneumococcal pneumonia mortality because the vaccine
eﬃcacy against pneumococcal pneumonia could be
lower than has previously been estimated.49 Given the
much larger attributable fraction after the adjustment
was made and wide uncertainty of the ﬁnal estimates,
further studies to conﬁrm and precisely quantify the
diﬀerence in vaccine eﬃcacy between invasive and noninvasive disease are needed. Data availability limitations,
particularly for vaccine eﬃcacy data across age groups,
hindered our ability to conduct pathogen attribution
analyses for H inﬂuenzae type b among populations aged
5 years and older; a similar lack of data made estimating
population attributable fractions and pathogen-speciﬁc
mortality for neonates analytically infeasible.
While mortality rates from most infectious diseases
fell, dengue emerged as a notable counterexample. The
combination of new data and an improved dengue trend
covariate (methods appendix p 82) enabled our model to
better capture these trends. Compared with GBD 2013
estimates, our GBD 2015 dengue mortality estimates are
higher for the most recent decade, yielding a pronounced
upward trend that is more consistent with case reports,
GBD 2013 incidence estimates, and expert consensus.79
The increasing geographic range of dengue and, in some
areas (eg, Latin America) increasing transmission
intensity, contribute to growing concerns about other
viruses that are transmitted by Aedes mosquitoes,
including the chikungunya and Zika viruses.80 Progress
in dengue vaccine development, including the licensure
of the CYD-TDV vaccine in 2015,81 is promising, but the
eventual impact of such vaccines remains unclear.
In GBD we follow the ICD principles of underlying
cause of death. According to this principle, a single
underlying cause is assigned to each death. In some
cases, somewhat arbitrary rules are used to deal with
interactions between pathogens or disease processes—
eg, all deaths from opportunistic infections, such as
fungal infections, in HIV-positive patients are assigned
to HIV/AIDS as the underlying cause. Underlying cause
assignment is distinct from the notion of excess mortality,
whereby a condition or disease can be associated with
increased risk of death from other pathophysiological
processes. In some cases, the underlying cause of death
rules embedded in the ICD could lead to lower death
estimates for some neglected tropical diseases. For
example, anaemia is a sequela of various diﬀerent
conditions, some of which are parasitic. Hookworm
infections can cause iron-deﬁciency anaemia,82 which is
then recorded as the underlying cause of death. Similarly,
infections by Clonorchis spp have been associated with
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increased risk of cholangiocarcinoma83 and are classiﬁed
as a Group 1 carcinogen by the International Agency for
Research on Cancer (IARC);84 however, the cause of death
will be listed as cholangiocarcinoma and will be captured
within the total cancer estimates. Alternative post-hoc
analyses might be useful for some of these neglected
tropical diseases to characterise the excess mortality that
could be related to the disease.
Pandemics were incorporated into GBD as fatal
discontinuities in the same way as armed conﬂicts and
natural disasters.7,85 In late 2013 an epidemic of Ebola
virus disease started in west Africa. Slow national and
international responses allowed the virus to spread
throughout 2014 and to become a Public Health
Emergency of International Concern,86 which was
eventually brought under control in 2015 after a sustained
multilateral eﬀort. These estimates of mortality are of the
direct deaths attributable to Ebola virus disease and do
not account for the full eﬀects of mechanisms such as
the breakdown of health systems or critical infrastructure
and their subsequent potential health repercussions.87,88
Previous estimates of mortality86 combined with these
destabilising eﬀects on wider health-care provisioning
within the three most aﬀected countries have already
resulted in appropriate introspection among the
international community on the ability of institutions to
cope with pandemic threats.89 Correctly establishing
the relative public health importance of pandemic
preparedness investments is non-trivial, because even if
there are no deaths in a year from a potential pandemic
cause, such as pandemic inﬂuenza, substantial excess
mortality risk remains.90 The need for better surveillance
and preparedness infrastructures to help to mitigate the
risk posed by potential pandemic infectious diseases has
been strongly advocated91 and has been underscored
again in 2016 with the rapid spread of Zika virus across
the Americas and the declaration of another Public
Health Emergency of International Concern.92
In GBD 2015, we have not estimated the burden of
drug-resistant tuberculosis as a cause distinct from
overall tuberculosis. Nor have we estimated deaths
related to drug-resistant bacteria or malaria. The
challenge that antimicrobial resistance poses both to
current and future health-care systems is becoming
increasingly documented and quantiﬁed,93 with an
estimated 3·3% of new tuberculosis cases and 20% of
previously treated cases having multidrug resistance.94
Incorporating the proportion of cases caused by
pathogens with drug resistance therefore represents a
signiﬁcant, but increasingly important, objective for
future estimates.95 Within the GBD framework, drug
resistance might be best assessed by examining
antimicrobial resistance as a risk factor rather than
estimation of subtypes of each pathogen.
Researchers have long foreseen health eﬀects caused by
changes in the environment, with a particular focus on
climate change.96 To date, our results do not show these
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trends being realised. Instead they show a substantial
global trend of improvement in SDI and notable
improvements in many of the infectious disease causes
that would be most sensitive to climate change such as
malaria,76 in a process known as the environmentalist’s
paradox.97 This lack of any association so far could be
related to time lags between global environmental change
and health outcomes and is widely hypothesised to be at
the expense of degradation of ecosystem services.98
It might also simply be much harder to detect changes
against the backdrop of rapid improvements that are
expected with SDI. The value expected from SDI might
therefore help to identify which countries or subnational
areas are improving at rates that are slower than expected.

Non-communicable diseases
From 2005 to 2015 age-standardised death rates due to
most types of cancer decreased, a reﬂection of risk factor
reduction, as well as improvements in some settings of
health systems equipped for early diagnosis and eﬀective
treatment of cancers. With respect to YLLs due to cancer,
lung cancer remains the leading cause globally and for
most countries, with YLLs increasing by almost 15%
over the past decade. Given that most cases of lung
cancer can be prevented,99 this observation stresses the
importance of tobacco and air pollution control. For
other types of cancer, the geographic pattern is more
diverse and reﬂects the vast diﬀerences in risk factors, as
well as health system capacity. Whereas colorectal,
breast, and pancreatic cancer are the leading causes of
cancer YLLs for most high-income countries, stomach,
liver, and oesophageal cancer dominate in countries
with low SDI. It is encouraging that global YLLs due to
stomach cancer have decreased over the past decade,
with the substantial decrease in age-speciﬁc death rates
counterbalancing population growth and ageing.
Oesophageal cancer is the other example for which YLLs
decreased from 2005 to 2015, with the decrease in agespeciﬁc death rates oﬀsetting the increase due to an
ageing and growing population. Translating the observed
changes in liver cancer mortality into public health
planning and policy requires knowledge of the
underlying aetiologies, as risk factors diﬀer substantially
between locations. This has become an even higher
priority now that eﬀective treatment for hepatitis C is
available.100 The increase in numbers of liver cancer
deaths due to hepatitis B from 2005 to 2015 was not
signiﬁcant, which contrasted with the signiﬁcant
increases in deaths, often 20–30%, observed for many
other types of cancer: this relative progress might be at
least partly attributable to hepatitis B vaccination.
A similar development for liver cancer due to hepatitis C
can be achieved in the coming decades if hepatitis C
treatment, which currently has high costs per patient,100
becomes accessible in high prevalence populations.
Data newly available to GBD 2015 improved our
understanding of global patterns of cardiovascular
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disease. High proportions of death due to cardiovascular
disease have been observed in Oceania. Previously, very
few data sources were available from Kiribati and Fiji,101
but with additional data from Tonga, Guam, American
Samoa, and the Northern Mariana Islands, it seems that
27–30% of deaths in this region were due to cardiovascular
disease causes. Newly available data from India show
that, similar to surveillance data previously available
from Bangladesh, cardiovascular disease accounts for a
large and increasing proportion of deaths. Updated data
from China now show a clear trend toward decreasing
risk of cardiovascular disease death in all age groups
since 2010, when comprehensive vital registration
became available. In GBD 2015 we examined agestandardised YLL rates by level of SDI. YLL rates for
ischaemic heart disease were lowest in countries with the
lowest SDI when country populations were examined by
SDI, rising steadily at higher levels of SDI, and only
reduced for populations in the quarter of countries with
the highest SDI. This pattern was more pronounced
among males than females and diﬀers from that seen for
stroke, where YLL rates decrease gradually at higher
levels of SDI and then fall steeply for the highest SDI
populations. The result is that for overall cardiovascular
disease, YLL rates were lowest in both the lowest and
highest sociodemographic groups with an increase for
those in the middle of the sociodemographic rankings.
One hypothesis is that medical care in the highest SDI
populations might have increased life expectancy to the
point where cardiovascular disease is most prevalent,
while people in the lowest sociodemographic group are
dying from other conditions before reaching an age
where they would develop ischaemic heart disease and
stroke.102 In this scenario, people living in countries
categorised in the middle range of the sociodemographic
rankings are surviving long enough to develop ischaemic
heart disease but might not have access to optimal
medical or surgical treatment.
Deaths due to cirrhosis increased globally from 2005 to
2015, whereas age-standardised cirrhosis mortality rates
fell during the same period. Underlying the global picture,
though, are notably distinct regional trends, with
substantial reductions in cirrhosis mortality in east Asia
and central Europe, for example, and increases in cirrhosis
mortality in central Asia and north Africa and the Middle
East. These trends largely reﬂect changes in the major risk
factors for the disease, with some cirrhosis risk factors,
such as chronic hepatitis B infection, decreasing in the
face of widespread vaccination, and other risk factors, such
as alcohol consumption and chronic hepatitis C, increasing
in some parts of the world.103 The decades-long lag between
hepatitis B infection and cirrhosis death, and the increasing
use of the hepatitis B vaccine, suggest that the potential
eﬀect of vaccination on cirrhosis mortality is only
beginning to become apparent, and hepatitis B-attributable
cirrhosis deaths should continue to fall. Notably, with
nearly a quarter of cirrhosis deaths being due to chronic
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hepatitis C infection, improvements in blood screening
and new short-course oral treatments for hepatitis C have
the potential to reduce cirrhosis mortality in the future.103,104
Globally, total deaths from Alzheimer’s disease and
other dementias increased by almost 40% from 2005 to
2015. This increase is due to population increases and
ageing accompanied by a small but signiﬁcant decrease
in age-standardised death rates from Alzheimer’s disease
and other dementias, possibly reﬂecting the reduced
burden of cardiovascular disease and the contribution of
vascular brain injury to the dementia syndrome.105
A small reduction in mortality rates is consistent with
reports of a fall in the prevalence of dementia from two
cross-sectional surveys a decade apart in the UK and a
decline in incidence of dementia reported from the
Framingham Cohort Study in the USA.106,107 There is also
evidence that increased education and healthier lifestyles
can reduce disease incidence and delay disease
onset,105,107,108 partly reﬂecting the reduced burden of
cardiovascular disease and the contribution of vascular
brain injury to the dementia syndrome. Although the
reductions in rates are welcome news, the substantial
increase in the number of deaths from Alzheimer’s
disease and other dementias and the associated increase
in prevalence present challenges for health systems and
social support systems that need to address the needs of
these patients and their families.
We estimate small numbers of death due to mental
disorders as the underlying cause. We include
schizophrenia as a cause of death because high-quality
vital registration data every year show a stable, small
number of deaths from this cause. Many more deaths
occur in people with schizophrenia in excess of what
would be expected on the basis of general population
mortality rates. These deaths are certiﬁed and coded to
other diseases and injuries as the underlying cause, such
as self-harm, unintentional injuries, infectious diseases,
substance use, cardiovascular disease, and cancers, for
which excess mortality in people with schizophrenia has
been reported.109–111 Most deaths from self-harm can be
attributed to underlying mental and substance disorders
such as depression, anxiety disorders, schizophrenia,
bipolar disorder, and alcohol and drug use disorders, as
has been quantiﬁed based on GBD 2010 estimates.112
In future iterations of GBD, it might be useful to more
systematically and regularly quantify the excess mortality
associated with several mental disorders.
The estimate of 1·5 million deaths (95% UI 1·5 million
to 1·6 million) due to diabetes, plus 418 000 deaths
(389 000–441 000) from chronic kidney disease due to
diabetes mellitus, still underestimates the full impact of
diabetes on all-cause mortality because of the increased
risk of ischaemic heart disease, stroke, and tuberculosis
associated with diabetes.113–115 In the GBD framework,
computation of deaths attributable to elevated fasting
plasma glucose more comprehensively captures the
eﬀects of diabetes and pre-diabetes on mortality—see the
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GBD comparative risk assessment for 2015.116 Given the
strong association between diabetes and obesity and the
global rise of obesity, the ﬁnding that age-standardised
death rates for diabetes, including chronic kidney disease
due to diabetes mellitus, are not increasing suggests that
other protective factors such as treatment might have an
eﬀect.117,118 Spatial patterns show marked variation in
death rates, even in places with relatively similar
prevalence such as Mexico and the USA.119 These
variations in death rates could be related to variation in
cause of death certiﬁcation, with some medical
communities more likely than others to list diabetes as
the underlying cause of death, or they might be due to
treatment eﬀects. Given the importance of diabetes as a
cause of death already, and the likely global rise in
prevalence of diabetes, more research is needed to
understand the determinants of variation in diabetes
death rates.119
In this analysis we have estimated that there were
more deaths due to chronic kidney disease than in
previous analyses because of improved estimates within
countries with large populations such as China, India,
and Russia. We have also improved our chronic kidney
disease subtype estimation strategy by implementing
consistent data source inclusion, as well as estimation
strategy across the four subtypes. A further improvement
is that we have narrowed the deﬁnition of deaths due to
“chronic kidney disease other” so that deaths formerly
included in this category are now attributed to original
disease cause, such as polycystic kidney disease. Thus
chronic kidney disease subtype mortality results will
diﬀer notably from those of previous analyses. Our
results indicate that, globally, deaths from chronic
kidney disease increased among both males and females,
but age-standardised death rates remained relatively
unchanged in the past decade. Likely contributors
include an increase in the burden of chronic kidney
disease risk factors such as diabetes mellitus and
hypertension. In 2015 Latin America had the highest
chronic kidney disease death rates in the world. Within
Mexico, the country with the highest chronic kidney
disease death rate, more than half of patients with
incident end-stage renal disease have an underlying
diagnosis of diabetes mellitus.120 Unique aetiological
contributors, such as those suspected in chronic kidney
disease due to other causes, have been shown to cause
chronic kidney disease deaths mostly in younger adults
in El Salvador and Nicaragua, as well as Sri Lanka.121
Eﬀorts to delay deaths due to end-stage renal disease
currently depend on renal replacement therapy in
the form of either maintenance dialysis or renal
transplantation. These costly interventions require
appropriate medical infrastructure, as well as
government subsidisation, to be accessible to the general
population. Therefore, these interventions are currently
accessible mainly to populations in high-income
countries.122 If deaths due to chronic kidney disease
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continue to increase globally, further research into
possible ways to prevent chronic kidney disease, such as
with population-level or individual-level approaches, is
warranted. Given that many chronic kidney disease risk
factors overlap with cardiovascular risk factors,123–125
closer collaboration between these two specialties could
foster preventive strategies in the future.

Injuries and fatal discontinuities
Experience and evidence from studies on intervention
suggest that there is a potential to reduce road injury
deaths through a range of interventions. Drunk driving
bans, seat belt laws, road engineering including traﬃc
calming, safety devices in vehicles, speed limits,
mandatory helmet usage, bans on mobile phone use
while driving, and separation of vulnerable road users
from vehicles have all been shown to be eﬀective.126–130
Progress in reducing road injury can be rapid. From 2005
to 2015, western European countries such as Spain
(43·8%, 95% UI 39·9–47·3), Portugal (39·6%,
35·4–43·6), and Switzerland (18·8%, 11·8–25·4), had
signiﬁcant reductions in total deaths. Such rapid
decreases indicate that not only are there speciﬁc
interventions that can work,131,132 but also that populationlevel reductions are possible in a short period. A reverse
trend is apparent in low-income and middle-income
countries, partly because the growth in motorisation and
traﬃc density is outpacing the reductions associated
with infrastructural development and levels of law
enforcement. This trend is particularly the case for major
fast-growing BRICS economies (Brazil, Russia, India,
China, and South Africa).133–135
Global death rates due to interpersonal violence have
decreased since 2005, but regional trends were much more
diverse. Reductions were largest in Asian and European
countries, but rates of deaths due to interpersonal violence
in Latin America and southern sub-Saharan Africa
remained quite high. Interpersonal violence can often be
mitigated or reduced by addressing underlying drivers or
risks, such as the accessibility of weapons and use of
alcohol and psychoactive drugs.136–139 In 2015, self-harm was
the second-leading cause of death from injury. Nearly half
of all self-harm deaths occur in India and China, but the
trends in these countries have reversed, decreasing
signiﬁcantly in China but rising in India from 1990 to
2015. Over the past two decades China and India have both
experienced rapid economic growth and urbanisation, and
therefore the opposing trends might be explained by other
factors. Evidence from previous research has shown that a
combination of preventive approaches addressing multiple
factors, such as increased public awareness, programmes
based on behavioural change and coping strategies,
physician education, and decreased access to means of
self-harm is needed.140–143
Age-standardised death rates from drowning fell by
nearly 30% globally during the past decade, with greatest
reductions occurring in China, southeast Asia, central
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Asia, and eastern and central Europe. The highest rates of
death due to drowning in 2015 were in island nations of
Oceania and in the Indian Ocean, southeast Asia,
Afghanistan, Bangladesh, and sub-Saharan African
countries. Globally, drowning is a leading cause of death
in children younger than 5 years. There is potential to
reduce drowning deaths by preventive measures such as
installing barriers, controlling access to water, education,
swimming lessons and safe boating practices, and
shipping and ferry regulations.144–146 However, change in
access to open water with increasing urbanisation might
be a more important factor driving down drowning deaths
than speciﬁc prevention measures.
For GBD 2015 we systematically collected data on
major transport accidents, natural and man-made
disasters, wildﬁres, pandemics, and wars. Although the
accuracy of the death numbers due to some of these
causes vary by country (ie, they are usually more accurate
in stable or higher income countries), they tend to be
more reliable than are the estimates for wars. Indeed, it
has been challenging to accurately document the number
of casualties from wars and deaths resulting from
malnutrition, infections, or disruption in health services
during wars.147–150 The challenge is due to scarcity of vital
statistics during wars, the increase in refugee populations
who are displaced internally or externally, and the fact
that surveys can only capture mortality rates among
those who have remained in their households during the
time of interviews. Unfortunately, these estimates can
also be challenging to capture with a future census
because refugees might have settled in other countries.
For example, it is estimated that more than 3 million
Syrians have settled in neighbouring countries or
elsewhere.151,152 Nonetheless, we believe that providing
such estimates, even with a wide UI, will draw attention
to the devastating eﬀects of war on health and hopefully
lead to better methods to estimate morbidity and
mortality from wars.

Measurement challenges and opportunities
The assessment of all-cause mortality in GBD 2015 includes
important innovations that have substantially increased
uncertainty for adult mortality in some countries. We
believe this is a much more accurate reﬂection of our
knowledge of age-speciﬁc mortality in countries without
vital registration or sample registration systems. The most
important changes included processing of sibling history
data using single years rather than pooling data for 5-year
intervals, and the propagation of uncertainty in HIV/AIDS
crude death rates used in the ﬁrst stage of the spatiotemporal
Gaussian process regression model into the estimation of
45q15. In addition to these changes, we have greatly
improved our parameter selection process for both 5q0 and
45q15 Gaussian process regression to reﬂect data density
and quality of data partly represented by the data variance.
Combined, these changes led to an increased uncertainty
interval for 45q15. In many countries in Africa, the width of
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the uncertainty interval for 45q15 more than doubled. The
increase in the uncertainty interval for 45q15 directly leads
to higher uncertainty intervals for our age-speciﬁc mortality
rate estimates. This partly helped with the removal of an
arbitrary matching algorithm from GBD 2013, which
picked the pairs of draws of all-cause mortality and HIVspeciﬁc mortality estimates that were consistent. With the
widened uncertainty interval in all-cause mortality
estimates, we are able to apply the ensemble model to
combine draw-level HIV/AIDS mortality estimates
from the demographic estimation process and the
epidemiological model of EPP-Spectrum for all 1000 draws.
Cause of death data for low SDI countries in
sub-Saharan Africa were limited to a small number of
mostly local verbal autopsy data often with small sample
size. Members of the INDEPTH network of demographic
surveillance systems have been collecting verbal autopsy
data in some sites for many years.153 In the development
of the GBD cause of death database, we have been able to
make only limited use of INDEPTH verbal autopsy data
collected in multiple sites. Some INDEPTH members
like Matlab routinely release physician-certiﬁed verbal
autopsy data in full detail whereas others have published
periodic results in journal articles. In 2015, 22 INDEPTH
sites published INTERVA model predictions of individual
causes of death for the period 1992 to 2012.153 No primary
data from the verbal autopsy interviews have been
released to date. Unfortunately, INTERVA model
predictions are highly inaccurate. The only validation
study comparing INTERVA to an objectively deﬁned
cause of death standard at the individual level found it
accurately assigned the cause of death in 23·8% of adult
deaths, 30·3% of child deaths, and 19·4% of neonatal
deaths; at the population level, estimated cause-speciﬁc
mortality fractions were not better than random
guessing.154,155 This potentially important resource for
global health estimation is being underused because of
the limitations of current versions of the INTERVA tool
for cause ascertainment. Given that injury death
assignment might (although there are no objective
validation data on this issue) be more plausibly established
from INTERVA, we have chosen to use the INTERVA
results from INDEPTH for eight types of injuries:
transport injuries; falls; drowning; ﬁre, heat, and hot
substances; poisonings; venomous animal contact; selfharm; and interpersonal violence. Hopefully, a large
number of deaths from INDEPTH verbal autopsies will
be assessed using physician-certiﬁed verbal autopsy or
more robust computer algorithms in the future.
In GBD 2013, for select causes, we developed separate
CODEm models for countries with long series of
complete vital registration data in order that UI estimation
in these settings was not aﬀected by UI in settings with
either less complete or lower quality data. For GBD 2015,
we standardised this approach. We deﬁned countries with
extensive complete vital registration representation as
those with vital registration equal to or more than 95%
www.thelancet.com Vol 388 October 8, 2016

complete for more than 25 years. We also modiﬁed the
ranges of psi used in testing diﬀerent ensemble models
to be higher, eﬀectively allowing CODEm to evaluate outof-sample ensembles made up of fewer models. In
countries with nearly complete high-quality time series,
smaller numbers of models in the ensemble allow the
models to follow the data more closely with narrower UIs
for many but not all causes.
It is extremely diﬃcult to properly inform national and
global policy responses to reduce mortality when
available cause of death information is very sparse,
outdated, or unreliable. Fortunately, there is now
evidence of increased investment and technical support
being oﬀered to countries to improve their vital
registration systems. Important new partnerships have
been formed between major bilateral donors and
philanthropic organisations,156 building on earlier eﬀorts
of the Health Metrics Network and the Australian
development assistance program, AusAID.157,158 Regional
UN-led partnerships, particularly in Africa and the AsiaPaciﬁc region, are also helping governments to
understand the essential role of good vital registration
systems in development, and advocating for change. The
interventions now being oﬀered in many countries
include targeted and strategic training of doctors to
correctly ﬁll out death certiﬁcates that identify the
underlying cause of death; improving practices and
exploiting information technology advances to more
eﬀectively register deaths, consolidate and validate data,
and transfer information more eﬃciently to policyrelevant destinations; and, perhaps most importantly,
facilitating the widespread adoption of automated verbal
autopsy methods to cost-eﬀectively provide information
on causes of death in populations for which these data
are unavailable.2 Although the initial focus of these
eﬀorts is on improving data systems, a substantial impact
on data quality and availability can be reasonably expected
within the next 3–5 years.159 This will not only improve
the evidence base for guiding local policy decisions, but
will also lead to reduced uncertainty in global comparative
mortality assessments, such as the GBD study.
WHO led the process of developing new guidelines for
reporting on global health estimation.20 For GBD 2015,
we invested substantial resources to ensure that the
GBD 2015 studies, including this Article, are compliant
with the GATHER recommendations. Figures 1 and 2
provide detailed workﬂow diagrams. In appendices and
the Global Health Data Exchange, we also provide
detailed documentation of all sources used in the
analysis. For each step in the workﬂow diagrams,
computer code is either on GitHub, such as CODEm
2015 and DisMod-MR 2.1,160,161 or available on the IHME
website for download. Enhanced transparency and
documentation highlight the multiple interconnections
between analyses, for example, the strong connections
between HIV/AIDS incidence, prevalence, and mortality
estimation and all-cause mortality estimation in
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countries with large epidemics. Across this assessment,
there are hundreds of separate analytical steps; for each
we documented input data, code, and information on
model development and performance.

Limitations
Here we highlight some broad cross-cutting limitations
to the GBD mortality and cause of death analysis. The
analysis of all-cause mortality in countries without vital
registration systems is critically dependent on the validity
of sibling history data for measuring adult mortality.
Although we show, with appropriate corrections for
survivor bias (methods appendix pp 21–24), that sibling
history data are unbiased when compared with vital
registration data, these comparisons are not available for
sub-Saharan Africa, where sibling history data are of key
importance. Sibling histories in some African countries
might underestimate mortality due to the practice of
adoption in some countries, but empirical studies in
these settings have not conﬁrmed any consistent
underestimation of adult mortality.162
All-cause mortality in settings with vital registration is
corrected for under-registration using the three available
demographic methods for the detection of underregistration: generalised growth balance, synthetic
extinct generations, and a hybrid approach of these two
methods. However, these methods, as shown in
simulation studies,26 are unbiased but imprecise. To
further stabilise our estimates of vital registration
completeness over time, we synthesise raw estimates of
completeness from death distribution methods and
implied child death registration completeness by
comparing vital registration to GBD under-5 mortality
estimates into one coherent time series. Despite these
eﬀorts, estimates of completeness can change between
GBD revisions as new census data become available or
new surveys are released. We propagate uncertainty into
the all-cause mortality in the analysis of completeness,
but these UIs might be underestimates in some settings
because of the scarcity of available data.
Because of the close connection between the estimation
of all-cause mortality and HIV/AIDS incidence,
prevalence, and mortality in countries with large
epidemics, all limitations pertaining to HIV modelling
also apply to our estimates of all-cause mortality. For
GBD 2015, we used an ensemble model for HIV in which
the demographic model and the natural history model of
HIV/AIDS death are combined. Despite these attempts
to triangulate on the magnitude of the HIV/AIDS
epidemic, we assume that the CD4 progression rate,
oﬀ-ART death rates, and on-ART death rates for
age–sex–CD4 categories are the same throughout subSaharan Africa. Because of other factors, such as coinfections with tropical diseases or nutritional status,
CD4 progression rates can vary across populations. It is
also likely that the quality of and access to ART
programmes varies across communities, and thus
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on-ART death rates might well vary. Because of the
strong assumptions made in the natural history models
(assumptions also made by UNAIDS163) about the
consistency of these parameter values across countries,
we might be underestimating the true variation in
HIV/AIDS death rates and all-cause mortality.
Our cause of death analysis depends substantially on
the validity of medical certiﬁcation of causes of death and
physician-certiﬁed verbal autopsies. Although eﬀorts to
redistribute garbage codes to likely underlying causes of
death help to enhance comparability, our ﬁndings are
aﬀected by systematic bias in medical certiﬁcation of
causes of death. We see in the rapid increase in certain
causes of death on death certiﬁcates—such as
Alzheimer’s and other dementias, or atrial ﬁbrillation—
evidence of diagnostic trends that are generally
incompatible with time series data even after garbage
code redistribution. For these reasons, we used other
methods to estimate these particular causes of death.
However, these patterns suggest that garbage coding
practices not only vary by country but also across time.
Our results depend critically on the validity of our
approach to garbage code redistribution. As we further
utilised statistical methods to establish redistribution
algorithms over the development of the GBD 2015 results,
we saw sizeable changes in major causes of death. For
example, changes in how left-sided heart failure and rightsided heart failure are analysed substantially changed
the number of deaths reassigned to pneumoconiosis,
haemoglobinopathies, or COPD. We believe these changes
reﬂect improvements in our methods, but they also show
how some causes of death, even though they result in lower
absolute levels of mortality, can be profoundly aﬀected by
the redistribution of large garbage codes such as heart
failure or sepsis. The sensitivity of our ﬁndings to how
major garbage codes, such as heart failure, sepsis, or
ICD-X59 (exposure to unspeciﬁed factor), are redistributed
emphasises the importance of more systematic research on
garbage code practices and improvements in primary data
collection to avoid deaths being certiﬁed to garbage codes.
We used CODEm to model all causes for which
suﬃcient numbers of deaths are observed in vital
registration, sample registration, or verbal autopsy
datasets. For these 167 causes, we conducted rigorous
out-of-sample validation exercises and documented
prediction error and UI coverage. However, for the
remaining causes, particularly those modelled with
natural history models, the design of validation tests was
severely limited by data sparseness. In the absence of
better data collection, particularly for causes of death that
mostly occur in data-sparse geographies, our options for
more robust model validation will remain limited. The
analysis of causes of death in India also has important
ramiﬁcations for global estimates. The three major
sources of cause of death information for India are the
Medical Certiﬁcation of Causes of Death (MCCD), largely
collected in urban areas; the Survey of Causes of Death
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(Rural; SCD[R]); and verbal autopsy data collected for
deaths recorded in the Sample Registration System (SRS)
from 2001 to 2013. All three systems are or
were maintained by the Registrar-General of India.
Unfortunately, whereas the MCCD and SCD(R) data
have been released in considerable age, sex, and cause
detail for states in India, the SRS data have been released
only for large aggregates and not at the state level,
although various academic works using data for 2002–04
have been published for speciﬁc causes with varying
levels of detail. The rich resource of the SRS verbal
autopsy data could be much more informative if the
standard WHO table of ICD code, age, and sex were
publicly released.
Available data from some countries in sub-Saharan
Africa pose substantial challenges for cause of death
analysis. Only extremely scarce verbal autopsy data are
currently available for large populations. Given
substantial gradients in mortality within Nigeria, for
example, there is substantial risk of over-interpreting the
limited verbal autopsy data. Civil registration data are
collected in Nigeria, but the completeness is low and the
level of garbage coding is very high. New data for
countries in the sub-Saharan African region would
substantially narrow a major source of uncertainty in
sub-Saharan African causes of death.
It is possible that some of the heterogeneity reported in
observed and expected causes of early death in diﬀerent
geographies has been artiﬁcially created by variations in
data quality and the use of diﬀerent methods. The GBD
group makes extensive eﬀorts to try to reduce the eﬀects
of variable data quality, and we have used standardised
methods for each cause that are the same for all countries.
Lastly, although our estimates of uncertainty intervals
reﬂect multiple sources of uncertainty, they do not
include every possible source of uncertainty. For all-cause
mortality, we include uncertainty due to the following:
sampling error in the underlying data; non-sampling
error associated with particular child or adult mortality
data types; HIV/AIDS crude death rate; and reference
age pattern of mortality used in the GBD model life table.
We do not, however, include uncertainty in the
measurement of income per capita or educational
attainment, and we do not include uncertainty from the
choice of our model speciﬁcation for the ﬁrst stage of the
spatiotemporal Gaussian process regression analysis.
For causes of death, we capture sampling uncertainty,
model speciﬁcation uncertainty through the creation of
CODEm ensembles, and non-sampling error from
subnational or non-representative datasets. We do not,
however, capture uncertainty due to garbage code
redistribution, uncertainty in the covariates used in the
models, or uncertainty due to cause of death assignment
in verbal autopsy data. With each iteration of the GBD we
have sought to include more comprehensively diﬀerent
sources of uncertainty, and we expect this evolution to
continue in the future.
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Comparison of diﬀerent global health estimates
The GBD 2015 estimates for under-5 deaths due to
diarrhoea and lower respiratory infection diﬀer from
estimates by other agencies, such as the WHO
Department of Evidence, Information, and Research and
the Maternal and Child Epidemiology Estimation
(MCEE) group (results appendix pp 3985–89).164 In 2015,
we estimated the number of under-5 deaths as
5·8 million (95% UI 5·7 million to 6·0 million), which
was lower than the MCEE’s estimate of 5 945 000 (95%
CI 5 707 000–6 395 000) for that year.165 Our estimates of
under-5 deaths due to diarrhoea for 2015 were also lower,
at 499 000 (447 000–558 000), than those of the MCEE
group (526 000), although we attributed more diarrhoeal
deaths among neonates. For 2015, our results for under-5
lower respiratory infection deaths were notably lower
than the estimates produced by MCEE, especially
for children aged 1 to 59 months (ie, 557 000
[488 000–633 000]) from GBD 2015 and 760 000 from
MCEE. Based on the latest estimates for aetiologies of
diarrhoea and lower respiratory infection produced by
the Child Health Epidemiology Research Group
(CHERG), which is now known as MCEE,166 we found
that our estimates for rotavirus are similar for the year
2010. However, in GBD 2015, the estimates for
Cryptosporidium were ﬁve times higher than those of
CHERG, and the estimates for Shigella were 2·5 times
higher. These diﬀerences might arise from variations in
estimation approaches, as well as the use of various
sources and types of data. For example, CHERG
generated estimates of pathogen-speciﬁc diarrhoea
based on the proportion of hospitalised cases of
diarrhoea that tested positive for each pathogen,167
whereas the GBD study uses a counterfactual approach
that includes odds ratios of disease given exposure and
corrects pathogen prevalence estimates using the results
from a PCR analysis of samples from GEMS.78 Estimates
of deaths due to rotavirus in GBD 2015 and CHERG
were similar, which is not surprising given the good
diagnostic validity of ELISA for rotavirus. However, GBD
2015 estimates for bacterial pathogens were generally
higher, which reﬂects the relatively low sensitivity and
speciﬁcity of conventional diagnostic methods for these
pathogens.77 For pneumonia, estimates for bacterial
aetiologies from GBD 2015 were similar to those from
CHERG in terms of total lower respiratory infection
deaths and generating similarly large wide uncertainty
intervals. However, H inﬂuenzae type b estimates were
lower than the CHERG results for GBD 2015, and our
estimates for under-5 deaths due to pneumococcal
pneumonia deaths were higher than the CHERG
estimates. These diﬀerences probably stem from our
eﬀorts to correct for vaccine eﬃcacy against bacteraemic
pneumococcal disease to instead represent the eﬃcacy
against pneumococcal pneumonia. This correction
greatly increases the attributable fraction, and
uncertainty, for pneumococcal pneumonia.
1529

Articles

IARC last produced cancer estimates by country, age,
sex, and cancer site for 2012 (GLOBOCAN).168 GBD
and GLOBOCAN deﬁnitions are compatible for
25 cancer types. For these cancer sites, the total estimated
number of deaths from GLOBOCAN is 7 498 760 in 2012.
By comparison, the GBD 2015 estimate was 7 823 429
(7 374 053–8 241 385) for 2012. Worldwide, the largest
diﬀerences between estimates were for larynx cancer,
other pharynx cancers, thyroid cancer, nasopharynx
cancer, and myeloma, with diﬀerences of 20–85%.
GLOBOCAN has been a source for descriptive global
cancer epidemiology for many years. However, GBD
analyses have some advantages over the past
GLOBOCAN estimates. One advantage is that the
annual GBD updates allow for the incorporation of new
data rapidly. We expect the availability of cancer registry
data in low-income and middle-income countries to
increase due to the Global Initiative for Cancer Registry
Development, which is led by IARC. These data, in
addition to increasing the availability of cause of death
data, will lead to improvements in cancer estimates,
especially for regions with sparse data, and will allow
policy makers to adjust health-care strategies in
accordance with the latest evidence. The GBD study also
provides the unique opportunity for direct comparison
of the cancer burden with that of other diseases and
therefore for health system investments guided
by objective, comprehensive estimates rather than
incomplete, unreliable data and advocacy. Furthermore,
the GBD 2015 study is compliant with the GATHER
guidelines, including reporting uncertainty intervals for
each cancer estimate.
A comparison of GBD 2013, GBD 2015, and the two
most recent UNAIDS assessments of global HIV/AIDS
mortality over time is shown in the results appendix p 4).
Although, as noted, GBD methods have changed
substantially, our results at the global level are fairly
consistent with previous iterations of GBD analyses.
UNAIDS, in their latest revision, noticeably changed
their assessment of peak global HIV/AIDS mortality
from 2·24 million deaths in 2005 to 2·0 million deaths,169
rendering increased consistency between the latest
UNAIDS statistics and GBD 2015. Although it is
encouraging that thoughtful analyses of the epidemic
and its mortality consequences are converging, additional
analysis is needed to discern the diﬀerences between the
estimates from GBD and UNAIDS, and the changes that
occurred in the estimation series by GBD or UNAIDS.
It is important to understand diﬀerences and changes in
models and underlying assumptions such as on-ART
and oﬀ-ART mortality and their eﬀects on the metrics of
HIV/AIDS incidence, prevalence, and mortality provided
by GBD and UNAIDS. GBD 2015 mostly used
epidemiological and programmatic data provided by
UNAIDS in its 2015 iteration. The signiﬁcant diﬀerence
between GBD and UNAIDS might mark the important
diﬀerence in assumptions for on-ART and oﬀ-ART
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mortality, CD4 progression ratio, and background
mortality rates. In the GBD studies, we have also found
that results are highly sensitive to the assumptions of
initial CD4 count used in both the analysis of pre-ART
cohort data and the initial population distribution of CD4
count for new infections.11
The other major eﬀort to estimate age-speciﬁc
all-cause mortality and life expectancy other than the
annual GBD is the biennial United Nations Population
Division assessment published in the World Population
Prospects.170 Although the UN calculates estimates for
each age–sex–country–year, the UN Population Division
publishes data for most metrics only in 5-year intervals.
The UN has yet to publish since the introduction of the
new WHO GATHER guidelines and, in most cases, the
statistical method used to generate estimates of
age-speciﬁc mortality is unclear for any given country
and hard to reproduce with no codes made available.
A comparison of GBD 2015 life expectancy estimates
and the UN Population Division estimates for the
midpoint of 2010–15 is available in the results appendix
(p 5). For the 189 countries for which both series provide
estimates, GBD 2015 tends to have higher estimates of
life expectancy at birth for both males (111 countries)
and females (112 countries). The diﬀerences are even
more prominent for the time period 1980–85, for which
GBD life expectancy is higher for 139 countries and
territories for males and 134 for females. Although the
correlation between the two sets of estimates is 0·94 for
males and 0·97 for females for the period 1980 to 2015,
there are systematic diﬀerences in all four GBD
geographical regions in Africa, north Africa and the
Middle east, south Asia, and Oceania, for which the
correlation coeﬃcient is less than 0·9. In southern subSaharan Africa, the UN Population Division estimates
are 0·1 year (95% UI −3·9 to 3·6) lower for males and
1·7 years (−6·3 to 3·3 years) lower for females on
average in these countries around the peak of the
HIV/AIDS epidemic in 2002. This diﬀerence exists
mainly because their estimates are based on estimated
under-5 death rates and model life tables, based on
patterns of mortality in the Coale-Demeny model life
table system and the United Nations Model Life Tables
for Developing Countries, that are in turn based on
observations of age patterns of mortality before
1980.31,32,170 Unlike UN estimates, GBD estimates of adult
mortality rates take into account corrected sibling
history data collected in household surveys, which
provide direct measurements of adult mortality. The
empirical information about adult mortality, used as an
entry parameter to GBD’s model life table system,
certainly helps to improve the accuracy of our mortality
age pattern assessment, even in countries aﬀected by
the HIV/AIDS epidemic.
Another important diﬀerence emerged between the
GBD and UN Population Division assessments:
mortality and population numbers among youths.
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For the period 2010–14, the UN Population Division
estimates that 6·3 million deaths occurred globally
among people aged 5–14 years, whereas GBD estimates
this number at 4·6 million.170 The diﬀerence is mostly
driven by the diﬀerences between the Coale-Demeny
life tables used by the UN compared with our life tables,
which use much more recent empirical patterns of
mortality, and diﬀerent assessments of under-5
mortality rate that come from diﬀerences in both
treatment of data and data synthesis methods. Hill and
colleagues171 reported that, based on complete birth
histories in the Demographic and Health Surveys
(DHS), which are mostly based in low-income and
middle-income countries, mortality among youths
might also be much higher than was estimated in
GBD 2010. As a data source, long-term recall by mothers
of their 5–14-year-old children’s deaths, using complete
birth histories, has not been validated. We examined the
estimates of mortality in India in the 5–14 years age
groups from the SRS, which directly measures
age-speciﬁc mortality in a sample of 7597 villages in
rural areas and census enumeration blocks in urban
areas in India. We compared these estimates with those
from the GBD 2015 and found that estimates from the
two series are highly concordant, with a correlation
coeﬃcient of 0·95 for the 5–14 years age group and a
mean relative diﬀerence of −2·2% for the probability of
death between the ages of 10 and 14 years in the period
1980 to 2012. Our estimated age pattern of mortality for
India is mainly informed by data from the SRS, with
exceptions in children younger than 5 years, for whom
our under-5 mortality rate data synthesis takes into
account under-5 mortality rate estimates from other
sources, including the India DHS. As shown in the
methods appendix (pp 293–96), for the 5–9 years age
group, GBD 2015 estimates of probability of death are
mostly consistent with those extracted from the DHS.
For the 10–14 years age group, GBD estimates are
consistent with both DHS and SRS.
In 2014, WHO published cause-speciﬁc mortality
estimates at global, regional, and country levels for the
years 2000 and 2012.172 WHO used GBD 2010 mortality
results for all but 12 cause groups, for which WHO and
UN agencies have historically produced estimates.172–174
These 12 causes are tuberculosis, HIV/AIDS and other
sexually transmitted infections, malaria, whooping
cough, measles, schistosomiasis, maternal disorders,
cancers, alcohol and drug use disorders, epilepsy, conﬂict
and natural disasters, and road traﬃc accidents.172,173
WHO has also generated estimates of YLLs, but
comparisons of WHO estimates with those of GBD are
limited because WHO chose to use the highest projected
life expectancy for 2050—91·9 years—rather than the
GBD 2010 normative standard life expectancy of
86·0 years for 2010.172 GBD 2010 did not include mortality
estimates for the year 2012, so WHO estimates for that
year were interpolated.
www.thelancet.com Vol 388 October 8, 2016

Conclusion
A key goal, if not the fundamental goal, of a health
system is to prolong life, especially healthy life, into
old age. To do so, decision makers in health need
comprehensive and disaggregated evidence on comparative mortality levels in populations, particularly for
causes of death that are largely preventable through
political action, either through improving health services
or strengthening prevention programmes. Traditionally,
this evidence has been limited to the ﬁndings of
relatively conventional and straightforward mortality
analyses. As our results show, more novel approaches
can provide much more detailed and systematic
descriptions of how survival status and cause of death
patterns vary according to measures such as SDI, which
are becoming increasingly relevant for policy as overall
mortality levels fall. Overall population health is likely to
improve more rapidly in places where the relationships
between determinants of health and cause-speciﬁc
mortality patterns are understood—especially areas
where addressing of these gradients is a key priority for
health and development policy. Our analyses provide
important new evidence on where such gradients in
survival among populations are greatest, and for which
causes of death. Thus, although we found continued
reductions in major communicable diseases such as
HIV/AIDS and malaria in response to concerted global
action, and further, albeit more modest reductions in the
risk of death from NCDs and injuries, the comprehensive
analysis of the eﬀect of SDI on health, across and among
countries, is likely to be much more relevant for
accelerating global health progress.
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